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ABSTRACT  
 
In 2001, apolipoprotein (apo) A-V was discovered by two independent groups to be a strong plasma 
triglyceride (TG) modulator and a potential liver regeneration factor. ApoA-V knockout (KO) mice 
displayed 4-fold elevated plasma TG and transgenic mice showed 1/3 plasma TG compared with wildtype 
(WT) mice, indicating a strong inverse relationship between apoA-V expression and plasma TG levels. 
ApoA-V was also found upregulated 6 h after partial hepatectomy although its role in early liver 
regeneration remains unknown. In humans, various apoA-V single nucleotide polymorphisms (SNPs) 
correlate with hypertriglyceridemia and risk for cardiovascular and metabolic diseases. Intravenous 
injection of apoA-V protein to apoA-V KO mice can lower plasma TG by 50%, demonstrating exogenous 
administration of apoA-V can alter plasma TG.  
 
For the past decade, a number of mechanisms have been proposed for apoA-V: 1) enhancing plasma 
lipolysis of TG-rich lipoproteins, 2) increasing hepatic uptake of lipoprotein remnant particles, and 3) 
influencing lipid droplet formation in the hepatocyte. However, apoA-V is only made in the liver and has 
a low plasma concentration: 1,000 times lower than apoB and 10,000 times lower than apoA-I on a molar 
basis. With its low plasma concentration, how apoA-V can so greatly modulate plasma TG levels has been 
unclear, particularly in the postprandial state. This dissertation investigates the role of apoA-V in dietary 
fat absorption and one potential mode of action of the liver-made protein on the gut.  
 
Previous reports showed that apoA-V suppressed the surge of TG-rich lipoproteins in the plasma after a 
dietary fat load. Since apoA-V is not made in the gut, mechanisms had focused on lipolysis with the gut 
largely ignored. We hypothesize that apoA-V affects the gut by suppressing the absorption rate of dietary 
TG. Using lymph fistula mice, we report that apoA-V deficiency dramatically enhances the production of 
chylomicrons, in both rate and particle number, suggesting that apoA-V is important in controlling the surge 
 
 
of postprandial TG by modulating the absorption rate of lipids. 
 
If apoA-V is only made in the liver, then how does it affect the gut? We hypothesize that its mode of action 
is via the biliary route. Using bile fistula rats, we found that apoA-V is indeed present in bile. Additionally, 
we found that the secretion of apoA-V into bile is increased in response to two separate scenarios: 1) a 
dietary lipid bolus and 2) bile drainage after bile fistula surgery, independent of luminal phospholipid and 
bile salt.  
 
Because apoA-V was previously found on plasma chylomicrons, we wondered if this apoA-V originates 
from lymph. We found that apoA-V is indeed present on lymph chylomicrons but only during active fat 
absorption.  
 
In summary, this dissertation introduces a new mechanism by which apoA-V may affect postprandial lipid 
metabolism: by regulating the production of chylomicrons, which may be mediated through biliary delivery 
to enterocytes. In addition to the work on apoA-V, we also report a novel role for ABCG5/G8 in the 
formation and secretion of chylomicrons. These interesting findings are detailed in a supplementary chapter.  
 
  
 
 
COPYRIGHT NOTICE 
 
This dissertation is based on the following papers, referred to in the text by their Roman numeral. 
I. Apolipoprotein A-V deficiency in mice results in increased triglyceride and cholesterol 
absorption. 
 
II. Apolipoprotein A-V is present in bile and its secretion increases with dietary lipid in 
Sprague-Dawley rats. 
 
III. Apolipoprotein A-V is present in lymph and is associated with chylomicrons during active 
fat absorption in rats. 
 
IV.  ABCG5/G8 deficiency results in reduced dietary triacylglycerol and cholesterol transport 
into the lymph.  
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1. INTRODUCTION 
 
1.1 Apolipoproteins in Lipid Transport  
 
The type of protein under study in this dissertation controls the fate of lipid transport and metabolism in 
our bodies. An apolipoprotein is a protein that associates with lipids. The Greek prefix “apo” means “away 
from” or “separate from.” It can be argued that any protein associated with lipids or lipoproteins can be 
considered an apolipoprotein. First attempts to identify the protein companions of lipids began in the 1960s 
by Fredrickson (1967). The subsequent 1970s revealed the existence of at least four classes of 
apolipoproteins, now referred as “classical apolipoproteins.” These classifications are discussed below.  
 
Lipids encompass a group of hydrophobic (water-fearing) molecules necessary for bodily function: for 
energy, for the synthesis of hormones, for cell membranes, etc. However, an imbalance of lipids can result 
in cardiovascular or metabolic disease. The bulk of lipids comprise the fats, also known as triglycerides 
(TG). Lipids also include phospholipids, sterols (cholesterol and plant sterols), and water insoluble 
vitamins. Because lipids are not soluble in aqueous solutions, such as plasma or other bodily fluids, special 
transport vehicles are needed to stabilize and transport lipids in the bloodstream and throughout the body. 
These vehicles are lipoproteins, which consist of a surface monolayer made of phospholipids, free 
cholesterol, and apolipoproteins encapsulating a hydrophobic core of non-polar lipids, mainly triglycerides 
and esterified cholesterol.  
 
The mere notion of a fat transport system was conceived nearly 400 years ago; it was Asellius in 1622 who 
first noticed a milky appearance in the intestinal lymphatics (lacteals) after a meal. Pecquet in 1650 
connected these lymphatic vessels to the veins of the neck (subclavian). Boyle in 1665 showed that the 
white appearance in the intestinal lacteals made the blood serum milky. In 1774, Hewson postulated that 
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this milky fluid contained fat: upon paper it left a grease mark; under the microscope it showed many 
particles. It wasn’t until probably the 1800s when the concept of lipoproteins emerged. Inspired by the 
works of Hewson, Gulliver noted in special papers that the particles in the lacteal fluid and serum formed 
“the molecular basis of chyle.”  In 1877, Edwards observed the milky blood serum under a dark-field 
microscope and described the particles as “motes in a sunbeam.”  
 
A fundamental question arose: “What is the nature of the fine particles which give the milky appearance to 
the chyle and to the blood serum?”  
 
These fascinating first accounts of intestinal fat absorption can be read in Gage’s text (Gage 1882) which 
is easily found online. A description of the lacteal architecture and its relevance to fat absorption is given 
in Chapter 3.  
 
Lipoproteins are classified according to their relative density: chylomicrons, very-low-density lipoproteins 
(VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and high-density 
lipoproteins (HDL). This dissertation examines mainly the chylomicron, which carries dietary fats and 
cholesterol from the small intestine to the rest of the body. The term chylomicron was officially introduced 
by Gage in 1920, referring to mostly 0.5 to 1 µm diameter particles in the intestinal lacteal and plasma after 
a fatty meal (Gage 1920). Before the term chylomicron, fat particles had various names: fat dust, blood 
dust, or hemokonia. “Chylomicron” was informative because it indicated the origin and size of the particles. 
A detailed report of the nature of these particles were published by Gage and Fish in 1924 (Gage and Fish 
1924). Chylomicrons are synthesized only in the small intestine and are the largest of all lipoproteins. The 
size of a chylomicron ranges between 2000 to over 6000 Å for humans (Haberbosch 1982) whereas the size 
of the largest liver-made lipoprotein, the VLDL, is 600 Å. How lipids assemble into chylomicrons is 
detailed in Chapter 3.  
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Apolipoproteins control the fate of lipoproteins through interactions with receptors, enzymes, or other lipid 
transport proteins. The four main classes of apolipoproteins are: the A-apolipoproteins associated primarily 
with the α-lipoproteins (HDL); the B-apolipoproteins associated with β-lipoproteins and chylomicrons; the 
C-apolipoproteins associated with all lipoproteins except LDL; and the E-apolipoproteins associated with 
VLDL, IDL and HDL. Apolipoproteins can be either nonexchangeable or exchangeable. ApoB-100 
(present on VLDL, IDL, and LDL) and apoB-48 (present on chylomicrons) are nonexchangeable 
apolipoproteins. The others, such as apoA-I, apoA-II, apoE, and apoCs, are exchangeable and are found on 
all lipoprotein classes. In this dissertation, we will examine a relatively newly discovered apolipoprotein, 
apoA-V, which was discovered by two independent investigators in 2001. While apoA-V shares many 
structural and functional features with the other apolipoproteins, the investigations presented in this 
dissertation reveal apoA-V to be quite atypical. A background and current literature on this fascinating 
apolipoprotein are given in the remaining sections of this chapter.  
 
1.2 Apolipoprotein A-V: A Historical Perspective  
 
ApoA-V was discovered a few decades after the discoveries of the classical apolipoproteins: in 2001 by 
two independent groups (Pennacchio 2001; van der Vliet 2001). The two reports were published within a 
month of each other. Following 2001, studies aimed at elucidating the mechanisms of apoA-V dramatically 
increased, which are detailed in several reviews (Forte 2008, Merkel 2011, Garelnabi 2013). This section 
briefly reviews the history of the two discoveries to provide the reader insight into the unique properties 
of apoA-V. 
 
ApoA-V in Mice and Men 
One group, Pennacchio and colleagues, were interested in discovering new functional genes around the 
gene cluster APOAI/CIII/AIV, a region well known to influence lipid metabolism. Upon comparing the 
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human and mouse gene sequence, they discovered a conserved region about 30 kbp proximal to the gene 
cluster that contained a putative apolipoprotein-like gene (now known as apoA-V) (Pennacchio 2001). 
Further analyses of the gene revealed a strong similarity to the mouse apoA-IV gene. Its encoded protein 
was predicted to have several amphipathic helices and an N-terminal signal peptide, both characteristic of 
a lipid-binding apolipoprotein. The gene was expressed in the liver and not in other tissues they examined 
(heart, brain, spleen, lung, skeletal muscle, kidney, and testis in mouse; heart, brain, placenta, lung, skeletal 
muscle, kidney, and pancreas in human). More details regarding the gene and protein in the mouse are 
described in Table 1.  
 
TABLE 1: Gene and protein characteristics of the mouse, rat, and human apoA-V.  
 
 Mouse Rat Human 
GENE    
Tissue 
expression Liver Liver Liver 
cDNA 
1.3, 1.9 kbp 
(likely from alternative 
polyadenylation) 
1282 bp, 1834 bp 
(identical, except the latter has 
additional 522 bp at -3’ end) 
 
Sequence 
homology 
~90% to rat 
~70% to human 
~24-28% to apoA-IV 
~90% to mouse 
~80% to human 
20-28% to apoA-I & apoA-IV 
~70% to mouse 
~80% to rat 
Exon/Intron 
organization 4 exons 
3 exons: 58, 111, 1137/1679 bp 
2 introns: 112, 517 bp  
PROTEIN    
Amino acids 383 bp 367 bp 363 bp 
Structure Several α-helical domains 60% overall α-helical content 
Less α-helical 
content than rat 
Cleavable 
Signal Peptide First 20 amino acids First 20 amino acids First 23 amino acids 
Predicted MW 41 kDa 41 kDa (precursor) 39 kDa (mature) 40 kDa 
Plasma 
concentration 24 ng/ml 1 ug/ml 24–406 ng/ml 
Presence on 
lipoproteins HDL, VLDL Large HDL, not LDL or VLDL 
HDL, VLDL, plasma 
chylomicrons 
Adapted from Refs: Pennacchio 2001, Van der Vliet 2001, O’Brien 2004, Beckstead 2003, Vaessen 2009 
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To determine if apoA-V had physiologic function, they generated mice that overexpressed human apoA-
V (transgenic) or lacked endogenous apoA-V (knockout, KO). Comparing fasting plasma TG levels of the 
mice to wild type (WT) mice, they observed dramatic results: the transgenic mice had plasma TG levels 
only one-third of WT, and the KO mice had plasma TG levels four times greater than WT. This suggested 
a dramatic inverse relationship between apoA-V expression and plasma TG levels. Additionally, these 
effects were not entirely explained by compensatory expression of apoC-III, which existed on the same 
gene cluster and, in contrast, had a positive relationship between its expression and plasma TG levels (Chan 
2008). Groups in later years explored the relationship between apoA-V, apoC-III, and plasma TG levels 
and agreed to an independent effect of apoA-V (Fruchart Najib 2004; Baroukh, etc). The mechanisms of 
apoA-V are discussed in the following section (1.3).  
 
Pennacchio and colleagues further explored the presence of apoA-V mutations in humans. They identified 
four single nucleotide polymorphisms (SNPs) across the APOA5 gene locus. Four apoA-V SNPs were 
identified to have relatively high frequencies of the minor allele (>8%) in 500 unrelated Caucasians. Three 
SNPs were significantly associated and defined the haplotype APOA5*2, consisting of polymorphisms 
c.1259T>C, IVS3+476G>A and -1131T>C. Independent analyses of each SNP revealed a strong 
association with elevated (20-30%) plasma TG levels. In 2002, Pennacchio and colleagues described a third 
haplotype (APOA5*3), which contained SNP c.56C>G and was independently associated with high plasma 
TG levels in three different ethnic populations (Pennacchio 2002). APOA5*1 (representing the major 
allele), APOA5*2, and APOA5*3 comprised 98% of APOA5 haplotypes in the Caucasian population 
(Berkeley Lipid Study Population). APOA5*2 and APOA5*3 haplotypes were found in 25-50% of African-
Americans, Hispanics, and Caucasians, indicating that the APOA5 locus contributed significantly to inter-
individual variation in plasma TG levels in humans.  
 
 
 
6 
 
ApoA-V in Rat and Liver Regeneration  
The other group that discovered apoA-V in 2001 was van der Vliet and colleagues and had a very different 
intent: to identify novel factors upregulated during early liver regeneration. The liver has a unique capacity 
to regenerate itself after damage or loss of cell mass. One to four hours after partial hepatectomy (PHx), a 
surgical model for liver regeneration, the remaining hepatic cells re-enter the cell cycle by transitioning 
from a quiescent G0 phase to G1 phase. DNA synthesis starts 12-16 h and peaks 22-24 h after PHx. The 
liver can regain its original mass within 7 days. While many genes are essential for the early phase of gene 
activation, van der Vliet and colleagues thought that the delayed phase response was also necessary. To 
identify novel delayed phase factors, they characterized gene expression profiles in rat livers 6 h after PHx. 
Compared to rat livers from sham surgery, they found a novel gene that was appreciably upregulated 3-12 
h (peaked at 6 h) after PHx (Van der Vliet 2001) and is now known as apoA-V. Plasma apoA-V protein 
levels also peaked at 6 h but decreased thereafter and normalized rapidly. The fact that apoA-V mRNA 
and protein levels were constant after sham surgery indicated that the increase in apoA-V was likely not 
an acute phase response and was specific to liver regeneration.  
 
Similar to the report by Pennacchio and colleagues in the mouse, they found that apoA-V was expressed 
only in the liver and in no other tissues examined (skeletal muscle, spleen, kidney, heart, brain, lung in rat; 
brain, heart, skeletal muscle, colon, thymus, spleen, kidney, small intestine, placenta, lung, leukocytes in 
human). In the liver, apoA-V was expressed only in hepatocytes, and interestingly, the expression of apoA-
V increased in the periportal but not in the pericentral areas of the hepatic acinus after PHx. More details 
regarding the gene and protein in the rat are described in Table 1.  
 
Van der Vliet and colleagues did not further report on the role of apoA-V in liver regeneration but they 
made some interesting speculations. Because of its proximity to the gene cluster APOAI/CIII/AIV, they 
speculated that apoA-V might be involved in lipid transport, such as uptake of lipids by the liver to 
regenerate cell membranes. However, since apoA-V in the plasma peaked at 6 h after PHx and cell mitosis 
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occurred 20 h later, they reasoned that the timing mismatch made the notion unlikely. Therefore, they 
speculated that apoA-V might be an early signal released by the liver to protect against a lipid overload 
during the stages of early liver regeneration when liver function is compromised. Although this dissertation 
does not examine liver regeneration, it supports the notion that apoA-V acts as a signal released by the 
liver to antagonize lipid uptake, making apoA-V a “gut-liver signal protein.” 
 
1.3 Current Mechanisms of Action 
 
Several authors have described apoA-V as “a potent triglyceride reducer” (Nilsson 2011) or having “low 
concentration, high impact” (Rensen 2015). These descriptions are quite warranted with the plasma 
concentration of apoA-V being 1,000 x lower than apoB and 10,000 x lower than apoA-I (on a molar 
basis). In fact, its low concentration in the plasma may have contributed to its elusiveness from discovery. 
Its low concentration has also stimulated wonder as to how apoA-V might physically interact with 
lipoproteins or enzymes in the plasma. Currently, the mechanisms are thought to be extracellular (occurring 
in the plasma) or intracellular (occurring within the hepatocyte) and are briefly discussed below. 
 
Extracellular mechanisms  
Much evidence supports the notion that apoA-V enhances lipolysis of TG-rich lipoproteins by interacting 
with lipoprotein lipase (LPL) and other factors. Within the protein structure of apoA-V (FIGURE 1) lies 
a segment of positive-charged amino acids that interacts with heparin (Lookene 2005; Nilsson 2007), 
heparin sulfate proteoglycans (HSPGs) (Merkel 2005), and glycosylphosphatidylinositol high-density 
lipoprotein binding protein 1 (GPIHBP1) (Gin 2008). ApoA-V interacts with HSPG (Merkel 2005) and 
GPIHBP1 (Gin 2007), which are both present on the endothelial cell surface of the capillary lumen, to 
enhance LPL-mediated lipolysis. However, apoA-V cannot increase lipolysis without LPL, as its 
enhancement is abolished by blocking LPL activity with the inhibitor tetrahydrolipstatin (Merkel 2005). 
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GPIHBP1 is another key player in lipolysis and its deficiency in mice results in plasma TG levels as high 
as 5000 mg/dl (even on a low-fat diet) (Beigneux 2007)! The ability of apoA-V to enhance lipolysis 
requires the activity of GPIHBP1, as injecting exogenous apoA-V into GPIHBP1 KO mice failed to reduce 
plasma TG levels (Shu 2010). What is unclear is how apoA-V enhances lipolysis to dramatically alter 
plasma TG with its low plasma concentration and relatively short half-life (~2 h when recombinant apoA-
V is injected intravenously) (Shu 2010). It is speculated that as apoA-V is cleared from the plasma, it is 
replenished by newly secreted apoA-V from the liver, but these kinetics remain to be investigated.  
 
ApoA-V is also thought to enhance the hepatic uptake of remnant particles by interacting with the LDL 
receptor (LDLR) family (Nilsson 2007; Dichlberger 2007). Indeed, VLDL isolated from apoA-V KO mice 
have a lower affinity for LDLR (Grosskopf 2005). ApoA-V also interacts with the mosaic type I receptor 
SorLA (Nilsson 2007), which contains domains characteristic of members of the LDLR family (Gliemann 
2004). ApoA-V was found to be endocytosed by enterocytes through binding to low-density lipoprotein 
receptor related protein 1 (LRP1) (Zheng 2012). Whether apoA-V binds to VLDLR, another member of 
the LDLR family that is expressed in adipocytes, has yet to be studied. ApoA-V is also recently discovered 
to lower food intake after intra-ventricular injection in mice (van den Berg 2013), demonstrating a novel 
role of apoA-V in energy homeostasis through a central mechanism. Whether apoA-V is expressed and the 
identity of its receptor in the brain remain unknown.  
FIGURE 1. Protein structure of apoA-V. Adapted from Refs. Sun 2006 & Nilsson 2011.  
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Intracellular mechanisms 
While considerable evidence supports a role for apoA-V in regulating extracellular TG levels through 
enhanced lipolysis and clearance of lipoprotein remnants, its role in regulating intracellular TG metabolism 
is not as clear. ApoA-V has been proposed to inhibit the hepatic secretion of TG-rich lipoproteins, which 
was demonstrated by Schaap and colleagues (Schaap 2004). The authors observed that adenovirus-
mediated overexpression of apoA-V in C57Bl/6 mice decreased the hepatic secretion of VLDL-TG, 
resulting in smaller VLDL particles but an unchanged number of particles (measured by apoB) when 
compared with Ad-LacZ as the control. This suggested that apoA-V regulated intracellular lipid accrual 
on nascent VLDL particles by impairing lipidation. However, these data were not confirmed by other 
investigators, including us, who observed no effect on VLDL-TG secretion in studies using apoA-V 
transgenic mice (Merkel 2005; Fruchart-Najib 2004) or apoA-V KO mice (Grosskopf 2005; FIGURE 2). 
Transient apoA-V overexpression in Hep3B cells showed no effect on apoB100 particle secretion or 
lipidation state (Shu 2007), supporting the observations described above.  Additionally, apoA-V was not 
associated with apoB in the cell lysates but was associated with VLDL isolated from the culture medium, 
suggesting that apoA-V was not associated to the nascent lipoprotein but bound to VLDL after secretion 
(Shu 2007). 
 
FIGURE 2. Fasting hepatic secretion of TG and cholesterol accumulation in plasma were the same 
in apoA-V KO and WT mice. After an overnight fast, mice were injected with Poloxamer 407 at 1 
mg/kg ip. Tail vein blood was drawn hourly into heparin capillary tubes. (A) Plasma TG and (B) 
cholesterol were determined by chemical assay. Values are means ± SEM.  
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On the other hand, apoA-V was found associated with hepatic lipid droplets following transient 
transfection in Hep3B cells (Shu 2007). Studies using a different hepatocyte line, McARH7777 cells, 
showed that transfected apoA-V colocalized with adipocyte differentiation-related protein (ADRP), a 
marker specific for lipid droplets (Shu 2008). The C-terminus of apoA-V possesses a helix bundle motif 
that is required for lipid binding (Weinberg 2003) and can potentially bind the surface of lipid droplets; 
indeed when truncated, apoA-V no longer bound to lipid droplets (Shu 2008). In addition, in transiently 
transfected McA-RH7777 cells, oleic acid was found to increase intracellular apoA-V and coincided with 
increased TG associated with lipid droplets (Blade 2011). Induction of apoA-V expression using a 
doxycycline (Dox) inducible promoter resulted in an accumulation of intracellular TG and a reduction of 
TG secretion in a dose-dependent manner (Blade 2011), supporting the notion that apoA-V drives retention 
of TG within the cell.  
 
One might ask: how can apoA-V associate with cytoplasmic lipid droplets when it is synthesized with an 
N-terminal signal sequence (Pennacchio 2001; van der Vliet 2001) that predestines the protein for secretion 
from cells?  An excellent discussion can be found in the review by Sharma, Ryan, and Forte (Sharma 
2013). The strong lipid-binding properties and the spatial location of apoA-V within the cell might 
predispose the protein to associate with lipid droplets. As nascent lipid droplets grow in size within the 
phospholipid bilayer of the ER and bulge into the cytosol, apoA-V may localize to the phospholipid 
membrane that coats the lipid droplets as they expand. Interestingly, without the signal peptide, such as in 
Hep3B cells transfected with a signal peptide-deficient apoA-V protein, significant morphological changes 
occur within the cell, replacing cytoplasmic lipid droplets with “amorphous lipid-staining entities” (Shu 
2008). Further, there is evidence that other proteins synthesized with a signal sequence are retained within 
the cell. ApoO, which possesses a signal sequence, associates with lipid droplets in cardiomyocytes 
(Lamant 2006). Taken together, a balance must be maintained between intracellular and extracellular 
trafficking of apoA-V to avoid the conundrum where apoA-V can lower plasma TG (and lower 
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cardiovascular risk) but consequently accumulate lipid droplets in the liver and create risk for fatty liver 
disease. The role of apoA-V in the development of disease will be discussed in the following section.  
 
1.4 Role of ApoA-V in Diseases  
 
Obesity  
Obesity is defined as having a body mass index (BMI) greater than 30 kg/m2. Significant evidence show 
an association between certain APOA5 SNPs with increased BMI and obesity. The most commonly 
reported APOA5 SNP associated with obesity is the -1131T>C polymorphism and shows significant 
association in both adults (Niculescu 2007) and children (Horvatovich 2011).  
 
Interestingly, dietary fat intake was shown to modulate the effect of the -1131T>C polymorphism on lipid 
parameters, BMI, and risk for obesity. Aberle and colleagues examined the effect of short-term dietary 
intervention (fat restriction) on lipid levels and BMI in WT and carriers of the -1131 T>C polymorphism 
in a total of 606 hyperlipemic and overweight men. Interestingly, after 3 months of fat restriction, BMI 
was reduced in both groups but was significantly greater in carriers of the C minor allele (Aberle 2005), 
suggesting that dietary fat intervention could be an important therapeutic approach to lessen the allele-
associated risk of coronary heart disease. Another study by Corella and colleagues found that when fat 
intake was >30% of energy, the -1131T homozygotes had a 3-fold higher risk of obesity compared with 
wild type (Corella 2007), supporting the association of -1131T>C on diet-induced obesity.  
 
It should be noted that not all APOA5 polymorphisms correlate with obesity. Data from the Framingham 
Study (N=2273) show a lower prevalence of obesity among carriers of the c.1259T>C allele (APOA5*5 
haplotype) (Elosua 2006). The association of various APOA5 polymorphisms with obesity is recently 
reviewed by Zheng and colleagues (Zheng 2012). The authors also found that apoA-V can be internalized 
by human adipocytes, where it localized to lipid droplets and significantly decreased cellular TG content 
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(Zheng 2012), demonstrating a role for apoA-V in protecting against obesity by limiting TG accumulation 
in the adipocyte.  
 
Non Alcoholic Fatty Liver Disease  
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver diseases, from simple steatosis 
(accumulation of lipid droplets) to non-alcoholic steatohepatitis (which is accompanied by inflammation) 
to cirrhosis, liver failure and hepatocellular carcinoma (Ong & Younossi 2007). NAFLD affects up to 30% 
of the population worldwide (Lazo 2013), a prevalence similar to that of obesity (Ng 2014). In fact, NAFLD 
is strongly associated with obesity and presents in ~90% of severely obese patients undergoing bariatric 
surgery (Machado 2006).  
 
The observations that apoA-V associates with hepatic lipid droplets and influences intracellular TG 
accumulation in vitro and in animal models (see Section 1.3) have led to examining its role in the 
development of NAFLD. Ress and colleagues were first to study this concept by analyzing hepatic apoA-
V expression levels and liver parameters in obese bariatric surgery patients with NAFLD (Ress 2011). They 
discovered that bariatric surgery improved hepatic steatosis and the improvement correlated with a 
reduction in hepatic apoA-V mRNA expression levels. They attempted to determine if the reduction of 
hepatic apoA-V caused improvement of hepatic steatosis by knocking down apoA-V using small interfering 
RNA in transfected HepG2 cells and found a subsequent reduction in intracellular TG accumulation.  
 
However, as mentioned earlier, the conundrum lies in using apoA-V to lower plasma TG (which would 
reduce atherosclerosis risk) but might subsequently drive lipid droplet assembly, induce lipotoxicity, and 
create risk for NAFLD. Right now it is still not clear whether apoA-V mediated lipid droplet assembly 
drives the development of NAFLD or whether apoA-V is merely a marker for increased TG accumulated 
in the form of lipid droplets.   
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Atherosclerosis 
Because hypertriglyceridemia and atherogenesis are strongly correlated (Talayero 2011), great interest has 
been placed on determining if apoA-V deficiency contributes to the development of atherosclerosis. 
Several studies show that the c.56C>G (S19W) SNP, which occurs in the signal peptide of apoA-V and is 
associated with elevated plasma TG (Ahituv 2007; Pennacchio 2002), correlates with various measures of 
atherosclerosis. Talmud and colleagues examined the progression of atherogenic lesion in subjects with 
this S19W polymorphism and indeed found a trend for increased atherogenesis (Talmud 2004). The 
Framingham Offspring study showed that patients who had undergone carotid ultrasound (n=2273) and 
carried the S19W polymorphism displayed a higher common carotid artery intimal medial thickness (ie 
increased atherosclerotic lesions) than WT carriers. The Lipoprotein and Coronary (LCAS) study showed 
that the S19W polymorphism was independently correlated to minimal lumen diameter of coronary 
atherosclerotic lesions and the number of coronary artery occlusions (Huang 2009). Other APOA5 
polymorphisms also have an association with development of atherosclerosis, such as the -1131T>C 
polymorphism, which correlated with increased intimal medial thickness in obese subjects even after 
adjusting for TG levels (Elosua 2006). ApoA-V was also shown to improve atherogenesis in animal studies 
using the dyslipidemic apoE2-knockin mouse, which showed that expression of human apoA-V was able 
to reduce atherosclerotic lesion formation compared with non-expressing controls (Mansouri 2008). 
 
1.5 Gap of Knowledge 
 
While these mechanisms are well supported, it should be pointed out that most studies performed in vivo 
are performed in the fasted state. During the postprandial state (after a meal), plasma TG levels increase 
dramatically (3-4 fold) as the intestine synthesizes large TG-rich chylomicron particles (incorporating 
exogenous dietary fat) and the liver synthesizes TG-rich VLDL. Postprandial TG metabolism is then 
determined by the rate of dietary fat absorption, the rate of VLDL production, and the rate and extent of 
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hydrolysis of fat and clearance of remnant particles. Up to this point, significant evidence supports the role 
of apoA-V in enhancing lipolysis and clearance, although it is unclear how apoA-V with its low plasma 
concentration can enhance these processes in the postprandial state where the plasma is overwhelmed by 
TG-rich lipoproteins. The next chapter examines evidence supporting an alternative role of apoA-V in 
postprandial metabolism and addresses the gap of knowledge: does apoA-V have a role in the gut?   
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2. AIMS OF THE CURRENT INVESTIGATIONS 
 
Because apoA-V exists in low concentration in the plasma, the mechanisms by which it enhances the 
metabolism of TG-rich lipoproteins is unclear, particularly in the postprandial (after a meal) state where 
plasma TG levels are very high. Under postprandial conditions, we propose an additional mechanism by 
which apoA-V regulates the metabolism of TG-rich lipoproteins. The central hypothesis is that apoA-V 
plays a role in the gut by modulating the production of chylomicrons, thus acting as a signal from the liver 
to the gut to regulate the flux of TG-rich lipoproteins into the circulation. The aims were: 
 
1. To test the hypothesis that apoA-V deficiency increases the transport of dietary lipids and its 
subsequent formation and secretion of chylomicrons into the lymph. While previous studies attribute 
the ability of apoA-V to reduce the postprandial surge of plasma TG to enhanced lipolysis, they do not 
examine the physiologic role of apoA-V in modulating the absorption of dietary lipids, based on the 
assumption that apoA-V is not synthesized in the gut. We examined this important aspect of postprandial 
lipoprotein metabolism by using the conscious lymph fistula model to study dietary lipid transport in apoA-
V KO and WT mice. The model allowed us to determine the rate-limiting step of the absorptive process: 
lipid uptake, mucosal assimilation, or secretion into lymph. Additional factors were determined, such as 
chylomicron production time, the intestinal secretion of apolipoproteins into lymph (such as apoB, to 
measure chylomicron particle number), and chylomicron particle size. Paper I describes our important 
findings that indeed, apoA-V deficiency results in enhanced uptake and secretion of dietary lipids into 
lymph which correlates with a greater production of chylomicron particles.  
 
2. To examine one potential route of liver-gut signaling: is apoA-V present in bile? If present, is its 
secretion into bile regulated by various physiological factors such as dietary lipid?  Bile contains many 
components that affect lipid absorption, such as bile salts and phospholipids. Because other apolipoproteins 
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were previously found in bile, namely, apoA-I, apoA-II, apoB, and apoE, we wondered if apoA-V was also 
present in bile. We used the conscious bile fistula rat model to collect hepatic bile. With the discovery of 
apoA-V in bile, we next determined if its biliary secretion was regulated by dietary lipid. Paper II describes 
our important findings that apoA-V is indeed present in bile and that its secretion into bile is upregulated 
in response to active chylomicron production. Additionally, we found that the secretion of apoA-V into bile 
steadily increased within the first day of bile cannulation surgery, suggesting that regulation of bile drainage 
on apoA-V secretion. Paper II also describes our findings that the increased secretion of apoA-V into bile 
after surgery is independent of of luminal phosphatidylcholine and taurocholate. 
 
3. To determine if apoA-V previously found on plasma chylomicron remnants originate from 
mesenteric lymph. Since apoA-V is an exchangeable apolipoprotein (Fruchart-Najib 2004), the apoA-V 
on plasma chylomicron remnants may come from other plasma lipoproteins, such as HDL. Unknown is 
whether the apoA-V on remnants originate from chylomicrons secreted by the small intestine. Using the 
conscious lymph fistula model and Sprague-Dawley rats, the presence of apoA-V in lymph was assayed by 
Western blotting analysis under fasting and postprandial conditions. Paper III describes our findings that 
apoA-V is indeed present in lymph, specifically associated with chylomicrons, mostly during active fat 
absorption. With the findings that apoA-V is present in both bile and lymph, the studies in Paper III also 
examine the notion that biliary apoA-V may be transported across the enterocyte into lymph.  
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3. ApoA-V and Postprandial Lipid Metabolism 
 
3.1 Postprandial Lipid Metabolism and Disease 
 
The relationship between plasma lipid levels and risk for cardiovascular disease is often based on 
measurements made in the fasted state. While these measures are traditionally used in the clinic, the fasted 
state is not typical of the modern human who eats several meals a day and spends a majority of time in the 
postprandial state. Therefore, assessing the ability of the individual to metabolize lipids in the postprandial 
state may be more relevant in assessing risk for cardiovascular disease (Kannel & Vasen 2009; Lambert & 
Parks 2012).  
 
It was Zilversmit in 1972 who presented the idea that TG-rich lipoprotein particles in the blood resulting 
from a meal were atherogenic (Zilversmit 1972). Since then, accumulating epidemiological and 
experimental evidence support the notion that elevated postprandial TG level is a significant independent 
risk factor for cardiovascular disease (Le 2007; Bansal 2007; Nordestgaard 2007).  
 
Postprandial TG response is defined by the extent and duration of the increase in plasma TG in response to 
a meal. The ability of the individual to respond to dietary fat is a measure of his/her homeostatic control, 
which is affected by various genetic and environmental factors (Perez-Martinez 2008). The fundamental 
determinants of postprandial TG response are: the rate of absorption of dietary lipid by the gut, the rate of 
production of TG-rich lipoproteins by the liver, the rate and extent of hydrolysis of TG-rich lipoproteins in 
the plasma, and the uptake of remnant particles by the liver. A defect in any one of these processes can 
result in an excess of TG in the plasma or hypertriglyceridemia.  
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While healthy lifestyle choices are recommended to control environmental factors, elucidating underlying 
genetic factors that affect the individual postprandial TG response is critical. ApoA-V is one gene found to 
strongly affect fasting plasma TG levels with apoA-V SNPs correlating with hypertriglyceridemia in 
multiple populations (Chapter 1). This chapter will explore the effect of apoA-V deficiency on postprandial 
lipid metabolism, which is the crux of the present dissertation. Knowledge of how apoA-V, as well as other 
genes, influence postprandial response would enhance understanding of genetic risk factors and improve 
the development of personalized nutrition or pharmacologic intervention to reduce postprandial lipid 
responses. The present dissertation will focus on one pillar of postprandial lipid metabolism: dietary lipid 
absorption.  
 
3.2 Fat Absorption  
 
The small intestine is the primary site of lipid absorption, with the enterocyte being the absorptive cell. As 
prefaced in Chapter 1, the bulk of dietary lipid is neutral fat, or TG. The diet also contains phospholipids, 
sterols (cholesterol and plant sterols), and minor lipids such as fat-soluble vitamins. In addition to dietary 
lipids, the small intestinal lumen also sees endogenous lipids (made by the body) derived from sloughed 
epithelial cells and bile, such as cholesterol and phospholipids. The process of fat absorption is elegantly 
reviewed (Williams 2008; Ji 2009) and will be briefly described below.  
 
While the process of fat digestion begins in the stomach, where lipases found in saliva and gastric juice 
digest some dietary TG, the bulk of digestion occurs in the small intestine. The two key digestive events 
are hydrolysis of TGs into digestion products and solubilization of the digestion products into micelles. 
Lipases secreted by the pancreas hydrolyze TG at positions 1 and 3, yielding 2-monoglycerides and two 
free fatty acids (FAs). Also secreted into the lumen are bile salts, which play key roles in emulsifying the 
lipids and facilitating digestion by pancreatic lipase. Once liberated by hydrolysis, the 2-monoglycerides 
and FAs associate with bile acids and other lipids (such as phospholipids (PL)) to form lipid micelles 
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(Hofmann & Borgstrom 1964), which are essentially small amphipathic aggregates that are soluble in water. 
Micelles are crucial for absorption because they can solubilize hydrophobic lipids and carry them across 
the unstirred water layer (UWL) that lines the brush border membrane of the enterocyte.  
 
The concept of the UWL was originally developed by Noyes and Whitney in 1897, further explored by 
Nernst in 1904 and extended by Teorell in 1936, Dainty, House, Ginzburg and Kalchalsky in 1963 (quoted 
by Thomson & Dietschy 1984). These investigators called attention to the significance of the UWL that 
bordered the surface of biological interfaces in absorption. The fluid in this layer, although unstirred, is not 
stationary; it is rather of a slow laminar flow by which the only mechanism of transport is diffusion. The 
thickness is not a real thickness but an operational value. The UWL mixes poorly with the bulk fluid phase 
and forms an acidic microclimate with intestinal mucus that forms in this layer. It is believed that the Na+/H+ 
and Cl-/HCO3- exchange transporters on the apical surface of enterocytes contribute to this acidic 
microclimate (Thomson 1993). Solute molecules in the intestinal lumen must cross the UWL to gain access 
to the brush border membrane, thus making the UWL a major diffusional barrier of lipids and hydrophobic 
molecules. So FA, MG, and other hydrophobic molecules diffuse very slowly across the UWL. However, 
micellar solubilization of the lipids greatly enhances their solubility (Westergaard & Dietschy 1976) and 
transport across the UWL despite slower diffusion rates (resulting from the larger size of the micelle 
compared with a single molecule) simply due to the mass transport.  
 
Once across, the micelles can present the lipids to the enterocyte for uptake. Micelles themselves are not 
believed to be absorbed intact by the brush border (Simmonds 1972; Hoffman 1970).  Because of the low 
pH at the surface of the enterocyte, FAs are protonated before dissociating from the micelles (Shiau 1985) 
and diffusing across the membrane into the cell. Although most MGs and FAs enter the enterocytes by 
simple diffusion (Green & Wiley 1981; Ling 1989; Schulthess 1994), cholesterol (Davis & Altmann 2009) 
and a considerable fraction of FAs enter through specific transporters (Altmann 2004; Stremmel 1988; Goré 
1994, Stahl 1999).  
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Phospholipids (predominantly phosphatidylcholine (PC)), which are the second most abundant lipid in the 
intestinal lumen after TG, are also almost completely absorbed (>90%). Phospholipids are digested in the 
small intestine (since lingual and gastric lipases cannot hydrolyze PC) which is carried out primarily by 
pancreatic phospholipase A2 (PLA2). In the presence of bile salts, PLA2 interacts with PL at the sn-2 
position to yield free FA and lysoPC. These components, in addition to the fat digestion products, are taken 
up by mucosal cells (Arnesjo 1969).  
 
Following uptake, lysoPC has several fates within the cell: 1) re-esterification with FA to form PC, which 
provides the surface coat for nascent chylomicrons and for generation of cell membranes (Scow 1967; 
Mansbach 1977), 2) complete hydrolysis to release FA for TG synthesis (Shrivastava 1967; Baxter 1966; 
Ockner 1969), or 3) direct absorption into the portal circulation (Boucrat 1972). MG and FA are transported 
into the endoplasmic reticulum (ER) where they are resynthesized into TG. The majority of FAs are 
synthesized into TG via the monoacylglycerol pathway, but some go through the phosphatidic acid pathway 
(Mansbach 1982). In the presence of dietary fat, the monoacylglycerol pathway accounts for the bulk of 
TG synthesis (~70%) using 2-monoglycerides and free FAs as substrates. However, the phosphatidic acid 
pathway becomes the primary pathway for TG synthesis if 2-monoglycerides and FAs are absent. Along 
the ER and Golgi, the TGs are then packaged with esterified cholesterol, phospholipids, and apolipoproteins 
into particles called chylomicrons. The newly formed chylomicrons then exit the basolateral side of the 
enterocyte (Tso & Balint 1986) to enter the lymphatic system.  
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Instead of transport into blood circulation like other 
macronutrients such as amino acids and sugars, 
chylomicrons are carried into the lymphatics before 
entering the blood circulation. Chylomicrons are very 
large particles (>200 nm), and are too large to enter the 
“pores” of blood capillaries (~5 nm for mesenteric 
capillaries) (Sarin 2010). Every intestinal villus contains a 
blunt end of a lymphatic vessel called a lacteal (FIGURE 
3), which has fenestrated junctions that allow 
chylomicrons to enter more easily. While the general 
consensus is that the particles enter through lacteal 
junctions by paracellular transport (Casley-Smith 1962, 
Dixon 2010), some studies suggest that entry might be 
partially mediated by vesicular transport (Dobbins III 
1971). The chylomicrons are transported from the lacteal 
to the intestinal (mesenteric) lymphatic vessel, which 
merges with the thoracic duct (drains lymph from the liver 
and kidneys), pools into the cisternae chyli, and ultimately drains into general circulation via the subclavian 
vein. Once in circulation, the chylomicrons deliver the lipids to peripheral tissues by lipolysis of their TG-
cores before their remnants are taken up by the liver.  
 
3.3 Lymph Fistula Animal Model (versus other models) 
 
This dissertation is largely based on results that have been collected using the lymph fistula model, which 
is briefly described below. However, it is not the aim to cover the details but to merely highlight the 
FIGURE 3. Architecture of the intestinal 
villus. Each villus contains a lacteal surrounded 
by a blood capillary network. The epithelium 
consists of absorptive cells (enterocytes), goblet 
cells, and enteroendocrine cells.  
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important features including advantages and limitations of the model. For a technical guide of the lymph 
fistula surgeries and considerations in experimental design, please see an excellent reference by Kohan and 
colleagues (Kohan, Howles & Tso 2012). 
 
The conscious lymph fistula model is an established model used to study the digestion, uptake, and 
lymphatic transport of lipids. This model involves a steady infusion of lipid by way of an intraduodenal 
cannula. A continuous infusion at a constant rate allows analysis to be performed in the steady state although 
a bolus dose of lipid can also be infused. The amount of lipid infused over a typical 6 h study is equivalent 
to the total amount of lipid typically consumed in a day. Although the cannula bypasses the stomach, the 
maximum absorption rate of the intestine is similar to the rate at which fat leaves the stomach if lipid was 
administered intragastrically (Bennett & Simmonds 1961). 
 
The lipid infusate usually contains radiolabeled lipid (such as 3H-TG or 14C-cholesterol) for tracking of the 
lipid from the intestinal lumen to lymph. Also in the infusate are PC and taurocholate to ensure 
solubilization, digestion, and lymphatic transport of the lipid. Steady state is achieved after ~3-4 h of 
infusion. The model allows collection of lymph every hour, so it is possible to determine the transport 
profile of lipids into the lymph. By comparing the lymphatic output of lipids with infused lipids, absorption 
can be measured. Additionally, if a radiolabeled-FA 
(such as 14C-oleic acid) is infused, it is possible to 
measure the time it takes for FA to be synthesized 
into a TG in the enterocyte, packaged into 
chylomicrons, and transported to lymph (FIGURE 
4). Finally, analysis of the radiolabel remaining in 
the lumen, mucosa, and lymph at the end of 6 h 
period (when transport has achieved steady state) 
FIGURE 4. A schematic of measuring 
chylomicron appearance time. This represents the 
time for 14C-oleic acid to be taken up the enterocyte, 
resynthesized as TG, packaged, and secreted as 
chylomicrons. 
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can give information regarding the uptake, mucosal retention, and transport of lipids into lymph. 
 
The conscious lymph fistula model has a number of advantages. The animals are studied in a conscious 
state, thereby devoid of anesthesia, which was previously found to suppress lymph flow and chylomicron 
production. The model allows for continuous sampling of lymph during the course of the experiment. 
Chylomicron particles are well preserved in whole lymph versus chylomicrons collected from plasma, 
which are rapidly metabolized and become remnants, and reflect what is newly secreted by the intestine. 
Steady infusion of lipid intraduodenally allows investigators to measure lipid absorption rates, not just total 
absorption.  
 
A strength in the lymph fistula in vivo model lies in its ability to investigate assembly and secretion of 
lipoprotein particles. While in vitro models are sometimes used to study uptake and metabolism of lipid, 
they are inadequate to study lipid secretion under physiologic conditions. A few common in vitro models 
are discussed below: 
 
Everted sacs 
The everted gut sac model was introduced in 1954 by Wilson and Wiseman (Wilson and Wiseman 1954). 
Since then, improvements have been made to increase the viability of tissues and to maintain an intact 
mucosal epithelium. An intestinal sac is prepared by inverting a segment of the intestine over a glass rod, 
which turns the mucosal epithelium inside out. Both ends are tied off, and the inner compartment is filled 
with buffer to create a fluid sac. The sac is placed in a beaker of a well-oxygenated solution containing the 
compound of study. Analysis of transport is determined by its retention within the tissue and its 
accumulation in the inner compartment. 
 
The advantages of the model include 1) the relatively large surface area available for absorption and the 
presence of a mucous layer, and 2) the ability to investigate the differences along the length of the GI tract. 
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However, the model has several limitations. One is tissue viability: the recommended time to measure the 
metabolic activity of the intestine under physiological conditions is approximately 2 h. Another limitation 
is the isolation of the absorptive cells from the intestinal blood supply, as blood flow rate is a variable in 
the absorption of substances of high absorbability (Winne 1980).  Finally, the small volume of the inner 
compartment can cause a rapid rise in the concentration of the compound within the sac, resulting in a 
possible reverse flux and distortion of kinetics. Thus, while the everted gut sac may be a good model for 
studying the uptake of substances, it is not good for studying secretion. For an excellent reference, please 
read the review by Alam and colleagues (Alam 2012).  
 
Primary intestinal enterocytes 
A culture of primary enterocytes seems to be an ideal system to study transport of compounds across the 
intestinal epithelium, without complications of the musculature and submucosa. The process involves 
removing an intestinal segment from the animal and filling it with a physiologic buffer containing agents 
that can dissociate cells (proteolytic enzymes such as trypsin, chelating agents such as EDTA). Enterocytes 
are then released into the buffer solution.  
 
However, there are a number of limitations. Proteins in the membranes, or the cell membrane itself, can be 
damaged (Eade 1984; Kimmich 1990). Because of the large variability in the viability, cell number, or types 
of cells isolated, reproducibility is difficult to obtain. Another limitation is cell viability, as primary cell 
colonies last about 48 h when cultured on fibronectin and up to 4 days when grown on an intestinal 
biomatrix (Hahn 1987). Isolated enterocytes also do not attach to filter inserts so no monolayers can be 
obtained. Therefore, experiments must be done rapidly using freshly isolated enterocytes in suspension, 
which only allows for the study of uptake, not transport, and cannot distinguish uptake apically versus 
basolaterally. Additionally, cell-cell interaction and tight junction formation, normally key features of 
enterocytes critical for promoting the proliferation and survival of endodermal cells and other functions 
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(Louvard 1992), are lost in primary cell culture. Currently, this method is not widely used to study intestinal 
absorption.  
 
Caco-2 cells 
While primary enterocyte cell culture is not commonly used, a popular cell culture model is the use of Caco-
2 cells grown on permeable filter supports. The advantage of this model is that cultures can be controlled 
and performed in large quantities. Caco-2 cells, derived from a human colon carcinoma, spontaneously 
differentiate once confluent, forming a polarized monolayer with a well-defined brush border membrane 
and tight junctions with morphology and function that resemble enterocytes (Pinto 1983, Hidalgo 1989).  
Differentiation remains for 30 days after reaching confluence (Vachon 1992). Because of the resemblance 
to enterocytes and ability to remain in culture for a long period, Caco-2 cells make a good model to study 
intestinal lipid processing and lipoprotein secretion. 
 
It is important to point out that conditions to study transport are optimal when Caco-2 cells are cultured for 
2-4 weeks on permeable filter supports, versus plastic plates. The cell layer can form a barrier between two 
compartments (apical/mucosal versus basolateral/serosal), which allows adding a compound to one 
compartment and measuring its secretion in the other. Additionally, and very interestingly, apoB production 
is different when culturing on filter versus plastic. Caco-2 cells, when cultured on plastic plates, secrete 
only apoB100 (Lee 1988; Hughes 1988), unlike enterocytes which secrete only apoB48. When cultured on 
filter supports, they secrete more apoB48 particles than apoB100 (Traber 1987, Jiao 1990). 
 
Other limitations relate to the differences between Caco-2 cells and native intestinal cells. Although Caco-
2 cells express many known drug transporters and carrier systems of the small intestine, their expression 
level and substrate specificity are not the same as in vivo systems. They also have very tight junctions 
resulting in lower paracellular permeability and resemble more of fetal colon cells instead of intestinal cells. 
Additionally, the fatty-acid binding protein in the Caco-2 cell is of a liver type rather than an intestinal type 
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(Le Beyec 1997). Finally, the activity of monoacylphosphate acyltransferase is very low in Caco-2 cells, 
thereby leading to an almost inactive monoacylglyceride pathway for TG synthesis (Trotter 1993). Taken 
together, although Caco-2 cells are relatively easy to use, caution must be taken when extrapolating results 
to native enterocytes.  
 
3.4 Role of ApoA-V in Chylomicron Formation and Secretion 
 
While significant evidence supports the idea that apoA-V can profoundly modulate plasma TG in the fasted 
state, only three studies to our knowledge have examined the role of apoA-V in handling postprandial 
lipemia. Fruchart-Najib and colleagues observed a very small plasma TG response in mice overexpressing 
a human apoA-V transgene after an intragastric bolus of sunflower oil (plasma TG in WT peaked at ~150 
mg/dl vs transgenic ~40 mg/dl at 3 h) (Fruchart-Najib 2004). They concluded “apoA-V may reduce diet-
induced hypertriglyceridemia through an increase in dietary TG catabolism rather than inhibition of lipid 
absorption (since apoA-V is not expressed in the intestine).” Schapp and colleagues observed that 
overexpression of apoA-V in WT mice by adenoviral gene transfer dose-dependently lowered postprandial 
TG response (63, 73, 88% reduction compared with control at adenoviral-apoA-V doses of 1x108, 2.5x108, 
and 5x108 pfu) (Schapp 2004). They concluded that apoA-V overexpression resulted in a rapid clearance 
of chylomicron-TG, and “because apoA-V is not expressed by the small intestine, a direct effect of apoA-
V on intestinal lipid absorption is unlikely.”   
 
Merkel and colleagues, however, did investigate lipid absorption in apoA-V human transgenic mice and 
found no difference in the intestinal secretion of 3H-TG after an intragastric oil gavage when compared with 
WT mice (Merkel 2004), concluding that apoA-V did not play a role in lipid absorption. However, it may 
be possible that super-physiologic levels of apoA-V may not be able to further modulate absorption. 
Furthermore, delivery of lipids into the stomach instead of duodenum introduces potential variability related 
to gastric emptying.  
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The above studies stimulated a critical question that became the basis of Paper I. Is there a direct effect of 
apoA-V on the gut? We proposed that an alternative mechanism by which apoA-V regulates postprandial 
lipemia is direct action on the gut. The aim of Paper I was to determine if apoA-V plays a physiologic role 
in the absorption rate of dietary TG. Using the lymph fistula model as described earlier, we examined the 
transport of radiolabeled lipids into the lymph in apoA-V KO (loss of function) and WT control mice.  
 
The first and central finding of Paper I was that apoA-V 
deficiency in mice dramatically increased the transport of 
3H-TG (reflective of dietary TG) into the lymph. While 
lymph flow was not different between apoA-V KO and 
WT mice (Paper I, Fig. 1), the transport rate of 3H-TG 
into lymph of apoA-V KO mice was nearly double, with 
differences seen within the first hour of lipid infusion 
(Paper I, Fig. 2A). Total TG in lymph tended to be higher 
in apoA-V KO mice (FIGURE 5), which is the sum of 
exogenous + endogenous TG, and reflects the difference 
seen with the radiolabel. In addition, the transport of 14C-cholesterol (reflective of dietary cholesterol) was 
also significantly increased (Paper I, Fig. 1B), suggesting that apoA-V deficiency affected the production 
of chylomicrons, since TG and cholesterol are both packaged in chylomicrons in the enterocyte. With the 
lymph fistula model, we were able to observe these differences between apoA-V KO and WT mice in their 
transport of lipids into the lymph. With intraduodenal delivery of lipid, we avoided variability related to 
stomach emptying. These findings are first to provide evidence that apoA-V, a protein made only in the 
liver, can act on the gut to modulate absorption. 
 
FIGURE 5. ApoA-V KO mice had elevated 
lymphatic transport of total TG (which 
represents endogenous + exogenous TG) 
compared to WT mice. TG was measured by 
chemical assay. Values are means ±SEM. 
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With enhanced transport of lipid in apoA-V KO animals, is there enhanced uptake or increased rate of 
intracellular transport? We found that apoA-V KO animals had significantly less 3H-TG retained in the 
intestinal mucosa (specifically in the duodenum and jejunum, the primary sites of fat absorption (Paper I, 
Fig. 3A) and a tendency of less in the intestinal lumen (Paper I, Fig. 4B). To quantify uptake and secretion 
of lipid, we calculated the absorptive index and lymphatic transport index for TG. These indices were first 
described by Bergstedt and colleagues (Bergstedt 1990) and are important analytical tools to describe the 
ability of the intestine to take up lipid (absorptive index) and to secrete lipid into lymph, independent of the 
amount taken up (lymphatic transport index). To illustrate: if X amount of lipid is recovered from the lymph, 
then is that amount due to increased uptake and transport across the cell or merely increased secretion? We 
calculated both a higher absorptive and lymphatic transport index for TG in apoA-V KO animals (Paper I, 
Table 1), indicating more efficient uptake as well as secretion of lipid into the lymph. In other words, apoA-
V deficiency seemed to result in a rapid transport of dietary TG from the lumen into the mucosa, and from 
the mucosa into the lymph.  
 
The transport of 14C-cholesterol occurred in a similar fashion: apoA-V KO mice had a tendency for 
decreased 14C-cholesterol in the intestinal lumen and more in the lymph (Paper I, Fig. 4B). There was no 
large difference in 14C-cholesterol recovery in the intestinal mucosa between the groups (Paper I, Figs. 3B, 
4B), suggesting that either apoA-V deficiency impacts TG transport differently from cholesterol, or 
possibly, that a large intracellular cholesterol pool diluted the exogenous labeled cholesterol. Calculating 
the absorptive and lymphatic transport indices for cholesterol revealed that apoA-V KO mice had a higher 
lymphatic transport index (Paper I, Table 1), indicating more efficient secretion of cholesterol into lymph. 
Combined with the TG data, these results suggest that apoA-V KO mice are more efficient than WT mice 
at producing chylomicrons (which package dietary TG and cholesterol).  
 
When we measured chylomicron appearance time, apoA-V KO mice took a shorter time to produce 
chylomicrons (Paper I, Fig. 5). We introduced a bolus of 14C-oleic acid into the intestinal lumen at the 
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steady state of TG transport (hour 4 of the continuous lipid infusion) and measured the time for 14C to 
appear in lymph (FIGURE 4). This represented the time for the 14C-oleic acid to be taken up by the 
enterocyte, resynthesized into TG, packaged, and secreted as chylomicrons. Thus measuring radioactivity 
in the lymph is an indicator for the efficiency of chylomicron formation and secretion. Since the 14C-oleic 
acid is infused into the duodenum the same time as the infusion of TG, the majority of the fatty acid will 
be resynthesized as TG via the monoacylglycerol pathway (Mansbach 1982). Our finding that apoA-V KO 
mice took a shorter time to secrete the 14C-oleic acid provided further evidence that apoA-V deficiency 
enhances the formation and secretion of chylomicrons.  
 
Up to this point, the data suggested that chylomicron production is enhanced in the state of apoA-V 
deficiency, resulting in increased transport of TG and cholesterol into the lymph. Are these particles bigger 
or are they of increased number? To gauge particle number, we next measured the lymphatic output of 
apoB, since only one apoB protein is present on each chylomicron particle (Albers 1996). We found that 
the apoA-V KO mice had increased lymphatic output of apoB (Paper I, Figs. 6A, B) suggesting that the 
mice produced a greater number of chylomicron particles over time. This differed from WT mice (Paper 
I, Figs. 6A, B), which produced a steady output of apoB particles (which indicates that the chylomicrons 
become bigger over time to accommodate the increase in lipid (Hayashi 1990)). Although apoA-V KO 
mice produce more chylomicron particles, do they also produce chylomicrons of a bigger size? Preliminary 
studies showed largely no difference in the chylomicron particle size distribution between the two groups 
(WT 1151 ± 315 Å versus KO 1046 ± 402 Å averaging 200 particles per group (3 animals pooled per 
group)) (FIGURES 6A, B). Thus, the increase in lymphatic output of TG and cholesterol seems to be 
manifested in a greater number of chylomicron particles and not chylomicron size. Interestingly, in the 
fasted state, apoA-V KO animals appeared to be producing chylomicron particles of a bigger size range 
(FIGURE 6C). Although the reason remains unknown, the finding suggests that more endogenous TG are 
packaged into chylomicrons in apoA-V KO mice during the fasted state.  
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In summary, the work in Paper I demonstrates for the first time that apoA-V deficiency significantly 
increases the production rate of chylomicrons, manifested in a greater production of intestinal apoB48 
particles, in C57BL6/J mice.  
 
How does this apply to the human population? Do humans with apoA-V SNPs have increased dietary 
absorption rates or at least, a higher postprandial lipid excursion? There are only a few reports on the 
association between apoA-V SNPs and postprandial plasma TG response. These initial reports show Korean 
or Caucasian populations with particular apoA-V SNPs (such as -1131C>T or c.56C>G) indeed having 
higher postprandial TG excursions after a lipid meal (Jang 2004, Moreno 2006, Moreno-Luna 2007).  
 
FIGURE 6. Preliminary studies on intestinal 
lipoprotein size distribution collected from 
mesenteric lymph (A) during hour 3 of lipid 
infusion and (B) under fasting conditions in WT 
and apoA-V KO mice. (C) Representative 
electron microscope images of lymph 
lipoproteins. Fresh lymph samples were 
collected from 2-3 WT and KO animals and 
stained with 2% phosphotungstic acid (pH 6.0) 
for 5 min and examined with a transmission 
electron microscope. For distribution, 200 
particles were counted for each group.  
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Jang and colleagues determined the association of the -1131T>C polymorphism on the postprandial lipemic 
response in 158 healthy non-obese Korean subjects divided into 3 genotype groups: TT (n=85), TC (n=56), 
CC (n=17). After consumption of a mixed meal, they found that the carriers of the C allele had significantly 
greater increases in total chylomicron and VLDL-TG than did TT genotype (Jang 2004).  
 
Moreno and colleagues studied the effect of the -1131T>C polymorphism on the composition of 
postprandial TG-rich lipoproteins in normolipemic Caucasian males. Only 12 with the -1131CC/CT 
genotype and 39 with the -1131TT genotype were selected. They found that subjects with the -1131CT/CC 
genotype had a higher postprandial response of total plasma TG, large TG-rich lipoproteins, large TRL-
cholesterol, small TRL-cholesterol, and small TRL-retinol palmitate (RP) than subjects with the -1131TT 
genotype (Moreno 2006). Although there was no statistical significance between large TRL apoB48 
(8.36+9.44 for CT/CC vs 3.37+2.72 for TT) and small TRL apoB48 (6.22+8.86 for CT/CC vs 3.04+4.47 
for TT), the -1131CT/CC carriers displayed larger variability and a tendency of elevated apoB48 particles. 
RP is a marker for the TRL of intestinal origin and apoB48 indicates particle number. 
 
Moreno-Luna and colleagues explored the impact of other APOA5 haplotypes (APOA5*1, APOA5*2, 
APOA5*3) on the postprandial response of healthy Caucasian males. Eight-eight volunteers (-1131T and 
56C) APOA5*1 haplotypes, 12 with (-1131C and 56C) APOA5*2 haplotype, and nine with (-1131T and 
56G APOA5*3 haplotype) underwent a vitamin A fat loading test. They found that subjects with the 
APOA5*2 and APOA5*3 haplotypes had a higher postprandial TG response, manifested in large TRL, 
small TRL, and elevated apoB100 (Moreno-Luna 2007).  
 
Although not extensively explored in these human studies, the most probable mechanism was speculated 
to be slower TG hydrolysis or removal of remnant particles based on evidence in rodent studies. Based on 
our findings, it is possible that populations with apoA-V SNPs have a faster absorption rate of dietary TG 
and a greater production of chylomicrons, thereby introducing a greater TG-rich lipoprotein flux to the 
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circulation. Under these conditions, a lack of apoA-V in these populations would result in impaired lipolytic 
ability and clearance of high influx of TG-rich particles. Additionally, our findings show an association 
between apoA-V deficiency and a higher level of apoB48 particles, which is found burdened in 
atherosclerotic plaques (Pal 2003; Proctor 2003) and was linked to cardiovascular events (See Review by 
Tomkin 2012).  
 
Objections can be raised against studies measuring lipid absorption using the lymph fistula model since it 
involves surgery and cannulations of the duodenum and lymph duct. However, it is the only model that can 
assess the kinetics of lipid transport and the production of chylomicrons without interference from stomach 
emptying or metabolism that occurs in the plasma. Another question that might be raised is: how does total 
lipid absorption compare in apoA-V KO mice versus WT mice, which are already very efficient at 
absorbing fat even at high lipid loads (Petit 2007)?  To measure total fat absorption, one can implement a 
non-invasive method that was developed by Jandecek, Heubi & Tso (Jandacek, Heubi & Tso 2004) which 
measures the ratio of FA versus a nonabsorbable fat marker in the feces. However, it should be pointed out 
that differences in total absorption and absorption rates do not necessarily correlate. Such is the case with 
CD36 and intestinal TG transport. Total TG absorption was no different between CD36 KO and WT mice 
but the CD36 KO mice had a significantly lower TG transport rate than WT over the course of 6 h (Nauli 
2006). Since total fat absorption in WT animals is already efficient (~95%), the possibility that apoA-V KO 
mice would absorb even higher total amount of fat is questionable. One would then wonder if the 
postprandial TG excursion in apoA-V KO mice is higher since that has not been examined in the literature. 
Interesting, a study was published after Paper I was submitted examined postprandial lipid excursions in 
apoA-V knock-down mice (70% less apoA-V expressed in liver) and showed a higher plasma TG excursion 
after a lipid load (Camporez 2014). 
 
33 
 
An important question that arises is: how is apoA-V affecting the production of chylomicrons by the gut if 
it is only made in the liver? We confirm that apoA-V is only synthesized in the small intestine, both in the 
fasting and feeding state (FIGURE 7). ApoA-V would then affect gut function extra-intestinally. One 
possibility is via the biliary route, and if apoA-V is present in bile, then it would act on the apical side of 
enterocytes. Other apolipoproteins, such as apoB, 
apoC-II, apoC-III, apoA-I, and apoA-II, were 
previously found in the bile (Sewell et al., 1983). 
This possibility is explored in Chapter 4 and is the 
crux of Paper II. An alternative possibility is that 
apoA-V may filter from intestinal capillaries, 
which are made more permeable during active fat 
absorption (Borgstrom & Laurell 1953; Granger 
1982; Simonds 1954).  
 
Another major question is how apoA-V regulates lipidation of chylomicrons and their secretion into lymph? 
An intracellular role has been ascribed to apoA-V for hepatocytes in stabilizing lipid droplets (Shu et al., 
2007; Shu et al., 2008; Blade et al., 2011). It is possible that apoA-V may serve to stabilize TG droplets 
that form on the inner leaflet of the ER in enterocytes (Hussain et al., 2000). Thus, a lack of apoA-V would 
cause a more rapid movement of the newly synthesized TG to the apoB lipoprotein particle. ApoA-V may 
also affect the expression or activity of other critical proteins involved in intracellular assembly, such as 
microsomal transfer protein (MTP). With altered apoB production in apoA-V KO mice, it is unclear if apoB 
synthesis is increased or if apoB degradation is decreased. These studies have not been performed and their 
completion would provide insight into how apoA-V is affecting intestinal lipid transport and assembly.  
  
FIGURE 7. ApoA-V mRNA expression in liver and 
intestinal segments during fasting and lipid-fed (2 hours 
after olive oil gavage) quantified by RT-PCR with 
cyclophilin as an internal control. Values are means ± SEM.  
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4. LIVER-GUT SIGNALING THROUGH BILE 
 
4.1 The Liver and its Secretion of Bile  
 
Thousands of hexagonally shaped units called lobules divide the liver. At the corners of each unit are the 
“portal triads” which consist of the portal vein, the hepatic artery, and the collecting bile duct. In the 
middle lies the central vein (FIGURE 8). The vascular network is organized to allow unidirectional blood 
flow from the portal vein and hepatic artery through the sinusoids and into to the central veins. The central 
FIGURE 8. Organization of the liver lobule. The corners of each unit are the “portal triads” which 
consist of the portal vein, the hepatic artery, and the collecting bile duct. The middle of each lobule 
lies the central vein. Each lobule is divided into three zones according to distance from arterial blood 
supply. Image adapted from http://en.wikipedia.org/wiki/Image:Hepatic_lobule.JPG.  
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veins merge into the hepatic vein which ultimately connects to the inferior vena cava. Each lobule is 
divided into three general zones: periportal (zone 1), transitional (zone 2), and pericentral (zone 3), 
numbered according to the distance from the arterial blood supply. Cells in Zone 1 are closest to the 
arterioles and are best oxygenated while cells in Zone 3 have the poorest oxygen supply. 
 
The primary cell type that make up the body of the liver is the hepatocyte. These cells organize into cords 
that line the intricate vascular network, with borders that either face the sinusoids or adjacent hepatocytes. 
The endothelial cells of the sinusoids are fenestrated, which allow blood to make contact with the cells. 
The space between the sinusoids and hepatocytes is called the Space of Disse, which allows a portal flow 
of venous blood coming from the small intestine to bathe the hepatocytes. After a meal, this plasma is very 
rich in nutrients.  
 
Hepatocytes also produce bile, which is secreted from the apical membrane into channels called the bile 
canaliculi that run between hepatocytes to the periphery of the lobules to form bile ducts. Together the 
interlobular bile ducts assemble into the hepatic duct outside of the liver. The hepatic duct merges with the 
common bile duct, which delivers bile into the duodenum (FIGURE 9). In many species, such as humans 
and mice, bile is diverted to the gallbladder, which stores bile between meals. Rats do not have a gallbladder 
and continually secrete bile into the duodenum. The bile fistula model, described in the following section, 
involves cannulation of the common bile duct to collect bile for experimental measurements. 
 
The human liver produces 500 – 800 ml of bile daily. Rats produce about 5-15 ml of bile daily. Bile has 
the same osmolality as plasma and contains mostly water and electrolytes. Bile also contains organic 
compounds such as phospholipids, bile salts, cholesterol, bile pigments, and other endogenously 
synthesized or ingested compounds. The yellow-green color of bile comes from bile pigments, or bilirubin, 
which are metabolic breakdown products of red blood cells. Bacteria in the colon further metabolize these 
pigments, which gives feces its brown color.  
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Two fundamental functions of bile include: 1) to provide bile salts and phospholipids to the small intestine 
that are critical for the digestion and absorption of dietary fat and 2) to serve as a receptacle for waste 
products which are ultimately excreted in feces.   
 
Bile salts in the body are recycled and go through the enterohepatic circulation. Specific transporters in 
the ileum move bile salts into intestinal capillaries, 
which are transported directly to the liver via the 
hepatic portal blood. Hepatocytes take up bile salts 
from the blood and secrete them into the bile 
canaliculi. Thus, the bile salts are circulated: blood  
hepatocyte bile gut  blood. The enterohepatic 
circulation recycles 95% of bile salts and 5% are lost 
into feces per day (Dowling 1973). Conditions that 
deplete bile salts (such as bile drainage or the use of 
pharmacologic agents such as bile salt sequestrants) 
stimulate hepatocytes to increase bile salt production 
endogenously (See Review by Packard & Sheperd 
1982). The precursor to bile salts is cholesterol. When 
there is an abundance of bile salt in circulation (such 
as with bile salt feeding), the hepatocytes would 
down-regulate synthesis (See Review by Danielsson 
& Sjövall 1975), although taurocholate feeding stimulates bile acid production in the short-term (Shefer 
1983). Much of this regulation is mediated by the nuclear receptor, farnesoid X receptor (FXR) and is 
discussed later in this dissertation. 
 
FIGURE 9. Organization of the hepatic bile 
ducts. The bile fistula model involves cannulation 
of the common bile duct.  
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While much is known about the hepatic secretion of lipids or bile salts into bile (See review by Corring 
1989), less is known about biliary proteins. Proteins constitute 5% by weight of biliary components while 
bile salts, phospholipids, cholesterol constitute 65%, 20%, 3% respectively. A detailed account of biliary 
proteins and their mechanisms of secretion is reviewed (LaRusso 1984, Reuben 1984). The second aim of 
this dissertation was to explore apolipoproteins, namely apoA-V, in bile. Sewell and colleagues were first 
to discover apolipoproteins in both human and rat bile, namely apolipoproteins A-I, A-II, B, C-II, and C-
III, by radioimmunoassay (Sewell 1983). Their presence in bile was unlikely due to blood contamination 
because every bile sample contained apolipoproteins, which was also the case in our studies. Their 
findings introduced the possibility that the hepatocyte may either directly secrete apolipoproteins into bile, 
or take up lipoproteins from the plasma and secrete their components into bile. The exact transport 
mechanism remains to be elucidated. 
 
The functions of biliary apolipoproteins remain largely unknown and speculative. One possibility is that 
they serve similar functions as they would in the plasma, such as the transport and solubilization of lipids. 
In this dissertation, we find that apoA-V is present in bile and may serve to modulate the absorption of 
dietary lipid.  
 
4.2 Bile Fistula Rat Model 
 
The bile fistula model is commonly used for two purposes: 1) to study bile production and its components 
in response to stimuli, and 2) to study physiologic responses to bile diversion, such as its effects on dietary 
fat absorption (Borgstrom 1952; Saunders 1963; Morgan 1969). For pharmaceutical applications, the bile 
fistula rat model (also known as the bile duct cannulated, BDC, rat) is the standard animal model in ADME 
(Absorption, Distribution, Metabolism, Excretion) studies to estimate biliary elimination and potential 
enterohepatic circulation of compounds. The rat differs from humans in that it does not have a gallbladder. 
This makes the rat a suitable model to measure bile production rates, such as assessing the effects of 
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compounds on choleresis (stimulating bile production) or cholestasis (decreased bile production) 
(Paumgartner 1979). Additionally, both rats and humans produce taurine-conjugated bile salts (Hardison 
1977), although humans also secrete glycine-conjugated bile salts (Sjovall 1960). For studies involving 
bile acid composition, the hamster would be the best animal model (Kuroki 1983). The work described in 
the present dissertation employs the bile fistula rat model to determine the biliary production rates of 
apolipoproteins, lipids, and bile salts. 
 
The animal model involves cannulation of the common bile duct to collect hepatic bile at varying time 
points. The use of the bile fistula rat model dates back several decades (Eriksson 1957) with several types 
of modifications made over the years. Such changes include single versus double cannulations, location 
of cannula placement, and the inclusion of additional cannulas (such as for blood sampling) (See Review 
by Bachir-Cherif 2011). For studies in our laboratory, we employ a single cannulation of the common bile 
duct, and similar to our lymph fistula model, a duodenal tube is used for a direct infusion of saline or 
nutrients.  
 
Briefly, rats are exposed to isoflurane anesthesia through a nose cone during surgical procedures. Like the 
lymph fistula model, a laparotomy is performed to gain access to the abdominal cavity and a silicon tube 
is inserted into the duodenum for infusion of nutrients or saline. The common bile duct, located right 
below the two hepatic ducts, is cannulated with polyvinyl chloride tubing tipped with polyethylene tubing. 
Immediately after surgery, anesthesia is withdrawn, and the animals are restrained in Bollman cages. The 
animals quickly recover from anesthesia and are allowed to recover from surgery overnight. Saline is 
continuously infused into the duodenum by an infusion pump to replenish fluid and electrolytes lost during 
bile drainage. Saline infusion is essential for maintaining health and survival of the animals as bile 
drainage results in significant electrolyte loss. In fact, if water was given instead of saline, animals develop 
hyponatremia, hypochloremia, and acute renal failure within a few days (Mizuta 1999). For absorption 
studies, a fat infusion (bolus or continuous) is given intraduodenally the day after surgery. 
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Our studies involve hourly collections of bile by gravity drainage for up to two days. Collection on the 
second day after surgery is advantageous in that the production rates of bile salt and other biliary 
components have stabilized, as well as bile flow. Additionally, the animals have recovered from effects 
of anesthesia for a full 24 h and are fully conscious during the collection period. However, a limitation of 
the single cannulation method is that external bile drainage interrupts the enterohepatic circulation of bile 
salt, as well as drains other biliary components. In studies detailed in Paper II, we examine the effects of 
bile drainage on biliary parameters and attempt to partially restore the enterohepatic circulation with bile 
salt and phospholipid infusion. To avoid long-term effects of bile drainage, we limited our studies to two 
days.  
 
4.3 ApoA-V Secretion in Bile Is Regulated By Dietary Lipids (Paper II) 
 
Previously, in Chapter 3, a novel role for apoA-V in lipid absorption by the gut was described. A question 
that followed was: how does a protein made only by the liver affect the gut? One potential mode of action 
is through the bile. As discussed above, apolipoproteins have previously been found in bile and are 
postulated to aid in the transport or absorption of lipids. Biliary components such as bile salts also aid in 
absorption (See Review by Holt 1972) and serve as signaling molecules, such as stimulating fibroblast 
growth factor 19 in the gut to suppress its own synthesis in the liver (Kim 2007). The initial aims of Paper 
II were to determine if apoA-V is present in bile, and if present, whether its secretion into bile is regulated 
by dietary lipid. 
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ApoA-V was indeed present in bile, determined by Western 
blotting (Paper II, Fig. 1A), of rats that recovered overnight 
from surgery and received a continuous infusion of saline. 
Using an antibody specific to apoA-V (FIGURE 10), we found 
a single band around 40 kDa, which is the predicted molecular 
weight of rat apoA-V (Chapter 1). The antibody did not react 
with any other proteins in the bile samples. During this period, 
while bile flow was constant (Paper II, Fig. 1B), apoA-V was 
secreted at a constant rate (Paper II, Fig. 1A). These findings 
introduce the possibility that apoA-V in bile may modulate lipid 
absorption, either by affecting luminal digestion or by direct 
interaction on enterocytes.   
 
A number of physiological processes occur during ingestion of dietary fat. For example, dietary fat induces 
the secretion of a gastrointestinal peptide hormone, cholecystokinine (CCK), which stimulates hepatic 
production of bile and gallbladder contraction, plus a number of other effects related to satiety and energy 
balance (Review by Beglinger 2004). Long term fat ingestion can also stimulate bile salt secretion 
(Dowling 1971; Redinger 1973). We next tested if dietary lipids could stimulate the hepatic production of 
apoA-V into bile.  
 
In order to measure the biliary response of apoA-V to dietary fat, fat absorption must be re-instated in bile 
fistula rats, since bile fistula rats transport dietary fats poorly into lymph (Borgstrom 1952, Saunders 
1963). To do this, two major components in bile must be restored: bile salts, which solubilize lipid 
digestion products in the lumen, and phospholipids, which emulsify large lipid aggregates in the lumen 
into finer, more stable lipid droplets, since bile salts alone are poor emulsifiers (Dreher 1967). 
Additionally, biliary phospholipids, specifically phosphatidylcholine, play a critical role in translocating 
FIGURE 10. ApoA-V antibody is 
specific to apoA-V as indicated by no 
antibody-protein binding in plasmas 
from apoA-V KO mice, as analyzed by 
Western blot. Numbers 1-4 represents 
plasmas from 4 different KO mice. 
Antibody is goat anti-rat/mouse used at 
1:5000.  
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fats from the intestinal mucosa in the lymph (Tso 1977). Consistent with previous findings, Paper II shows 
bile fistula rats transporting significantly less TG into lymph compared with bile intact rats (Paper II, Fig. 
2). However, infusing taurocholate and phosphatidylcholine intraduodenally at a concentration to promote 
micellization was able to restore lymphatic transport of TG, in both extent and timing, in bile fistula rats.  
 
Under conditions of restored lymphatic transport of lipid, apoA-V secretion into bile was increased 4 h 
after a lipid bolus administration (Paper II, Fig. 3A), while bile flow remained constant (Paper II, Fig. 
3B). The increase was concomitant to when the lymphatic output of TG was highest, suggesting that a 
notable level of TG, packaged as chylomicrons, was needed to stimulate hepatic apoA-V secretion. 
Conditions of poor lymphatic transport of lipid did not stimulate biliary apoA-V secretion (Paper II, Fig. 
3D). Dietary lipid did not significantly stimulate the secretions of other apolipoproteins in bile (Paper II, 
Fig. 3C) nor of biliary cholesterol, phospholipid, or bile salts (Paper II, Fig. 4). These findings indicate 
that dietary lipid absorption and subsequent delivery of chylomicron particles is needed to stimulate the 
hepatic apoA-V secretion into bile.   
 
Initially, we hypothesized that the liver would secrete more apoA-V into bile in response to dietary lipid 
so that apoA-V in the lumen may regulate lipid absorption. The delay in the lipid-induced increase in 
biliary apoA-V suggests that this might not be the case. However, biliary phospholipids and bile salts, 
which are well known to modulate fat absorption, are not significantly increased after an acute bolus of 
lipid but are increased after fat feeding (Corring 1989). Perhaps the same applies to apoA-V secretion: 
that is, longer term fat feeding (opposed to an acute bolus injection of lipid) would upregulate its secretion 
into bile and would then serve an inhibitory role for fat absorption. This remains to be tested.  
 
How would dietary lipid regulate the hepatic secretion of apoA-V? Hepatic apoA-V expression was 
previously found to increase in response to fibrates (Vu-Dac 2003), which are hypolipidemic drugs and 
activators of the peroxisome proliferator-activated receptor (PPAR)-α (Review by Raalte 2004). PPARα 
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is a ligand-activated transcriptional factor that regulates the expression of genes involved in FA oxidation 
and energy homeostasis. While fibrates are pharmacologic activators, dietary lipids are natural ligands for 
PPARα. In vitro studies revealed a functional PPAR response element in the apoA-V gene (Vu-Dac 2003). 
It is possible that lipid-induced stimulation of the biliary apoA-V is mediated through PPARα activation 
in hepatocytes. Interestingly, apoA-I is also responsive to fibrates via PPARα (Zhang 2010) and its 
secretion into bile is also increased with dietary lipid (Paper II, Fig. 3C), although not as significantly 
(Paper II, Fig. 3A).  
 
These notions bring up the question of whether the lipid-induced stimulation of apoA-V production is 
specific to secretion into bile or rather a general hepatic up-regulation. Whether plasma concentrations 
of apoA-V is increased (and at what time point?) in response to dietary lipid has yet to be tested. These 
studies would provide insight into how apoA-V might act on the gut: 1) via bile to act on enterocytes 
apically or 2) via the circulation to act on enterocytes either basolaterally or to enhance lipolysis.  
 
The finding that apoA-V is present in bile introduces questions about the structure and function of apoA-
V in the intestinal lumen and its potential uptake by enterocytes. Does apoA-V escape proteolysis in the 
intestinal lumen? Most dietary proteins are digested into free amino acids and small peptides by gastric 
and pancreatic enzymes, and further by peptidases in the intestinal brush border membrane. Even so, 
substantial evidence show that some proteins can escape degradation and be absorbed intact, which is of 
high interest to designing pharmaceutical proteins for oral drug delivery (Soltero & Ekwuribe 2002). Two 
examples are insulin and bile salt-dependent lipase (BSDL). Ziv and colleagues were first to report 
evidence for the absorption of insulin in 1987 (Ziv 1987). They later found that under certain conditions, 
insulin was transported by endosomes through enterocytes to the blood with biological activity (Ziv 2000; 
Ziv & Bendayan 2000). Their laboratory also showed that BSDL, a larger protein of 74 kDa, can be 
endocytosed by enterocytes (Bruneau 1998; 2003a; 2003b) by mechanisms that may involve binding to 
heparin-like molecules on the cell surface (Bosner 1988). Further, pancreatic enzymes (such as lipase and 
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amylase) can also cross the intestine by transcytosis to reach the intestinal subepithelial space (Cloutier 
2006). Since apoA-V can bind HSPGs (Merkel 2005), it may be possible that enterocytes can take up 
apoA-V by way of HSPGs on the brush border membrane. If taken up by enterocytes, can it be transported 
into the lymph? We will cover the possibility of lymphatic transport of apoA-V in Chapter 5.  
 
4.4 ApoA-V Secretion In Response To Bile Drainage (Paper II) 
 
While bile cannulation is needed to measure biliary components, the procedure drains bile and disrupts 
the enterohepatic circulation. Usually after bile cannulation, bile flow and the biliary outputs of bile salts 
and lipids decrease (Klaassen 1971; Paper II, Fig. 6) and stabilizes the following day. Another aim was 
to determine if bile drainage affected the biliary secretion of apoA-V since the gene promoter was found 
to be regulated by bile salts via FXR in vitro (Prieur 2003). Therefore, apoA-V output was measured in 
bile immediately after surgery. 
 
The secretion of apoA-V into bile increased steadily with time of bile drainage (Paper II, Fig. 5A) while 
the secretion of other apolipoproteins remained constant (Paper II, Fig. 5B). This increase in apoA-V was 
also seen in the mouse (unpublished results, David Q.-H Wang). Restoring the two primary components 
of bile, phosphatidylcholine and taurocholate, by continuous intraduodenal infusion did not abolish the 
increase in apoA-V secretion (Paper II, Fig. 7A). In fact, the infusion further stimulated the biliary 
secretion of apoA-V (Paper II, Fig. 7C), on top of increasing bile flow (Paper II, Fig. 7B). This 
observation supports the notion proposed by Prieur and colleagues that bile salts can induce apoA-V 
synthesis, which has not been tested in vivo. However, since phospholipid was also in our infusion, further 
studies are needed to explore whether the effect was due to phospholipid or bile salt.  
 
The observation in Paper II that apoA-V in bile increases after bile fistula surgery is intriguing and warrants 
further investigation. Why biliary apoA-V is increased is not known at this point. One possibility is an 
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acute phase response to the surgical procedures. ApoA-V was previously found to be an acute phase protein 
to endotoxin-mediated infection (Khovidhunkit 2004) but the response to bacteria versus to surgery may 
be entirely different. Additionally, apoA-IV and apoE are also acute phase proteins increased in plasma 
(Khovidhunkit 2004; Li 2008) but found constantly secreted into bile in our studies. An experiment that 
might provide insight is to see if apoA-V (and other apolipoproteins) in plasma is also increased in response 
to bile fistula surgery or surgery in general. However, the drainage of bile as a confounding variable might 
render data difficult to interpret.   
 
Another possibility is that bile drainage can affect liver function in alternative ways, such as its regenerative 
capacity. Hepatocyte growth factor (HGF), a potent mitogen for mature hepatocytes (Nakamura 1984), 
was found increased in bile several-fold after hepatectomy (Takeuchi 1997). HGF in bile was postulated 
to play a significant role in liver regeneration, and external biliary drainage suppressed regeneration by 
affecting bile HGF. Interleukin (IL)-6, another important factor in early liver regeneration, was detected in 
bile after liver transplantation (Umeshita 1996). After hepatectomy, biliary IL-6 concentrations were 
increased 37-fold in human subjects without liver failure and increased 7-fold in patients with liver failure 
(Maeda 1999). The increased biliary IL-6 concentrations after hepatectomy may reflect the hepatic 
regenerative capacity, and biliary IL-6 concentrations may serve as a clinical marker for liver failure. Since 
apoA-V is thought to be another liver regenerative factor (van der Vliet 2001), it may be possible that bile 
drainage negatively affects the liver and is reflected by the increased apoA-V secretion. The connection 
between biliary apoA-V and liver regeneration remains to be explored.  
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5. APOA-V: A POTENTIAL ENTEROHEPATIC PROTEIN 
 
ApoA-V is unique in the sense that it could dramatically modulate plasma TG levels while existing in very 
low concentrations in the plasma (Chapter 1). The recent discovery of a role for apoA-V in the gut (Zhang 
2015) makes apoA-V a novel liver-to-gut signal protein (Chapter 3; Paper I). The discovery of apoA-V in 
bile (Chapter 4; Paper II) suggests a potential route of signaling from the liver to the gut. 
 
Since apoA-V was found on human chylomicrons in the plasma (O’Brien 2004), we wondered if apoA-V 
was also present on lymph chylomicrons since chylomicrons originate from the small intestine and are 
secreted into the mesenteric lymph. The fourth aim of this dissertation was: 1) to determine if apoA-V was 
present in lymph and 2) to test the hypothesis that biliary apoA-V is transported into the lymph. Paper IV 
details these findings. 
 
5.1 Apolipoprotein A-V is Present on Lymph Chylomicrons  
 
Using conscious lymph fistula Sprague-Dawley male adult rats given an intraduodenal bolus of intralipid 
or saline, we assayed for apoA-V in mesenteric lymph by Western blotting. ApoA-V was indeed present 
in lymph as a 40 kDa protein but mostly after administration of dietary lipid. Little or no apoA-V protein 
was detected during fasting or after saline administration (Paper III, Figs. 1A, B), although small amounts 
were detectable in some animals. The concentration of lymph apoA-V at its maximal level (~hour 1 after 
lipid administration) was one-third that of plasma (Paper III, Fig 1C). Compared to TG output into lymph 
(Paper III, Fig. 1F), the maximal output of apoA-V preceded TG. Ultracentrifugation of lymph showed 
that apoA-V associated with chylomicrons and was not present in free form in the infranatant (Paper III, 
Figure 2). The data show that apoA-V is present on lymph chylomicrons during fat absorption.  
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These findings introduce a possibility that the intestine transports apoA-V onto chylomicrons during the 
absorptive process. Since the intestine constitutively secretes apoB48 particles regardless of fasting or 
feeding (see review Tso 1984), the association with chylomicrons would likely occur after lipidation of 
apoB48 since apoA-V is not present in fasting lymph. In the hepatocyte, the association of apoA-V with 
VLDL is thought to be a post-secretory event (Shu 2007; Blade 2011) or related to the lipidation (Shu 2007, 
Shu 2008). However, the observation that the lymphatic output of apoA-V peaks a few hours earlier than 
TG suggests that apoA-V association with chylomicrons and lipidation are not necessarily correlated.  Since 
the intestine does not synthesize apoA-V (Chapter 1; FIGURE 7), where might lymph apoA-V originate? 
The next section explores one possibility (5.2). 
 
5.2 Potential Transport of Biliary ApoA-V into Lymph 
 
Although most proteins in the intestinal lumen are digested into free amino acids and small peptides, by 
gastric and pancreatic enzymes and by peptidases on the intestinal brush border membrane (See Review by 
Erickson & Kim 1990), substantial evidence shows that some can be absorbed intact. Such examples are 
insulin, BSDL, and lipases described in Chapter 4.3.  
 
The observations that apoA-V is present in bile (Zhang 2015) and exists in the intestinal lumen as an intact 
protein that can be taken up by enterocytes through a caveolin-1-mediated mechanism (Siddiqi 2015) 
support the notion that apoA-V is transported basolaterally. To explore this possibility, we employed bile 
fistula rats to divert a source of apoA-V and assayed for its presence in the lymph. 
 
Bile diversion decreased the appearance of apoA-V in lymph (Paper III, Fig. 3A), supporting the notion 
that the apoA-V in lymph may originate from bile. However, bile diversion also impedes intestinal transport 
of TG into lymph (Paper III, Fig. 3D). The results could arise from two possibilities: 1) the transport of 
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apoA-V from bile to lymph requires the production of TG-rich chylomicrons or 2) the reduction of apoA-
V in lymph is a general result of reduced lymphatic TG transport and not of a diversion of bile.  
 
To explore the possibilities, bile fistula rats were given an intraduodenal supplement of phosphatidylcholine 
and taurocholate to solubilize lipid and enable transport into the lymph, much like the procedure described 
in Paper II. Under these conditions, apoA-V in lymph was significantly increased (Paper III, Figs. 4A, B), 
at levels higher than a bile-intact animal (Paper III, Fig. 1A). These results suggest that the appearance of 
apoA-V in lymph required the active secretion of TG; it does not seem to require the presence of bile in the 
lumen. However, there may be a possibility that a pool of apoA-V resides in the enterocyte (even after bile 
diversion) and is “pushed out” upon administration of dietary fat. A way to test this is to isolate enterocytes 
from a bile-diverted rat and assay for the presence of apoA-V in cell lysates. This has yet to be performed. 
 
Lymph apoA-V may very feasibly originate from circulation, since capillary permeability is increased 
during fat absorption (Granger 1982). ApoA-V associated with plasma HDL may leak into the lymphatics 
and transfer onto chylomicrons, similar to its transfer from hepatic HDL to VLDL in mice (Fruchart-Najib 
2004; Nelbach 2007). These possibilities remain to be investigated. 
 
In conclusion, Paper III is the first report to describe the presence of apoA-V on mesenteric lymph 
chylomicrons by a process stimulated by active fat absorption. At this point, the exact origin of this apoA-
V remains to be determined: from bile or plasma. The intestine may internalize apoA-V basolaterally and 
secrete it onto chylomicrons during fat absorption. ApoA-V may also be taken up by the basolateral 
membrane itself and associates with chylomicrons extracellularly by a mechanism similar to what is 
speculated for hepatocytes (Forte 2008). Whether its mode of action is apical or basolateral to enterocytes 
(or both) is an intriguing question and warrants further investigation. 
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6. GENERAL SUMMARY & FUTURE DIRECTIONS  
 
The results of this dissertation lead to 4 general conclusions: 
1. ApoA-V deficiency results in enhanced formation and secretion of chylomicrons. 
2. ApoA-V is present in the bile and its secretion is increased in response to dietary fat absorption. 
3. Bile drainage upregulates the secretion of apoA-V into bile within the first day after surgery. 
4. ApoA-V is present on lymph chylomicrons in response to dietary fat absorption. 
  
I. ApoA-V deficiency results in enhanced formation and secretion of chylomicrons 
 
Paper I demonstrates that apoA-V deficiency in mice increases the transport rate of both dietary TG and 
cholesterol into lymph and accelerates the production rate of chylomicrons, manifesting in a greater 
production of apoB48 particles. Previous studies have shown that apoA-V can modulate postprandial TG 
response (Fruchart-Najib 2004, Schaap 2004, Camporez 2014) with the mechanisms related to lipolysis and 
clearance. Our studies introduce another aspect of the role of apoA-V in postprandial lipid metabolism, 
which is modulating the intestinal production of dietary TG. 
 
The results give rise to a number of future directions related to the impact of apoA-V on intestinal TG 
production. Unknown is the relative contribution of the gut versus liver/plasma on the postprandial 
response. To examine this, one can administer a vitamin-A (retinol) enriched fat load to measure the 
postprandial plasma excursions of retinol palmitate, apoB48, apoB100 associated with TG-rich lipoproteins 
(TRL) in apoA-V KO and WT mice. Administering retinol with dietary fat is a simple and sensitive way to 
label intestinally derived lipoproteins in both animal models (Ross & Zilversmit 1977) and humans (Lewis 
1990) because dietary retinyl esters are co-transported with esterified cholesterol in chylomicrons. While 
49 
 
esterified retinol in the remnant particles are removed by the liver, they are not recirculated in hepatic 
VLDL.  
 
The test can be applied to the human population with apoA-V SNPs to determine the contribution of 
intestinal TG-lipoproteins to the elevated postprandial TG response. Currently, very few studies have 
examined the effect of APOA5 polymorphisms on postprandial TG response, although the general trend 
shows that carriers of the -1131T>C minor allele display elevated postprandial lipid excursions (Chapter 
3). Based on our findings, populations with apoA-V SNPs could potentially have a greater production of 
apoB48 particles, and along with their impaired ability to hydrolyze and clear these particles, would have 
higher risks of atherosclerosis and cardiovascular events. Indeed, the study by Moreno and colleagues 
showed that subjects with the -1131CT/CC genotype had a higher level of small TRL-RP than subjects with 
the -1131TT genotype (Moreno 2006). The -1131CT/CC carriers also displayed larger variability and a 
tendency of elevated apoB48 particles, with is consistent with our studies in apoA-V KO mice (Paper I, 
Fig 6A). However, a follow-up study by Moreno-Luna and colleagues did not find statistical significance 
in TRL-RP and apoB48 particle number in select subjects with the APOA5*2 and APOA5*3 haplotype 
(Moreno-Luna 2007). Taken together, the results clearly indicate a need for further examination in 
controlled rodent experiments as well as larger human population studies.  
 
Another unanswered question is how might apoA-V be modulating chylomicron production? While our 
preliminary findings show that apoA-V KO mice have increased intestinal apoB production into lymph, 
what is unknown is whether apoB synthesis is increased or apoB degradation is decreased. To measure 
apoB synthesis, one would use the trichloroacetic acid (TCA) precipitation method to measure protein 
synthesis which has been previously used to measure the intestinal synthesis of apolipoproteins (Hayashi 
1990; Davidson & Glickman 1985). ApoB degradation can be measured by pulse-chase analysis of 3H-
leucine as previously studied (Jin 1999). ApoA-V may also affect the expression or activity of MTP, which 
would subsequently affect chylomicron production (Duez 2006; Iqbal 2008). 
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The ultimate test-of-concept experiment is to see if giving back apoA-V could reverse the phenotype of 
increased lymphatic TG transport in apoA-V KO mice. This can be done by giving recombinant apoA-V 
protein intraduodenally (to test if mode of action is apical to enterocytes), intravenously (to test if mode of 
action is basolateral to enterocytes), or by adenoviral gene transfer to the liver (to see if phenotype is 
generally reversible, under chronic re-expression). Will giving back apoA-V to KO mice result in constant 
intestinal apoB production as seen in WT mice? Completion of studies addressing these questions would 
provide insight into how apoA-V might be affecting intestinal lipid transport and assembly. Speculations 
on how apoA-V might physically gain access and traffic within enterocytes will be described in the 
following section. 
 
II. ApoA-V is present in bile and its secretion is increased in response to dietary fat 
absorption. 
 
The work in Paper II demonstrates that apoA-V is present in hepatic bile of rats and its secretion increases 
in response to lipid absorption, albeit 4 h after administration of lipid. This increase is specific to apoA-V 
and not to other apolipoproteins or biliary lipids and bile salt. The results suggest the possibility that as 
chylomicrons are assembled and secreted into lymph, the generation of remnants will lead to their uptake 
by liver and subsequently stimulate secretion of biliary apoA-V. 
 
Initially, the thought was that the secretion of apoA-V into bile would increase in response to dietary lipid 
so that apoA-V in the intestinal lumen would physically interact with lipid micelles or be taken up by 
enterocytes in an increased abundance to modulate lipid absorption. The fact that the increase in apoA-V 
in bile was delayed in response to dietary lipid suggests that this might not be the case. However, an 
important question to address would be if apoA-V secretion into bile would increase after a longer term 
of fat feeding (as opposed to an acute bolus of dietary lipid). Such is the case for other biliary components 
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that are well known to modulate fat absorption such as bile salts and phospholipids. While their secretions 
into bile are not increased after an acute bolus of lipid, they are increased after daily fat feeding.  
 
However, the fact that dietary lipid can stimulate the secretion of apoA-V into bile suggest that dietary 
lipids, or its byproducts, can regulate apoA-V expression or secretion, possibly through activation of 
peroxisome proliferator activated receptor alpha (PPARα) (Vu-Dac 2003). To determine if this is the case, 
a synthetic PPARα agonist can be administered and its effect on the biliary secretion of apoA-V can be 
evaluated. 
 
The findings also bring up the question of whether the lipid-induced stimulation of apoA-V secretion is 
specific to bile or rather a general hepatic up-regulation. Whether plasma apoA-V is increased in response 
to dietary lipid is yet to be tested. The idea would be that apoA-V secreted into the plasma would promote 
LPL-mediated hydrolysis while apoA-V delivered to bile would reach the intestine and inhibit 
chylomicron assembly and secretion. Both functions could serve to protect the liver from lipid overload 
simultaneously. 
 
The finding that apoA-V is present in bile introduces questions about the structure and function of apoA-
V in the intestinal lumen and its potential uptake by enterocytes. Does apoA-V escape proteolysis in the 
intestinal lumen? Siddiqi and colleagues have recently examined this question in an initial report (Siddiqi 
2015). Very interestingly, they found that apoA-V from the intestinal lumen bound to CD36 and caveolin-
1 (and not clathrin, like cholesterol ester lipase (CEL)). Additionally, this caveolin-1-mediated transport 
seemed to deliver apoA-V to the ER. If apoA-V can indeed be transported across the enterocyte as an intact 
protein, it would join the ranks of insulin and BSDL. Additionally, since apoA-V was previously shown to 
bind HSPGs, it may be possible that potential CD36-mediated uptake by apoA-V may involve HSPGs on 
the brush border membrane as well as lipid transport intracellularly. The coordinate activities of CD36 and 
52 
 
HSPG to mediate lipoprotein uptake and intracellular TG accumulation were shown in other cell types, 
such as adipocytes (Wilsie 2005). 
 
If apoA-V gains access to the enterocyte and is transported intracellularly (such as in a manner to affect 
apoB48 production), then what is the pathway of this transport? Nilsson and colleagues discovered that 
apoA-V (apoA-V-488) internalized by SorLA/sortilin in transfected HEK cells are first carried in 
endosomes before trafficking to the the trans-Golgi network (Nilsson 2008). One can feasibly study 
intracellular transport of apoA-V in intestinal cells by studying the co-localization of apoA-V-488 with 
EEA1, Rab1, LAMP1, TGN38, and calnexin, which are enterocytic markers for the early endosome, late 
endosome, lysosome, Golgi complex and ER (Cartiera 2009), respectively.  
 
III. Bile drainage upregulates the secretion of apoA-V within the first day after surgery. 
 
The observation in Paper II that apoA-V in bile increases after bile fistula surgery (beginning around 6-8 
h) is intriguing and warrants further investigation. This increase was specific to apoA-V as the secretion 
of other apolipoproteins into bile did not change. Even after replenishing phosphatidylcholine and 
taurocholate intraduodenally, the secretion of apoA-V into bile remained to be steadily increasing. It is not 
known at this point why apoA-V secretion into bile is increased after bile fistula surgery.  
 
In our studies, the two principal components of bile were given back to bile fistula rats: bile salt and 
phospholipid. A third major biliary component is cholesterol, which was not given back in our initial 
studies. Liver X receptor (LXR) agonists was previously found to downregulate apoA-V mRNA levels 
through activation of sterol regulatory element-binding protein 1c (SREBP-1c) in hepatocyte cell lines 
(Jakel 2004). Derived from cholesterol, natural LXR agonists are intracellular oxysterols. It may be 
possible that bile drainage, which depletes cholesterol, would conversely upregulate apoA-V expression 
and subsequent secretion into bile. However, bile drainage of bile salts should increase hepatic SREBP-1c 
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expression according to a previous report (Watanabe 2004), which would decrease apoA-V expression. 
Currently, it is unclear which factors responsible for upregulating hepatic apoA-V secretion into bile are 
stimulated by bile drainage. Additionally, only apoA-V protein in bile has been examined. Effects on 
hepatic apoA-V mRNA and protein levels are unknown. To further explore this direction, it will be 
important to consider if apoA-V gene and protein levels, as well as plasma levels, are increased in response 
to bile drainage.  
 
An ultimate test would be to give back native bile immediately after bile cannulation to determine its effects 
on biliary apoA-V secretion. However, the donor animal would require a continuous infusion of 
phospholipid/bile salt to stimulate its hepatic secretion of lipids and bile salt since the process of collecting 
bile would alter the composition of bile. Figure 11 shows results from one experiment, where bile was 
collected overnight (to obtain enough volume) from one animal 
that was given only 5% glucose-saline infusion. This bile was then 
infused intraduodenally into another animal. Bile was collected 
during the infusion, and apoA-V was assayed in bile. ApoA-V 
steadily increased. However, the composition of this infused bile 
was below-physiologic levels of biliary lipids and bile salts, and 
high levels of apoA-V. Additional studies with appropriate 
conditions for collecting native bile are needed to explore this 
direction. 
 
Another possibility is that bile drainage can affect liver function in non-metabolic ways, such as its 
regenerative capacity. Since apoA-V is thought to be another liver regenerative factor (van der Vliet 2001), 
it may be possible that bile drainage may negatively affect the liver, reflected in the increased apoA-V 
secretion. Bile drainage, a common clinical procedure, has been previously found to impede the initial 
FIGURE 11. ApoA-V increases 
in bile in rats given a continuous 
infusion of native rat bile 
(collected overnight from a donor 
rat). ApoA-V was assayed in bile 
collected immediately after bile 
fistula surgery by Western blot. 
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process of liver regeneration (Otao 2012, Saiki 1999, Ueda 2002). The connection between biliary apoA-
V and liver regeneration remains to be explored.  
IV. ApoA-V is present on lymph chylomicrons in response to dietary fat absorption. 
 
The work in Paper III describes the presence of apoA-V on mesenteric lymph chylomicrons, in which the 
process is stimulated by active fat absorption. While bile diversion significantly reduces the appearance of 
apoA-V in lymph, it also reduces secretion of TG into the lymph. Restoring this ability by supplementing 
lumenal phospholipid and bile salt resulted in a higher level of lymph apoA-V.  
 
At this point, the exact origin of this apoA-V remains to be determined. While lymph apoA-V may still 
originate from bile, another possibility is that apoA-V might originate from plasma. An experiment that 
would test this would be to give a continuous infusion of lipid to bile-diverted rats and assay for apoA-V 
in lymph. If apoA-V appears in lymph, then the source is likely from blood circulation and not from bile, 
since bile is diverted.  
 
While apoA-V is observed to be taken up by enterocytes apically by Siddiqi and colleagues, whether or not 
it is transported into lymph is untested. Two modes of action can co-exist. It may be possible that the 
intestine may take up apoA-V from plasma basolaterally and secrete it onto chylomicrons during active fat 
absorption. It may also be that apoA-V is taken up by the basolateral membrane of the enterocyte and 
associates with chylomicrons extracellularly. Whether its mode of action is apical or basolateral to 
enterocytes (or both) is an intriguing question and warrants further investigation. One could utilize the 
earlier mentioned experiment and give back apoA-V intraduodenally or intravenously to apoA-V KO mice 
and assay for the presence of apoA-V in lymph under the two scenarios.  
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7. Additional Investigation: Role of ABCG5/G8 in Chylomicron Production 
 
The present chapter covers work that was completed during the first year of my doctorate studies on the 
adenosine triphosphate binding cassette (ABC) G5/G8 transporter and its role in intestinal lipid transport, 
which was originally my dissertation topic. During the year, a fascinating report (Nyugen 2012) was 
published by another laboratory that explored many of the aims proposed for my dissertation. A decision 
was made to pursue a different topic, and apoA-V became fascinating to me. This chapter will introduce 
and summarize my work completed on ABCG5/G8. ABCG5/G8 is traditionally known to be a sterol 
transporter; however, during my studies, a novel role for ABCG5/G8 in chylomicron production was 
found.  
 
7.1 ABCG5/G8 Transporters and Sterol Transport   
 
Cholesterol is necessary for normal function of mammalian cells. However, like TG or any other lipid or 
element, balance is key. High plasma cholesterol levels contribute significantly to atherosclerotic and 
cardiovascular diseases (See Review by Glass & Witztum 2001). Because the level of cholesterol in the 
diet is correlated to the level in plasma (Grundy 1972), understanding how cholesterol is absorbed by the 
intestine is of great interest for public health. 
 
An average adult in America consumes approximately 80 g of fat, 300 mg of cholesterol, and 100-400 mg 
of plant sterols per day. The small intestine absorbs fats very efficiently, up to 500 g per day in humans 
(Kasper 1970), although the rates of absorption can vary (Chapter 3). The fascinating aspect of sterol 
absorption is that cholesterol is only partially absorbed, and plant sterols are virtually not absorbed. The 
absorption of cholesterol in healthy individuals averages 50% (Salen 1970) while the absorption of plant 
sterols is only 5% (Schoenheimer 1931). This difference is interesting because plant sterols and cholesterol 
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are very similar in structure, only differing in a carbon side chain. For a long time, what distinguished 
cholesterol from plant sterols in the intestine had remained unknown. 
 
Insights into the process of sterol absorption came after the discovery of the human disease sitosterolemia, 
which is characterized by dramatically elevated plasma plant sterol levels and relatively normal plasma 
cholesterol levels. Sitosterolemic individuals absorb 15-60% of β-sitosterol (the main plant sterol in the 
diet) and excrete very little into bile (Salen 1992; Miettinen 1981), causing dyslipidemia and premature 
atherosclerosis. It was Berge and colleagues in 2000 who discovered that the disease was due to defects in 
the ABCG5/G8 transporter (Berge 2000). 
 
The liver and intestine are two organs that express ABCG5/G8 (Berge 2000), specifically on the apical 
membranes of hepatocytes and enterocytes. In the liver, ABCG5/G8 is the primary transporter for excreting 
plant sterols and cholesterol into bile (Yu 2005; Yu 2002). In the intestine, ABCG5/G8 serves to limit the 
absorption of plant sterols, by excreting the sterols from within the enterocyte into the intestinal lumen. 
Although some studies suggest that ABCG5/G8 also limits the absorption of cholesterol (Berge 2000, Yu 
2002, Wang 2007), others have found no effect (Yu 2002, Tang 2008), so the extent to which this occurs 
remains unclear.  
 
Interestingly, ABCG5/G8 also has been recently implicated in intestinal TG metabolism (Mendez-Gonzales 
2011). Mendez-Gonzales and colleagues found that ABCG5/G8 KO mice had increased absorption and 
secretion of total TG by the intestine, suggesting that ABCG5/G8 also limited TG absorption. What was 
not known was whether ABCG5/G8 serves to limit intestinal absorption of lipids in general, or just of 
cholesterol. Since both dietary TG and cholesterol are carried in chylomicron particles during absorption, 
the hypothesis was made that ABCG5/G8 served to limit the formation and secretion of chylomicrons in 
the small intestine. The work testing this hypothesis is described in Paper IV. 
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7.2 Role of ABCG5/G8 in Intestinal Lipid Transport (Paper IV)  
 
The aim of Paper IV was to test the hypothesis that ABCG5/G8 served to limit the absorption of both TG 
and cholesterol by affecting the formation and secretion of chylomicrons by the gut. Similar to the 
experimental design described in Chapter 3 and Paper I, the conscious lymph fistula mouse model was used 
to investigate the effects of ABCG5/G8 deficiency on the uptake, mucosal assimilation, and lymphatic 
transport of dietary TG and cholesterol. We expected that ABCG5/G8 KO mice would have increased 
transport of TG and cholesterol into the lymph. 
 
Unexpectedly, ABCG5/G8 KO mice displayed significantly decreased transport of radiolabeled and total 
TG (Paper IV, Fig. 2) and cholesterol into lymph (Paper IV, Fig. 3), resulting in an overall reduction of 
lipids delivered to lymph over the course of the 6 h study (Paper IV, Figs. 5A, B). Lymph flow was the 
same with control WT mice (Paper IV, Fig. 1). The reduction in lymph lipids was accompanied by 
accumulation of both lipids in the intestinal lumen (Paper IV, Figs. 5A, B). The lipids did not accumulate 
in the intestinal mucosa (Paper IV, Figs. 4A, B). Calculating absorptive and lymphatic transport indices 
(Chapter 3) shows that ABCG5/G8 deficiency significantly decreases the efficiency of both uptake and 
intestinal secretion of TG and cholesterol (Paper IV, Table 2). Taken together, the data in Paper IV suggest 
that ABCG5/G8 does not limit but increase the formation and secretion of chylomicrons. Interestingly, 
ABCG5/G8 KO mice tended to have a lower body weight with less fat mass (Paper IV, Table 1), which 
agrees with the observation that these mice are transporting less fat. 
 
The findings suggest a novel role for ABCG5/G8 in intestinal TG transport and also question whether 
ABCG5/G8 is a cholesterol efflux transporter in the intestine. Although the results are opposite to those 
expected, they highlight several experimental factors: the technical method, the genetic background of the 
animals, and composition of the lipid infusate. These factors are discussed below. 
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While it is generally accepted that ABCG5/G8 limits the absorption of plant sterols by serving as efflux 
transporters (Tachibana 2007), the extent to which ABCG5/G8 regulates the absorption of cholesterol has 
not been as apparent. Studies using the fecal dual-isotope ratio method (Borgstrom 1968) found no 
differences in fractional cholesterol absorption between ABCG5/G8 KO and WT mice (Plosch 2004, Yu 
2002, Tang 2008). However, the method critically depended on a non-absorbable marker, traditionally a 
plant sterol, which is well-absorbed in ABCG5/G8 KO mice (Wang 2007). The lymph fistula model has 
the strength that the transport of a radiolabeled-lipid across the intestinal cells is directly tracked. 
 
The finding that ABCG5/G8 deficiency decreased the lymphatic transport rate of cholesterol seemed to 
contradict a previous finding by Wang and colleagues (Wang 2007), who found that ABCG8 KO mice had 
increased cholesterol transport into the lymph. However, their studies measured transport of a trace amount 
of radiolabeled-cholesterol, whereas our studies measured transport rates of a physiologic quantity in the 
steady state by continuous infusion. It is possible that the impact of ABCG5/G8 on transport kinetics is 
different under the two scenarios. They also administered medium-chain fatty acids as a vehicle for the 
radiolabeled-lipid, whereas we had administered long-chain fatty acids (derived from TG). Plausibly, the 
impact of ABCG5/G8 on cholesterol transport may depend on whether medium or long chain fatty acids 
are administered.   
 
The finding that ABCG5/G8 deficiency decreased the lymphatic transport rate of TG (as well as intestinal 
secretion rate in a separate experiment) was also surprising because it contrasted the report by Mendez-
Gonzales and colleagues, who found increased absorption and intestinal secretion rate of TG (Mendez-
Gonzales 2011). The exact reason for the discrepancy remains unclear. It is important to point out that the 
genetic backgrounds of the mice used in the two studies were different: 129S6SvEv x C57BL/6J strain used 
in their study versus a nearly pure C57BL/6J background used in our study. Differences in phenotype 
related to the genetic background have been documented (Funkat 2004; Paigen 1985).  
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However, the study that was published by Nguyen and colleagues showed that ABCG5/G8 KO mice had 
reduced cumulative cholesterol in the lymph, concomitant with reduced TG associated with chylomicrons 
(Nguyen 2012), which is very similar to what we observed (Paper IV, Figs. 2, 3). Although similar 
outcomes, it should be pointed out that their infusate included sitosterol, a plant sterol, which was speculated 
to have caused the reduction in the lymph cholesterol. Since we did not infuse plant sterols, this indicated 
that the effect was independent of dietary plant sterols. Although the animals were fasted before our 
experiments, we cannot exclude the possibility that plant sterols from plasma (Paper IV, Table 1) could 
have still accumulated in the mucosa, thus causing interference. 
 
Still unknown is the exact mechanism of how ABCG5/G8 handles cholesterol and TG in the intestine and 
why ABCG5/G8 deficiency results in lowered transport of both across the enterocyte. Nguyen and 
colleagues further analyzed chylomicron composition and found that ABCG5/G8 KO mice had lower 
chylomicron phospholipid, TG, and protein mass compared with WT (although their relative compositions 
were the same). Light scattering measurements showed that chylomicron particle size was also the same, 
suggesting that ABCG5/G8 KO mice produced fewer chylomicron particles of similar size (Nguyen 2012). 
Further analyses showed no altered gene expressions of MTP)and apoB, NPC1L1 protein levels (Tang 
2009) nor markers that would indicate ER stress (Nguyen 2012). 
 
Regardless of the mechanism, it is worth examining plasma TG parameters in human subjects with 
sitosterolemia. To our knowledge, no human studies have directly correlated the loss of ABCG5/G8 with 
TG metabolism. The few reports on fasting plasma TG values in sitosterolemic patients (TABLE 2) show 
an interesting trend: these patients have a tendency to have higher plasma TG values than their non-
sitosterolemic family members, which may be partially a result of impaired LPL activity (Mendez-Gonzales 
2011).  Revisiting plasma cholesterol values in these study show that these values are still within the normal 
range. Body weights between normal and a few sitosterolemic patients did not seem to differ (Cobb 1996, 
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Bhattacharyya 1991) although wide-scale association studies have not been performed. Basic science as 
well as clinical studies are further needed to evaluate the significance of ABCG5/G8 in TG homeostasis. 
 
 
TABLE 2: Reported plasma cholesterol and TG levels of sitosterolemic and normal subjects. 
 Sitosterolemic Normal Reference 
Cholesterol (mmol/L) 
TG (mmol/L) 
12.5, 10.8, 11.8, 9.24, 7.2 
3.86, 2.19, 0.93, 1.96, 2.1 
7.44, 4.70, 4.4, 4.0 
1.22, 0.53, 0.8, 0.7 Wang 2004 
Cholesterol (mmol/L) 
TG (mmol/L) 
5.32, 5.69, 3.48 
0.98, 0.90, 0.48 
2.90-5.71 range 
0.35-2.30 range Su 2006 
Cholesterol (mmol/L) 
TG (mmol/L) 
3.75 (n=7), 4.35 (n=30) 
2.2 (n=7), 1.66 (n=30) N/A Salen 2004 
Cholesterol (mg/dl) 
TG (mg/dL) 
184, 274, 206 
84, 121, 189 
200, 166, 154 
50, 46, 57 Lütjohann 1995 
Cholesterol (mg/dl) 
TG (mg/dl) 
189, 267, 246 
318, 142, 52 
125-250 range 
45-150 range Hideki 1990 
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Paper I: Apolipoprotein A-V deficiency in mice results in increased 
triglyceride and cholesterol absorption. 
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Zhang LS, Xu M, Yang Q, Ryan RO, Howles P, Tso P. Apolipoprotein
A-V deficiency enhances chylomicron production in lymph fistula mice. Am
J Physiol Gastrointest Liver Physiol 308: G634–G642, 2015. First published
January 23, 2015; doi:10.1152/ajpgi.00339.2014.—Apolipoprotein A-V
(apoA-V), a liver-synthesized apolipoprotein discovered in 2001,
strongly modulates fasting plasma triglycerides (TG). Little is re-
ported on the effect of apoA-V on postprandial plasma TG, an
independent predictor for atherosclerosis. Overexpressing apoA-V in
mice suppresses postprandial TG, but mechanisms focus on increased
lipolysis or clearance of remnant particles. Unknown is whether
apoA-V suppresses the absorption of dietary lipids by the gut. This
study examines how apoA-V deficiency affects the steady-state ab-
sorption and lymphatic transport of dietary lipids in chow-fed mice.
Using apoA-V knockout (KO, n  8) and wild-type (WT, n  8)
lymph fistula mice, we analyzed the uptake and lymphatic transport of
lipids during a continuous infusion of an emulsion containing
[3H]triolein and [14C]cholesterol. ApoA-V KO mice showed a two-
fold increase in 3H (P  0.001) and a threefold increase in 14C (P 
0.001) transport into the lymph compared with WT. The increased
lymphatic transport was accompanied by a twofold reduction (P 
0.05) in mucosal 3H, suggesting that apoA-V KO mice more rapidly
secreted [3H]TG out of the mucosa into the lymph. ApoA-V KO mice
also produced chylomicrons more rapidly than WT (P  0.05), as
measured by the transit time of [14C]oleic acid from the intestinal
lumen to lymph. Interestingly, apoA-V KO mice produced a steadily
increasing number of chylomicron particles over time, as measured by
lymphatic apoB output. The data suggest that apoA-V suppresses the
production of chylomicrons, playing a previously unknown role in
lipid metabolism that may contribute to the postprandial hypertriglyc-
eridemia associated with apoA-V deficiency.
absorption; intestine
AFTER DIETARY FAT INTAKE, the increase of plasma triglycerides
(TG) is a normal metabolic consequence characterized by a
transient accumulation of TG-rich lipoproteins comprised of
intestinally derived chylomicrons and liver-derived very low
density lipoprotein (VLDL). Hydrolysis of their TG cores
releases free fatty acids to be taken up by muscle and adipose
tissues, generating remnant particles that are efficiently re-
moved from the circulation by the liver. Aberrations in lipo-
protein metabolism result in elevated plasma TG and a pro-
longed accumulation of remnant particles that are atherogenic
(16, 76, 24) and constitute a major risk factor for cardiovas-
cular disease (51, 43).
Apolipoproteins play crucial roles in the regulation of lipo-
protein metabolism by acting as structural proteins, as cofac-
tors for enzymes involved in lipolysis, or as ligands for recep-
tor-mediated clearance of lipoproteins (35). Apolipoprotein
A-V (apoA-V) was discovered in 2001 to be expressed exclu-
sively in the liver and located 30 kb proximal to the APOAI/
CIII/AIV gene cluster (49, 69), a region well-known for reg-
ulating lipid metabolism (19). Early studies using genetically
engineered mouse models revealed apoA-V to be a potent
modulator of plasma TG. Knocking out apoA-V in mice
resulted in a fourfold increase in plasma TG while overexpress-
ing human apoA-V in mice reduced plasma TG by threefold
compared with WT mice (49). Structural analysis showed that
apoA-V is very hydrophobic and predominately lipid-bound
(3, 72), associating with plasma high-density lipoprotein,
VLDL, and chylomicrons (47). What potentially made apoA-V
elusive in its discovery was its low plasma concentration, a
range of 114–258 ng/ml in normolipemic individuals (26, 47,
59, 64). The interesting question is how can an apolipoprotein
of such low plasma concentration affect plasma TG so dramat-
ically?
Over the years, diverse functions have been proposed for
apoA-V. ApoA-V may facilitate lipolysis by interacting with
lipoprotein lipase (LPL) and heparin sulfate proteoglycans (38)
or with an endothelial cell surface protein, glycosylphosphati-
dylinositol high-density lipoprotein-binding protein 1 (4).
ApoA-V may also interact with members of the low-density
lipoprotein-receptor family to enhance receptor-mediated par-
ticle uptake (13, 20, 45, 46). However, its low plasma concen-
tration indicates that apoA-V exists on a subfraction of plasma
lipoproteins, 1 apoA-V molecule for every 24 VLDL parti-
cles (38), suggesting that apoA-V must be recycled for efficient
lipolysis or clearance of particles to occur. Some studies
suggest that apoA-V exerts its effects intracellularly rather than
extracellularly, by interacting with lipid droplets in hepatocytes
(8, 17, 62, 63). In the hepatocyte, and also in the enterocyte
although the mechanisms are nuanced, TG accumulates as
cytosolic lipid droplets on the endoplasmic reticulum (ER)
membrane before being incorporated into lipoproteins for se-
cretion (see Ref. 41). Hence apoA-V is proposed to facilitate
the intrahepatic accumulation of lipid (8, 64), which may
reduce the production rate of VLDL (8, 49), although this
effect was not seen in other studies (15, 20, 38).
In 2001, apoA-V was also discovered to be a novel factor
significantly upregulated during early liver regeneration (70).
Originally, the authors thought apoA-V stimulated lipid uptake
by the liver for regeneration of cell membranes. However, they
observed that apoA-V expression and plasma levels peaked at
6 h after partial hepatectomy, while cell mitosis began 20 h
later. ApoA-V was speculated to inhibit lipid flux to protect the
reduced-size liver against a possible lipid overload, thereby
behaving like a hepatic signal protein. It was apparent that,
since its discovery, apoA-V was thought as an atypical apoli-
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poprotein with its low plasma concentration and significant
ability to modulate plasma TG through a variety of proposed
mechanisms.
While mechanisms of apoA-V have been focused on the
liver or plasma, no studies have investigated its physiological
role in the gut. Only a few studies have looked at effects of
apoA-V on plasma TG after a fatty meal. High levels of
apoA-V in transgenic mice protected against postprandial li-
pemia after an intragastric dose of sunflower oil (15). Adeno-
viral gene transfer of apoA-V to mice also dose-dependently
reduced postprandial TG response (49). Authors of these stud-
ies concluded that, since apoA-V was only expressed in the
liver, the effects were unlikely a result from reduced absorption
but rather increased clearance of lipoproteins. However, what
has not been investigated thus far is the critical question: does
apoA-V play a role in the absorption of dietary lipids by the
gut?
The present study was designed to examine the effects of
apoA-V deficiency on the steady-state absorption and lym-
phatic transport of dietary lipids in chow-fed mice. Based on
previous observations of the effects of apoA-V on postprandial
TG levels (15, 49), and its association with lipid droplets and
potential facilitation of TG accumulation in the ER (8, 62, 63,
64), we hypothesized that apoA-V deficiency would increase
the transport of dietary TG across the enterocyte and its
subsequent secretion as chylomicrons. To test this, we em-
ployed the conscious lymph fistula model to directly examine
the transport of dietary lipids from the intestinal lumen to the
lymph in apoA-V knockout (KO) and wild-type (WT) mice,
providing insight into whether a lack of apoA-V affected
uptake, intracellular metabolism, or the secretion of lipid into
lymph. Our studies show that apoA-V deficiency in mice
significantly increases the absorption and lymphatic transport
of dietary lipids into lymph, providing compelling evidence for
a role of apoA-V in inhibiting lipid absorption and thereby
acting as a hepatic signal to modulate the production of
chylomicrons by the gut.
MATERIALS AND METHODS
Animals. ApoA-V KO mice used in this study were backcrossed to
a C57BL6/J background for at least eight generations, and their
genotypes were confirmed by PCR. ApoA-V KO and age-matched
WT control mice were maintained on standard rodent chow (LM-485
Mouse/Rat Sterilizable Diet; Harlan Laboratories, Madison, WI) un-
der a normal 12:12-h light-dark cycle at the University of Cincinnati
Laboratory Animal Medical Services. Only 3- to 4-mo-old males
were used in the study. All procedures performed were approved
by the University of Cincinnati Internal Animal Care and Use
Committee and complied with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
Lymph and duodenal cannulation. Before surgery, mice were
fasted overnight with free access to water. The following morning, the
animals were anesthetized with ketamine (80 mg/kg) and xylazine (20
mg/kg), and their intestinal lymph ducts were cannulated with poly-
vinylchloride (PVC) tubing (0.20 mm ID; 0.50 mm OD), with slight
modifications to the procedures originally described (9). Instead of
being secured with a suture string, the cannula was secured with a
drop of tissue glue. A surgical incision was made on the fundus of the
stomach, and a second PVC tubing (0.5 mm ID, 0.8 mm OD) was
introduced through the fundus of the stomach into the duodenum. The
tubing was secured by a purse-string and then with a drop of
cryanoacrylate glue. After surgery, the animals were allowed to
recover for at least 24 h in Bollman restraining cages that were
maintained at a warm temperature of 30°C. Despite the restraints, the
animals still had considerable freedom to move forward and
backward and laterally. During recovery, the animals received a
continuous infusion of a 5% saline-glucose solution at a constant
rate of 0.3 ml/h to compensate for fluid and electrolyte loss due to
lymphatic drainage.
Lipid infusion and lymph collection. A lipid emulsion was prepared
by dissolving triolein {labeled with [9,10-3H(N)]triolein}, cholesterol
{labeled with [1,2-14C(N)]cholesterol}, and egg phosphatidylcholine
in chloroform, which was then evaporated under nitrogen gas. The
chloroform-free mixture was emulsified with 19 mM sodium tauro-
cholate (NaTC) in phosphate-buffered saline (PBS) at pH 6.4. The
emulsion was pulse sonicated until the emulsion appeared homoge-
neous. Homogeneity was verified by determining radioactivity in
samples taken from the top, middle, and bottom of the emulsion.
Emulsions were considered homogeneous if the counts did not vary
1%. The morning after surgery, the overnight saline-glucose solu-
tion was replaced with the lipid emulsion described above. Each
mouse received a continuous intraduodenal infusion of the lipid
emulsion for 6 h at a rate of 0.3 ml/h. A continuous infusion enables
measurement of transport rates at the steady state (5). The hourly
infusate contained 4 mol triolein labeled with 1 Ci [3H]triolein,
0.78 mol cholesterol labeled with 0.1 Ci [14C]cholesterol, 0.78
mol egg phosphatidylcholine, and 5.7 mol NaTC in PBS. Lymph
samples were collected hourly in microcentrifuge tubes on ice. Be-
cause the animals are conscious during lipid infusion, our experiments
lacked the complications from anesthesia, which could affect the
production of chylomicrons (56).
Collection of intestinal tissues and luminal contents. At the end of
the 6-h study, mice were anesthetized in preparation for tissue and
organ removal. The small intestine was carefully removed with its
mucosal tissue left intact and cut into four equal-length segments
through three separate suture ties. The segments were labeled M1–M4
[M1, (duodenum), M2 and M3 (two equal length segments of the
jejunum), and M4 (ileum)]. The content from each segment was
emptied into a tube and followed by three washes of 10 mM of NaTC
solution. Luminal contents from the stomach, small intestine, and
colon were collected from three rinses of 10 mM NaTC. The mucosal
tissue of the small intestine was left intact and homogenized using a
Polytron homogenizer. Samples from the hourly lymph, luminal
washings, and intestinal tissues were taken for determination of
radioactivity by scintillation spectroscopy. Lipids recovered from
the intestinal lumen and mucosa at the end of the study allowed for
analysis of steady-state accumulation of lipids that were not
secreted (1).
Absorptive and lymphatic transport index calculations. To deter-
mine the efficiency of the enterocyte in absorbing and transporting
lipids into the lymph, absorptive and lymphatic transport indexes were
computed as previously described (7). The absorptive index represents
the percentage of infused lipid taken up by the enterocyte and is
calculated from the following equation: absorptive index  100% 
(%total dose recovered in the lumen). The lymphatic transport index
represents the percentage of absorbed lipid secreted into the lymph. It
determines the ability of the small intestine to transport the absorbed
lipid into the lymph independent of the amount of lipid absorbed. The
transport index is calculated from the equation: lymphatic transport
index  (%infused dose recovered in lymph)/(absorptive index) 
100.
Chylomicron appearance time. Chylomicron appearance time was
determined as previously described (67, 68). Mice were given a
continuous intraduodenal infusion of the same lipid emulsion as
described above at a rate of 0.3 ml/h. At the 4th h of lipid infusion
when steady-state lymphatic TG transport was reached, the infusion
pump was stopped, and a bolus dose of [14C]oleic acid (0.5 Ci in 100
l oleic acid) was injected intraduodenally. After injection, the
infusion was resumed to maintain steady-state lymphatic TG trans-
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port, and lymph samples were collected every minute for 45 min in
small glass scintillation vials. Radioactivity was determined by scin-
tillation counting. The first appearance of radioactivity (in min)
represented the time for radioactive oleic acid to be taken up by the
enterocyte, resynthesized as TG, packaged, and secreted as chylo-
microns in the lymph. It is very important to assess the cellular
packaging and release of chylomicrons at the steady state of
lymphatic output, since chylomicron production rates can depend
on factors such as lymph flow or interstitial fluid hydration as
previously studied (67, 68).
Measurement of lymphatic outputs of apoB and apoA-IV. The
lymphatic outputs of apoB and apoA-IV were measured by Western
blotting. Samples equivalent to 3 s of lymph flow were resolved on
4–15% polyacrylamide gradient gels and transferred to polyvi-
nylidene difluoride membranes. Following transfer, membranes were
blocked with 5% nonfat milk in 0.1% Tween 20 in Tris-buffered
saline (TBS) for 1 h. Membranes were incubated with antibodies
against apoB and apoA-IV (1:5,000) overnight. After being rinsed
with TBS plus 0.1% Tween 20, membranes were incubated with
peroxidase-conjugated anti-goat antibody at 1:10,000 for 30 min, and
signal was developed with Immobilon Western Chemiluminescent
HRP substrate (EMD Millipore, Billerica, MA). Protein bands were
quantified by densitometric analysis using Total Lab Quant Analysis
Software (Fotodyne, Hartland, WI).
Statistical analysis. The data shown are mean values 	 SE. To
compare groups throughout the 6-h infusion period, two-way repeated-
measures ANOVA with Tukey posttest analysis were used. For com-
parison of data that have two independent variables, two-way
ANOVA was used. A t-test was used for comparisons of only two
groups. Statistical analyses were performed using GraphPad Prism
version 6. Data were considered significant if P  0.05.
RESULTS
Lymphatic transport of lipids. Lymph flow was maintained
at 0.2–0.3 ml/h by setting the intraduodenal infusion rate at 0.3
ml/h (Fig. 1). There were no significant differences between
the two groups except at the 5th and 6th h, where the lymph
flow of the WT mice decreased to 0.11–0.12 ml/h. It should be
noted that this decrease occurred after steady state has been
achieved and does not affect our analyses of lymphatic output
of lipid (68).
The amount of TG transported into the lymph per hour was
measured by 3H and expressed as a percentage of the hourly
infused dose (Fig. 2A). Interestingly, apoA-V KO mice showed
substantially higher lymphatic 3H transport at the steady state
(52.9 	 3.3%) than WT controls (30.2 	 1.5%), with differ-
ences seen as early as 1 h after the start of lipid infusion.
Steady state was achieved within 3–4 h for both groups of
animals.
The amount of cholesterol transported into the lymph was
measured by 14C and expressed as a percentage of the hourly
infused dose (Fig. 2B). As with 3H, the lymphatic transport of
14C was also significantly higher in apoA-V KO (29.4	 2.9%)
than in WT mice (9.9 	 4.3%) at the 6th h, with differences
evident within 2 h after the start of lipid infusion. With
lymphatic transports of both 3H and 14C higher in apoA-V KO
mice, the data suggest that chylomicron production is signifi-
cantly higher in these mice, revealing a novel role for apoA-V
in regulating intestinal lipid secretion under physiological
conditions.
Distribution of lipid along segments of the small intestine.
With increased lymphatic transport of lipid in the apoA-V KO
mice, we wondered if the mucosa accumulation and distribu-
tion of lipids were different in these animals. Figure 3 illus-
trates the distribution of 3H and 14C accumulated along four
equal-length segments of the small intestine, M1–M4 (proxi-
mal to distal) at the end of the 6-h infusion period. The pattern
of accumulation of 3H and 14C for both groups of animals
showed a decrease from M1 to M4, confirming that the primary
Fig. 1. Lymph flow was maintained at 0.2–0.3 ml/h in apolipoprotein A-V
(apoA-V) knockout (KO) and wild-type (WT) mice. Mesenteric lymph flow
was measured hourly for 6 h. *P  0.05. Values are means 	 SE.
Fig. 2. ApoA-V KO mice show increased triglyceride (TG) and cholesterol
transport into the lymph compared with WT. Lymphatic outputs of 3H (A) and
14C (B) were expressed as percentages of the hourly dose. Lymph fistula mice
were intraduodenally infused with a lipid emulsion containing [3H]TG and
[14C]cholesterol for 6 h. *P  0.05. Values are means 	 SE.
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sites of lipid absorption were mainly located at the proximal
half of the intestine (44). ApoA-V KO mice had significantly
less 3H in the whole mucosa than WT (P  0.0004), with the
difference being significant in M1 (P  0.0025) and M2 (P 
0.0003) (Fig. 3A). The data are consistent with our notion that
A-V KO mice are more efficient in packaging the absorbed TG
into chylomicrons for secretion.
This trend was not seen with cholesterol recovery in the
mucosa. Although apoA-V KO mice had slightly more 14C
recovered from M1 (P  0.0359), they had a similar distribu-
tion of 14C recovered from the rest of the segments compared
with WT (Fig. 3B). Taken together, the data suggests that
apoA-V affects the handling of dietary TG and cholesterol in
the intestinal mucosa differently.
Recovery of radiolabeled lipid at the end of 6 h continuous
infusion. By accounting for the total amount of lipid from the
lymph and from the intestinal mucosa and lumen at the end of
the study, we were able to analyze how a lack of apoA-V
affected steady-state transport of lipids from lumen to lymph.
We also collected luminal contents from the stomach and colon
to account for lipids that may have refluxed or have been
excreted. Figure 4 illustrates the total amount of dietary TG
and cholesterol remaining in the lymph, intestinal mucosa,
intestinal lumen, stomach, and colon after 6 h of infusion.
ApoA-V KO mice showed significantly increased 3H in lymph
(P  0.0001) with a concomitant reduction in 3H recovered
from the intestinal mucosa (P  0.0004) and lumen (although
insignificant, P  0.0584) compared with WT (Fig. 4A).
apoA-V KO mice also had significantly increased 3H recovered
from the lymph (P  0.0001), with a possible slight reduction
in recovery from the lumen (P  0.08) compared with WT
(Fig. 4B). Total 3H recovery was no different between the
groups (WT 68.72 	 3.01 vs. KO 70.25 	 3.56%). Although
total recovery was 100%, the value obtained is consistent
with a number of previous studies showing incomplete absorp-
tion of long-chain TG into the lymph (10, 75), possibly due to
a small percentage of transport to the portal vein (25, 37) or
oxidation.
Unlike 3H recovery, there was no difference in the amount
of 14C recovered from the mucosa of the two groups of mice,
probably as a result of the mixing of labeled cholesterol with
unlabeled cholesterol in the various pools within the mu-
cosa. Very little amounts of 3H (Fig. 4A) and 14C (Fig. 4B)
were recovered from the stomach, indicating that the infused
lipids refluxed very minimally back into the stomach. Also,
very little 3H and 14C were recovered from the cecum,
showing that the infused lipids were minimally excreted
during our 6-h study. Overall, the data suggest that the
apoA-V KO mice were more efficient in taking up the TG
and cholesterol presented in the intestinal lumen and secret-
ing them in the lymph.
To numerically represent the efficiency of the intestine to
take up lipid and to transport the absorbed lipid into the lymph,
two indexes were calculated and shown in Table 1. Both the
absorptive index and lymph transport index for 3H were higher
in apoA-V KO mice than in WT, suggesting more efficient
uptake and secretion of dietary TG. The lymph transport index
for 14C was significantly higher in apoA-V KO mice, indicat-
ing more efficient secretion of dietary cholesterol into the
lymph. These indexes illustrate apoA-V deficiency results in
more efficient chylomicron secretion, independent of lipid
uptake.
Chylomicron appearance time. As an alternative measure
of chylomicron secretion efficiency, we measured the chy-
lomicron appearance time, which is the time for [14C]oleic
acid placed in the intestinal lumen to appear in the lymph as
14C chylomicrons during steady-state transport. It represents
the total time required for lipid uptake, resynthesis into TG,
assembly into chylomicrons, and secretion into the lymphat-
ics. Figure 5 shows the chylomicron appearance time is
significantly (P  0.05) shorter in apoA-V KO mice (21.5 	
3.3 min) than in WT mice (32.8 	 2.1 min), further
demonstrating that apoA-V KO mice are faster at generating
chylomicrons.
Lymphatic output of apoB and -A-IV. Because the data thus
far suggest that chylomicron production is enhanced in apoA-V
KO mice, we measured the lymphatic output of apoB, which
represented the number of chylomicrons produced over time,
since only one apoB protein is assumed to be one chylomicron
particle (2). While WT mice had a constant lymphatic output of
apoB as expected, apoA-V KO mice showed a steady increase
in the lymphatic output of apoB (Fig. 6, A and B), suggesting
a greater number of chylomicron particles produced over time.
Because apoA-IV is presumed to facilitate the assembly of
chylomicrons (73), we also measured the lymphatic output of
apoA-IV. There was no difference between the two groups in
the lymphatic output of apoA-IV relative to fasting (Fig. 6C)
although both groups displayed an 1.5-fold increase over 6 h
that is comparable to previous studies (22, 28). This suggests
Fig. 3. Distribution of 3H (A) and 14C (B) along the small intestine divided into
4 segments of equal length, from proximal to distal: M1 (duodenum), M2 and
M3 (jejunum), and M4 (ileum). *P  0.05. Values are means 	 SE.
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that apoA-V does not affect the lipid-stimulated secretion of
apoA-IV by the intestine. Overall, these data suggest that the
increased lymphatic output of dietary TG in apoA-V KO mice
is a result of increased production of chylomicron particles.
DISCUSSION
While apoA-V is well-demonstrated to profoundly regulate
fasting plasma TG in both mice (20, 49, 15, 49, 61, 70, 64) and
humans (1, 14, 23, 32, 21), little is known about the contribu-
tion of apoA-V to lipid absorption and postprandial TG me-
tabolism. Results from apoA-V transgenic mice (15) and ade-
novirus-mediated gene transfer experiments to mice (49) sug-
gest that apoA-V suppresses the surge in plasma TG after a
lipid meal. However, because apoA-V is only synthesized in
the liver (49, 69), mechanistic studies have been focused on
enhanced lipolysis (18, 38, 64) or clearance of plasma lipopro-
teins (20, 38) and not on actions in the gut. The present studies
demonstrate a novel role for apoA-V in the absorption of
dietary lipids and secretion of chylomicrons by the gut. We
show that apoA-V deficiency in mice enhances the transport
rate of dietary lipids across the enterocyte, which is accompa-
nied by their rapid secretion from the mucosa into the lymph.
This is the first report of apoA-V mediating physiological
actions in the intestine.
Postprandial hypertriglyceridemia is an independent risk
factor for coronary artery disease (see Ref. 30). The surge in
postprandial TG-rich lipoproteins, both intestinally derived
chylomicrons and hepatic-derived VLDL, are thought to have
deleterious effects on arterial vessel walls (53, 36) and thus
contribute to atherosclerosis (34, 71, 76). Increased postpran-
dial plasma TG is also an inherent feature of diabetic dyslipi-
demia (12, 33), but the underlying mechanisms remain unclear.
Since nearly all dietary lipids enter the bloodstream through the
intestine, understanding the contribution of intestine to post-
prandial hypertriglyceridemia is of high clinical and therapeu-
tic importance.
The lymph cannulation method allows us to examine chy-
lomicrons before entering the circulation, which dissociates
chylomicron production from clearance. A previous study by
Merkel et al. (38) reported that the intestinal secretion of
Fig. 4. Total recovery of 3H (A) and 14C (B) at the end
of the 6-h lipid infusion. Lymph refers to the total
radiolabeled lipid collected from the lymph from the 6-h
infusion period. Mucosa refers to radioactivity recov-
ered after homogenization of the small intestine. Lumen
refers to luminal contents from the small intestine that
were washed and collected at the end of infusion. Very
low amounts of TG were recovered from the colon and
stomach, indicating little excretion and reflux, respec-
tively. *P  0.05. Values are means 	 SE.
Table 1. Absorptive and lymphatic transport index
TG Cholesterol
Absorptive
Index
Lymphatic
Transport Index
Absorptive
Index
Lymphatic
Transport Index
WT 91.75 	 1.54 25.81	 3.56 74.80	 2.82 7.62	 1.51
apoA-V
KO 95.36 	 0.32* 49.08	 3.08* 81.23	 1.99 22.00	 1.30*
Values are means 	 SE. TG, triglyceride, WT, wild type; apoA-V, apoli-
poprotein A-V; KO, knockout. *P  0.05.
Fig. 5. ApoA-V KO mice have a shorter chylomicron appearance time (min)
after [14C]oleic acid injection in the intestinal lumen. apoA-V KO and WT
mice were infused intraduodenally with a lipid emulsion containing TG. At
the 4th h of lipid infusion when steady-state lymphatic TG transport was
reached, [14C]oleic acid was introduced into the lumen, and lymph samples
were collected every minute afterward for 60 min. *P  0.05. Values are
means 	 SE.
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dietary TG was not different in apoA-V transgenic mice
compared with WT, although the authors elegantly demon-
strated that apoA-V enhanced LPL-mediated hydrolysis of
lipoproteins in the plasma. The lipids were administered by
intragastric gavage, which is commonly used to measure total
absorption but cannot determine its absorptive ability due to
variability of stomach emptying (1, 5). Also, studies performed
with a bolus dose of lipid cannot give information on the
absorption rate of lipid at the steady state, which is an impor-
tant question when evaluating the contribution of chylomicron
delivery to the postprandial TG surge. Furthermore, in the
study by Merkel et al., it is possible that a superphysiological
level of apoA-V cannot alter the absorption of TG, hence the
lack of difference seen in apoA-V transgenic mice. Therefore,
to directly address the hypothesis that apoA-V plays an impor-
tant role in regulating the production rate of chylomicrons, we
employed the conscious lymph fistula model under a continu-
ous infusion setting in apoA-V-deficient mice and WT con-
trols.
The results of this study demonstrate that apoA-V deficiency
enhances the efficiency of the small intestine to absorb and
secrete dietary lipid into the lymph. We show that the transport
of [3H]TG from lumen to lymph is accelerated in apoA-V KO
mice, as reflected by an increase in the lymphatic transport rate
of 3H (Fig. 2A), a decrease in the amount of [3H]TG retained
in the intestinal mucosa, and a trend for decrease in the
intestinal lumen (Fig. 4A). Further quantitative analyses show
that apoA-V KO mice have a greater ability to take up [3H]TG
and secrete TG into the lymph (Table 1). This effect is seen
specifically in the proximal sections of the small intestine (Fig.
3A). Because more TG is transported as chylomicrons in the
apoA-V KO mice, more cholesterol is presumed to be trans-
ported out of the small intestine. We find that the transport of
14C from lumen to lymph is indeed enhanced in apoA-V KO
mice (Figs. 2B and 4B), indicating the effect of apoA-V
deficiency was not specific to TG. However, there is no
difference in 14C retained in the intestinal mucosa (Fig. 3B),
which could be explained by the large intracellular cholesterol
pool diluting the exogenous labeled cholesterol.
These results suggest a role for apoA-V in the lipidation of
primordial chylomicron particles, which is supported by stud-
ies in the hepatocytes where apoA-V is postulated to stabilize
lipid droplets (8, 62, 63). It is possible that apoA-V may gain
access to enterocyte lipid droplets and, in doing so, serve to
modulate TG secretion, and that apoA-V deficiency could
cause more rapid movement of intracellular TG into primordial
chylomicrons and subsequently enhances chylomicron produc-
tion. Indeed, when chylomicron appearance time was mea-
sured, we found that apoA-V KO mice took less time to
produce chylomicrons (Fig. 5) than WT mice, which further
strengthens the argument that apoA-V plays an important role
in suppressing chylomicron production.
While some reports (15, 20, 38), plus studies in our lab (data
not shown), have found no effect of apoA-V on hepatic VLDL
secretion, there is a body of evidence that shows that apoA-V
KO mice have impaired removal of lipoprotein remnants (15,
Fig. 6. ApoA-V KO mice have increased intestinal apoB secretion into the lymph. A: lymph samples were analyzed for apoB by Western blot. Protein
concentration was quantified by densitometric analysis and normalized to hour 0 (fasting). B: a representative blot is shown for lymphatic apoB output. C: lymph
samples were analyzed for apoA-IV by Western blot.
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20). Our finding that apoA-V deficiency resulted in greater
chylomicron particle secretion (Fig. 6, A and B) provides an
additional mechanism by which a lack of apoA-V contributes
to postprandial lipemia. An increased rate of chylomicron
production may result in a greater flux of chylomicron particles
to the remnant pool in the plasma. Because apoA-V-deficient
mice were previously shown to have reduced LPL activity
(20), the rapid influx of chylomicrons might tax the capacity
for hydrolysis of TG-rich lipoproteins (chylomicrons plus
VLDL) and thereby reduce their removal rate.
Applied to the human population, only a few studies have
examined the association of apoA-V polymorphisms with
postprandial plasma TG although a clear association of
apoA-V polymorphisms and elevated fasting plasma TG has
been documented in a wide range of ethnic groups (29, 32, 42,
50, 57). These studies observed an inverse relationship be-
tween plasma apoA-V and postprandial TG in patients after a
lipid meal. For example, the C allele of the T-1131C polymor-
phism was found to be associated with hypertriglyceridemia
and higher postprandial TG in nonobese Korean (27) and
Caucasian (39) populations. Additionally, healthy young males
with the APOA5*2 haplotype (1131CT) or APOA5*3
haplotype (c.56CG) also showed higher postprandial re-
sponse after a fat load test (40). However, the mechanisms
underlying these effects were not further explored and were
thought to be caused by slower TG hydrolysis and removal of
remnant lipoproteins based on evidence in mouse models. Our
studies direct attention to a major contribution by the gut in the
delivery of chylomicron particles in the postprandial state,
signifying the importance of dietary considerations or gut-
targeted therapeutics in patients with apoA-V polymorphisms.
Our findings are particularly important because they predict
higher levels of postprandial apoB48, and significant evidence
links increased apoB48 with adverse cardiovascular events (see
Ref. 66) and the presence of apoB48 in atherosclerotic plagues
(48, 54).
In summary, we have demonstrated for the first time that
apoA-V deficiency in mice significantly increases the produc-
tion rate of chylomicrons by the gut and that this effect seems
to come from more efficient shuttling of dietary TG out of the
mucosa and into the lymph. Our findings suggest that apoA-V
does not behave as a typical classical apolipoprotein but rather
a signal protein, communicating between the liver and the gut.
This suggestion was first put forth by Van der Vliet and
colleagues in 2001, who speculated that apoA-V may act as a
signal released by the liver during regeneration to protect
itself against a lipid overload (70). In a normal physiological
condition, apoA-V may be released by the liver to reduce
lipid flux from the gut. Interestingly, cases of apoA-V
deficiency in humans do demonstrate a higher postprandial
TG excursion (27, 31, 40). By extension, the postprandial
hypertriglyceridemia seen in these patient populations may
be attributed to an increased rate of delivery of dietary lipids
to the bloodstream.
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Paper I: Apolipoprotein A-V deficiency in mice results in increased 
triglyceride and cholesterol absorption. 
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ABSTRACT 
Apolipoprotein (apo) A-V is a protein synthesized only in the liver that dramatically modulates 
plasma triglyceride levels. Recent studies suggest a role for hepatic apoA-V in regulating the 
absorption of dietary triglycerides but its mode of action on the gut remains unknown. The aim of 
this study was to test for apoA-V in bile and to determine if its secretion is regulated by dietary 
lipid. After an overnight recovery, adult male Sprague-Dawley bile fistula rats indeed secreted 
apoA-V into bile at a constant rate under fasting conditions. An intraduodenal bolus of intralipid 
(n=12) increased the biliary secretion of apoA-V but not of other apolipoproteins, such as A-I, A-
IV, B and E. The lipid-induced increase of biliary apoA-V was abolished under conditions of poor 
lymphatic lipid transport, suggesting that the stimulation is regulated by the magnitude of lipid 
associated with chylomicrons transported into lymph. We also studied the secretion of apoA-V 
into bile immediately following bile duct cannulation.  Biliary apoA-V increased over time (~6-
fold increase in 16 h, n=8) but the secretions of other apolipoproteins remained constant. 
Replenishing luminal phosphatidylcholine and taurocholate (n=9) only enhanced apoA-V 
secretion in bile, suggesting that the increase was not due to depletion of phospholipids or bile 
salts. This is the first study to demonstrate that apoA-V is secreted into bile, introducing a potential 
route of delivery of hepatic apoA-V to the gut lumen. Our study also reveals the uniqueness of 
apoA-V secretion into bile that is regulated by mechanisms different from other apolipoproteins.   
 
Key words (5 but not in title): Bile fistula, fat absorption, negative feedback regulation, 
chylomicron, bile acids 
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INTRODUCTION 
 
 Secretion of bile is a unique function of the liver and serves many purposes: 1) bile salts 
enable the micellar solubilization and absorption of fat, 2) IgA in bile protects against infection, 
3) liver-derived metabolites, some toxic, are secreted into bile for excretion from the body. The 
composition of bile is complex, containing bile salts, lipids (namely phospholipids and 
cholesterol), and proteins (albumin, secretory component, IgA, apolipoproteins) and their 
secretions vary with the nutritional state of the individual (see Reviews 5, 35) 
Generally known to be synthesized in the liver (23, 36), apolipoprotein (apo) A-V 
profoundly modulates plasma triglyceride levels. Compared with wild type (WT) mice, apoA-V 
knockout (KO) mice have drastically elevated plasma triglyceride levels while transgenic mice 
overexpressing apoA-V have profoundly reduced plasma triglyceride levels (23). In humans, 
apoA-V polymorphisms correlate with hypertriglyceridemia and cardiovascular disease (23, 16, 
19, 22, 25). Intravenous injection of recombinant apoA-V protein can lower plasma triglyceride 
levels in hypertriglyceridemic apoA-V KO mice (30), demonstrating the therapeutic potential of 
apoA-V in hyperlipidemia.  
Recent studies from our laboratory revealed a novel role for apoA-V in modulating the 
absorption of dietary lipids and subsequent production of chylomicrons. ApoA-V KO mice display 
a twofold increase in the transport rate of dietary lipids into the lymph, which was correlated with 
increased intestinal apoB secretion (38). Since apoA-V is synthesized predominantly in the liver 
and not in the small intestine, an interesting question that arises is: how does hepatic apoA-V gain 
access to the small intestine? We hypothesize that the liver secretes apoA-V into bile to provide a 
luminal source of apoA-V that may regulate the formation and secretion of chylomicrons.  
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The aim of this study was to test for apoA-V secretion into bile and, if present, to study 
how its secretion into bile is regulated by dietary lipid absorption using the bile fistula rat model. 
In the present work, we show for the first time that apoA-V is indeed present in bile. Furthermore, 
we show that its secretion increases in response to absorption of dietary lipid and its transport into 
lymph. We also observe that bile drainage stimulates the secretion of apoA-V into bile during the 
day of surgery, which occurs independently of the deprivation of luminal phospholipids and bile 
salts.  
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MATERIALS AND METHODS 
 
Animal Models. Sprague-Dawley rats were purchased from Harlan Sprague Dawley 
(Indianapolis) and were allowed to acclimatize to the vivarium environment for at least two weeks 
prior to the experiment. The rats were maintained on standard rodent chow (LM-485 Mouse/Rat 
Sterilizable Diet; Harlan Laboratories, Madison, WI) and were housed under conditions of 
controlled temperature, humidity and a normal 12:12 h light-dark cycle at the University of 
Cincinnati Laboratory Animal Medical Services. Only 3 to 4 month old males were used in the 
study. Prior to surgery, animals were fasted overnight with free access to water. The following 
morning, the animals were anesthetized with isoflurane. The surgical procedures are detailed 
below. After surgery, the animals were placed in Bollman restraining cages in an environment 
maintained at a temperature of 30º C to prevent hypothermia. Normally animals nestle together to 
keep warm but they cannot do so due to restriction of the Bollman cages. Despite restraints, the 
animals still had considerable freedom to move forwards and backwards and sideways. The 
animals were allowed to recover overnight from surgery while receiving a continuous 
intraduodenal infusion of 5% glucose-saline solution. All procedures were performed in 
accordance with the University of Cincinnati Internal Animal Care and Use Committee and in 
compliance with the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals. 
 
Bile fistula surgery with duodenal cannulation. The common bile duct, just below the two hepatic 
ducts, was cannulated with polyvinylchloride tubing tipped with polyethylene tubing (0.20 mm 
inner diameter (ID); 0.50 mm outer diameter (OD), BIOCORP Aust PTY Ltd, Victoria, Australia) 
 
 
6 
 
and exteriorized through a stab wound in the animal’s right flank, as previously described (34). 
The fundus of the stomach was incised to introduce a silicone feeding tube (0.5 mm ID; 0.8 mm 
OD) through the stomach, about 2 cm into the duodenum. The tube was secured by a purse-string 
suture and the incision was sealed with a drop of tissue glue. After surgery, 5% glucose-saline was 
infused intraduodenally at 1.5 ml/h to replace fluid and electrolyte lost by bile diversion.  Bile was 
collected hourly by gravity drainage into micro-centrifuge tubes on ice for various times as 
indicated in Results. In some experiments the glucose-saline infusion was replaced by saline or by 
6.6 mM phosphatidylcholine for the phospholipid (PL) and 10 mM sodium taurocholate (NaTC) 
in saline to replenish the loss of these important components of bile through interruption of the 
enterohepatic circulation by bile drainage. Taurocholate was used because it is the primary bile 
acid in the rat (2) and used by previous investigators studying the rat (6, 28). 
 
Lymph fistula surgery with duodenal cannulation. To measure absorption and transport of lipid, 
we used the lymph fistula model in a separate cohort of animals. The mesenteric lymph duct was 
also cannulated with polyvinylchloride tubing (0.20 mm ID; 0.50 mm OD), with the slight 
modification of original procedures (4) by securing the cannula with a drop of tissue glue instead 
of suture. As described above, a silicon feeding tube was introduced through the stomach into the 
duodenum for saline or lipid infusions. After surgery, 5% glucose-saline was infused 
intraduodenally at a rate of 3.0 ml/h to compensate for fluid and electrolyte loss due to lymphatic 
drainage. After overnight recovery, the animals were given a 3 ml intraduodenal bolus of Liposyn 
III 20%, which contained 20% soybean oil, 1.2% egg phosphatides and 2.5% glycerin in water. 
To avoid a volume overload in the small intestine, we waited 30 minutes before giving a 
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continuous intraduodenal infusion of saline or 6.6 mM PL and 10 mM NaTC, as indicated in 
Results. Lymph was collected by gravity drainage in micro-centrifuge tubes on ice for 6 h.  
 
Measurement of apolipoproteins. Apolipoproteins A-I, A-IV, A-V, B, and E were quantitated by 
Western blotting. 2 µl bile samples were loaded onto 4-15% polyacrylamide gradient gels and 
transferred to polyvinylidene difluoride membranes. Following transfer, membranes were blocked 
with 5% nonfat milk in 0.1% Tween 20 in Tris-buffered saline (TBS) for 1 h. Membranes were 
incubated with antibodies raised against apoA-I, A-IV, A-V, B, and E (each 1:5000) overnight. 
After rinsing with TBS with 0.1% Tween 20, membranes were incubated with peroxidase-
conjugated anti-goat secondary antibody at 1:10,000 for 30 min and developed with Immobilon 
Western Chemiluminescent horseradish peroxidase substrate (Millipore Corporations, Billerica, 
MA). Protein quantification was performed by densitometric analysis of films using Total Lab 
Quant Analysis Software (TL100, FOTODYNE, Hartland, WI).  
 
Measurement of triglyceride, cholesterol, phospholipids, and bile salts. Triglyceride 
concentration was measured by Total Triglyceride assay kits (Randox Laboratories, Kearneysville, 
WV). Cholesterol was measured by chemical assay using Infinity Cholesterol Liquid Stable 
Reagent (Fisher Diagnostics, Thermo Scientific, Middletown, VA). Phospholipid was measured 
by chemical assay using Phospholipids C reagent (Wako Diagnostics, Mountain View, CA) after 
diluting samples 1:5 in saline. Bile acids were measured by enzymatic assay using Rat Total Bile 
Acids Kit (Crystal Chem, Downers Grove, IL) after bile samples were diluted 1:100 in 70% 
ethanol, as recommended by the manufacturer for bile. All assays were performed according to 
the manufacturer instructions.  
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Statistical Analysis. The data shown are mean values ± standard errors of the mean (SEM). Two-
way repeated measures analysis of variance (ANOVA) with Sidak multiple comparisons post-test 
analysis were used. Statistical analyses were performed using GraphPad Prism v6. Data were 
considered significant if P is less than 0.05. 
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RESULTS 
 
ApoA-V is Present in Bile and is Secreted at a Constant Rate under Fasting Conditions. After a 
24 h recovery from surgery, bile fistula rats received an intraduodenal infusion of saline at 1.5 ml/h 
while bile was collected hourly by gravity drainage. The presence of apoA-V in bile was 
quantitated by Western blot.  ApoA-V was indeed present in bile and was secreted at a constant 
rate under fasting conditions (Fig. 1A).  This is based on the fact that bile flow rate did not vary 
during the study (Fig. 1B). For the Western blot analysis, we used 2 l of each hourly bile sample. 
Biliary secretion, or output, was determined by relative concentration x bile flow.  
 
ApoA-V Secretion Into Bile Increases After Lipid Absorption. We next sought to determine if 
apoA-V secretion into bile is regulated by dietary lipid absorption. However, lipid digestion and 
transport into lymph is compromised in bile fistula rats (26), likely due to the lack of luminal 
phosphatidylcholine for the adequate coating of chylomicrons (33).  The lack of bile salts in the 
lumen of the bile fistula rats impaired the micellar solubilization of fatty acids monoacylglycerols 
for efficient uptake by the enterocytes (12) across the unstirred water layer that borders the luminal 
surface of intestinal cells (37). Therefore we infused 6.6 mM phosphatidylcholine and 10 mM 
sodium taurocholate (PL+NaTC) continuously into the duodenum at 1.5 ml/h for 2 h before 
administering the lipid bolus and then for the remainder of the experiment.  To confirm that lipid 
absorption in the bile fistula rats was restored by PL+NaTC infusion, a separate control experiment 
was performed with intestinal lymph collection in addition to bile diversion (see Methods). Fig. 2 
shows that our regimen of PL+NaTC infusion into bile fistula rats resulted in normal lymphatic 
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fat transport, both in timing and extent, compared to bile-intact control rats. As expected, 
lymphatic fat transport was reduced in bile fistula rats without the PL+NaTC supplement (Fig. 2). 
With these conditions, we proceeded to test the biliary response of apoA-V to dietary lipid. 
Fig. 3A shows that apoA-V secretion into bile increased ~6 fold in response to active dietary lipid 
absorption and did not increase in response to saline. The increase began 3 h after administration 
of the lipid bolus (P<0.01 at hour 6). Compared with the results shown in Fig. 2, the increase of 
biliary apoA-V was well correlated with the maximal triglyceride delivery into lymph. The lipid-
induced increase was abolished in animals given lipid but with no phospholipid/bile salt 
supplementation (Fig. 3), suggesting that biliary apoA-V stimulation required the lymphatic lipid 
flux associated with the production of TG-enriched chylomicrons.   
To determine if the lipid-induced increase was specific to apoA-V or a general response of 
the biliary secretion of apolipoproteins in response to lipid absorption, we measured the biliary 
outputs of the other apolipoproteins. Fig. 3B shows that, except for a modest 2-fold increase of 
apoA-I, the biliary secretions of other apolipoproteins (apoA-IV, apoB, apoE) were not affected 
by active dietary lipid absorption. This indicated that the dramatic increase of biliary apoA-V 
output in response to dietary lipid was specific, suggesting a possible role for apoA-V in dietary 
lipid absorption. Lipid treatment did not affect the rate of bile flow, which remained between 0.8-
1.0 ml/h (Fig. 3C). Taken together, the data show that apoA-V secretion into bile is regulated by 
active absorption of dietary fat. 
 
Dietary Lipid Does Not Significantly Stimulate Biliary Secretions of Lipids or Bile Salt. We next 
determined if the increase in biliary apoA-V secretion was correlated with increased secretion of 
biliary lipids or bile salt. Lipid treatment did not significantly change the biliary outputs of 
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cholesterol and bile salts when compared to saline treatment (Figs 4A, B). Lipid treatment 
increased total biliary phospholipid output (P<0.05 in treatment factor, two-way ANOVA) with 
the increase apparent at 1 and 2 h following administration of the lipid bolus, but there were no 
statistical differences between groups at individual time points (Fig 4C). Taken together, we 
conclude that a single bolus of dietary lipid does not significantly impact the biliary secretion of 
cholesterol and bile salts, with the possible exception of phospholipid, thus reinforcing the unique 
response of biliary apoA-V secretion to dietary lipid. 
 
Acute Response of Biliary ApoA-V to Bile Fistula Surgery. In the previous experiments, we 
allowed the animals to recover from surgery for 24 h before proceeding to our lipid studies. While 
this experimental design is consistent with previous studies (1, 15, 34), it diverts bile and interrupts 
the enterohepatic circulation. Because bile salts and farnesoid X receptor (FXR) ligands were 
found to stimulate hepatic apoA-V promoter activity in vitro (24), we wondered if the biliary 
output of apoA-V responded to bile drainage per se during the initial period after surgery. We 
expected that apoA-V secretion into bile would decrease with bile drainage, which is expected for 
bile flow and the biliary outputs of other lipids (32). Interestingly, the biliary output of apoA-V 
increased over time during the 16 h study (P<0.01 at hour 16 relative to hour 1 after bile duct 
cannulation) (Fig. 5A), while the outputs of other apolipoproteins remained constant (Fig 5B), 
suggesting that bile diversion uniquely upregulated the secretion of apoA-V into bile.  
 After bile fistula surgery, bile flow decreased from 0.80 ml/h (initial flow rate) to 0.60 ml/h 
during the 16 h period that we studied (Fig. 6A). Additionally, the biliary outputs of cholesterol 
(Fig. 6B), bile acid (Fig. 6C), and phospholipid (Fig. 6D) decreased ~50%, 60%, and 80% 
respectively. Taken together, the data show that while bile flow and biliary lipid and bile salt 
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outputs decreased, the biliary output of apoA-V increased with bile drainage after bile fistula 
surgery.  
 
Biliary ApoA-V in Response to Luminal Phospholipid and Bile Salt. To test if the increased 
output of apoA-V into bile was due to diversion of biliary phosphatidylcholine and bile salts from 
the enterohepatic circulation, we gave an intraduodenal infusion of phosphatidylcholine and 
taurocholate solution at physiologic concentrations (matched to the phospholipid and bile salt 
concentration immediately after surgery) to restore these components of the enterohepatic 
circulation. Interestingly, instead of preventing the increase of biliary apoA-V output, the 
phospholipid-taurocholate infusion further enhanced biliary apoA-V output dramatically after 16 
h compared with the saline group (statistically significance P<0.01 after 24 h) (Fig. 7A). 
 The phospholipid-taurocholate infusion did not change bile flow for the first 12 h of 
infusion (which dropped from 0.8 to 0.5 ml/h for both groups) but significantly increased bile flow 
after 16 h, from 0.5 ml/h to 1.0 ml/h (P<0.001) (Fig. 7B). This shows that phospholipid-
taurocholate stimulated the secretion of apoA-V into bile, in addition to stimulating bile flow. 
Importantly, the data indicate that loss of biliary phospholipid and bile salt with bile drainage was 
not responsible for the increased biliary output of apoA-V after bile fistula surgery.  
 
 
 
13 
 
DISCUSSION 
 
 ApoA-V is an apolipoprotein made in the liver that dramatically modulates plasma 
triglyceride levels, both fasting (23) and postprandially (8, 20), through mechanisms related to 
lipolysis, hepatic uptake, or hepatic secretion of lipoproteins which have been so ably reviewed by 
Forte et al. (7).  We have recently reported a role for apoA-V in the absorption of dietary lipids by 
modulating the uptake and secretion of lipid packaged as chylomicrons into the lymph (38). 
However, the mode of how hepatic apoA-V is delivered to the gut is unknown.  
While hepatocytes secrete triglycerides, cholesterol, cholesterol ester and phospholipids 
basolaterally into plasma as very low density and high density lipoproteins particles, hepatocytes 
also secrete bile salts as monomers as well as phospholipid and cholesterol as vesicles into bile. 
Apolipoproteins A-I, A-II, C-II, C-III, and B are also secreted into bile (27), either directly by 
hepatocytes or following uptake of lipoproteins from plasma (17). The functions of these biliary 
apolipoproteins are not well understood but they may be involved in the solubilization of biliary 
lipids. For example, apoA-I and apoA-II have been demonstrated to prolong the nucleation time 
of solid cholesterol monohydrate crystals as studied in model bile (28). Biliary apoA-I and the 
apolipoprotein Anionic Peptide Factor has been shown to regulate dietary cholesterol absorption 
(13).  
Our finding that apoA-V is present in bile introduces a second route, the first being via the 
circulation, by which this unique hepatic apolipoprotein may be presented to and affect the 
function of enterocytes. From the circulation, the effect of apoA-V would be mediated through the 
basolateral membrane of the hepatocyte, while the biliary route presents the possibility that apoA-
V may function apically: either through a luminal effect in the gut or intracellularly if it is taken 
 
 
14 
 
up apically by enterocytes. Although an intracellular function for this protein has been described 
in the liver (3, 29), its function in enterocytes has not been explored and will no doubt be actively 
investigated in other laboratories as well as ours.   A more fundamental question is if biliary apoA-
V escapes hydrolysis in the small intestinal lumen and if so, is it taken up by the enterocytes?  
Siddiqi and colleagues have recently examined this question in an initial report (31). Very 
interestingly, they found that apoA-V in the intestinal lumen can escape proteolysis and remain 
intact, and is taken up by enterocytes by a mechanism that involves interaction with CD36 and 
caveolin-1. Although apoA-V is generally established to be expressed exclusively in the liver, it 
should be pointed out that extremely low mRNA expression levels of apoA-V have been observed 
in intestinal tissues of C57BL/6J mice (1000 times lower than liver mRNA expression) and in 
intestinal polyA+mRNA samples of humans (32000 times lower than liver expression) (10). 
However, in that study, Western blotting analyses of colon and colon+jejunum tissues showed that 
apoA-V protein from intestinal lysates was one-sixth of that of liver lysates. Extrapolated from our 
study, the protein product recovered from tissue lysates may not necessarily came from intestinal 
synthesis but rather may represent sources such as the bile. Thus whether the small intestine 
synthesizes apoA-V remains a possibility; however the potential contribution from bile cannot and 
should not be ignored. Based on our data, the contribution of apoA-V from bile to enterocytes 
seems to significantly outweigh that produced endogenously by the gut.   
 Our finding that the secretion of apoA-V into bile increases in response to dietary lipid is 
consistent with our previous report that apoA-V modulates chylomicron production (38). The 
increase of biliary apoA-V occurred 4 h after lipid administration, concomitant with maximum 
lymphatic output of TG, which strongly suggests a link between lipid flux (as chylomicrons) from 
the small intestine and the stimulation of hepatic apoA-V secretion into bile.  Furthermore, our 
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finding that the increase in biliary apoA-V secretion was abolished when lymphatic fat transport 
was poor further reinforces the notion that a lipid flux is required to stimulate hepatic apoA-V 
secretion into bile. Whether the hepatic uptake of chylomicron remnants is the signal is a 
possibility and this question is currently being explored in our laboratory.  It should be pointed out 
that this research undertaking is complex, potentially involving numerous mechanisms and 
requires the appropriate controls.  
The fact that the biliary output of apoA-V increased significantly while the outputs of other 
apolipoproteins remained constant indicates that dietary lipid regulation of apoA-V is unique and 
is not a marker of generalized hepatic response to a physiologic challenge of diet or surgery. For 
instance, it has been demonstrated that the intestinal secretion of apoA-IV increases approximately 
two-fold during active fat absorption (11, 14, 38). Yet, our data show that active fat absorption did 
not modify the biliary secretion of apoA-IV. Additionally, the secretion of biliary lipid and bile 
salt in response to the fat load did not change significantly as expected (5, 9), with the possible 
exception of phospholipid, which is also in agreement with the response of apoA-V being a unique 
phenomenon. 
Independent of the lipid stimulus, we found that apoA-V secretion into bile increased after 
bile fistula surgery while the secretion of other apolipoproteins remained constant, suggesting that 
bile drainage specifically affected apoA-V. This effect is also recently seen in chow-fed C57BL/6J 
mice (David Q.-H. Wang, unpublished observations). Since the apoA-V promoter contains a FXR 
response element and its activity is stimulated by bile salt in vitro (24), we wondered if drainage 
of bile salt affected the secretion of apoA-V into bile. Unexpectedly, the secretion of apoA-V into 
bile increased steadily with time. However, when phospholipids and bile salts were restored by 
intraduodenal infusion, apoA-V secretion into bile increased several-fold higher than with only 
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saline infusion. This latter result, at least, is consistent with the idea of Prieur et al. that bile salts 
can stimulate hepatic apoA-V expression. Taken together, these results suggest that increased 
biliary apoA-V secretion after bile fistula surgery did not result from depletion of phospholipid 
and bile salts, two major components of bile.  
This is the first report of the presence of apoA-V in bile and we conclude that hepatic apoA-
V secretion into bile is regulated by active intestinal lipid absorption, although the mechanisms 
remain to be determined. Our current findings, combined with those reported previously (38), are 
consistent with a physiological role for biliary apoA-V in modulating lipid absorption in the 
intestinal lumen. Additionally, apoA-V was reported as a factor in early liver regeneration in 2001 
when it was discovered by van der Vliet and colleagues (36), who suggested that up-regulation of 
apoA-V served as a protective response by the liver to inhibit hepatic lipid uptake, to protect a 
hepatectomized liver from a lipid overload. Given the evidence that apoA-V inhibits triglyceride 
secretion in apoB-containing lipoproteins (3), one might also surmise that its upregulation in 
response to partial hepatectomy may be a means to retain lipids for new membrane assembly or 
for energy reserves, since regenerating liver hepatocytes accumulate fat micro-droplets within a 
day of partial hepatectomy (21).  We propose that increased apoA-V secretion into bile in response 
to lipid absorption occurs irrespective of bile drainage and constitutes a physiological mechanism 
to regulate the intestinal formation and secretion of chylomicrons. As such, apoA-V-dependent 
attenuation of chylomicron assembly and secretion may protect the liver from chylomicron 
remnant lipid flux overload.  Furthermore, we believe that apoA-V also serves as a link between 
the liver and the gut in coordinating lipid metabolism during physiologic states, e.g. fasting and 
during active lipid absorption.   
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ANOVA, analysis of variance 
FXR, farnesoid X receptor  
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Figure 1. Under fasting conditions, apoA-V is present in bile and secreted at a constant rate. 
(A) ApoA-V output into bile with a representative Western blot shown (20 second outputs of bile 
loaded into each well), P represents diluted plasma (1:5) as a comparative marker for apoA-V, (B) 
Bile flow rate. After a 24 h recovery from surgery, bile fistula rats were given a continuous 
intraduodenal infusion of saline. ApoA-V was measured in bile by Western blot and quantified by 
densitometry. Output was determined by concentration x bile flow. Values are mean ± SEM.  
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Figure 2. Supplementing bile fistula rats with a continuous intraduodenal infusion of 
phosphotidylcholine (PL) and taurocholate (NaTC) restored lymphatic triglyceride 
transport to the same level as bile intact rats. Bile intact and bile fistula rats were given an 
intraduodenal bolus of lipid. Another cohort of bile fistula rats was given an intraduodenal 
supplement of phospholipid-taurocholate showed the same lymphatic triglyceride output as bile-
intact rats. Without the phospholipid-taurocholate supplemental infusion, bile fistula rats 
transported triglycerides poorly into lymph. All values are mean ± SEM. **P<0.01, ***P<0.001 
is significance comparing Lipid, Bile fistula versus Lipid, Bile-intact. 
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Figure 3. Dietary lipid stimulated the secretion of apoA-V into bile and required transport 
of lipid into lymph. (A) Biliary apoA-V output in rats given an intraduodenal bolus of dietary 
lipid or saline (with PL+NaTC supplemental infusion), **P<0.01, (B) Biliary outputs of other 
apolipoproteins in response to dietary lipid, *P<0.05 **P<0.01 ApoA-I with lipid treatment versus 
with saline treatment, (C) Bile flow between the two groups, (D) Biliary apoA-V output in rats 
given dietary lipid but no PL+NaTC supplementation (a condition of poor lymphatic triglyceride 
transport). Apolipoprotein concentration in bile was determined by Western blot and quantified by 
densitometry. Output was determined by concentration x bile flow. Experimental protocols 
described in Materials and Methods. All values are mean ± SEM.  
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Figure 4. Effects of dietary lipid on the 
biliary outputs of (A) cholesterol, (B) bile 
acids and (C) phospholipids. Dietary lipid 
significantly affected total biliary 
phospholipid output (P<0.05 for treatment 
factor, Two-way ANOVA) but there was no 
statistical significance between groups at 
individual timepoints by multiple 
comparisons post-test analysis. Biliary 
concentrations were measured by chemical 
assays described in Materials and Methods. 
Output was determined by concentration x 
bile flow. All values are mean ± SEM.  
.  
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Figure 5. Biliary output of apoA-V in bile 
increased dramatically after bile fistula 
surgery while the outputs of other 
apolipoproteins remained constant. (A) 
Biliary apoA-V output with representative 
Western blot (20 second output of bile loaded 
into each well), (B) biliary outputs of apoA-I, 
apoA-IV, apoB, and apoE. Apolipoprotein 
concentration was determined by Western blot 
and quantified using densitometry. Output 
was determined by concentration x bile flow. 
All values are mean ± SEM. **P<0.01 is hour 
16 versus hour 1. 
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Figure 6. After bile fistula surgery, bile flow and biliary lipid and bile salt outputs decrease. 
(A) Bile flow rate, and biliary outputs of (B) cholesterol, (C) bile acids, (D) phospholipids. Bile 
fistula rats were given a continuous intraduodenal infusion of 5% glucose-saline immediately after 
surgery. Biliary concentrations of lipids were measured by chemical assays. Output is determined 
by concentration x bile flow. All values are mean ± SEM.  
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Figure 7. Biliary apoA-V output remained increased after bile fistula surgery even after 
phospholipid-taurocholate treatment. (A) Biliary apoA-V output, (B) bile flow. Immediately 
after bile fistula surgery, rats were given either a continuous intraduodenal infusion of 5% glucose-
saline or a physiologic concentration of phospholipid-taurocholate for 27 h. Biliary apoA-V 
concentration was determined by Western blot and quantified by densitometry. Output was 
determined by concentration x bile flow. All values are mean ± SEM. *P<0.05, **P<0.01, 
***P<0.001 
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ABSTRACT 
 
Apolipoprotein (apo) A-V is a liver-synthesized protein that strongly modulates plasma triglyceride (TG) 
levels. We have recently reported a role for apoA-V in the intestinal production of chylomicrons. Since 
apoA-V was previously found on plasma chylomicron remnants, we wondered if apoA-V was present on 
chylomicrons in  lymph. The aim of this study was to examine if apoA-V is present in lymph under fasting 
and postprandial conditions. Using Sprague-Dawley rats equipped with mesenteric lymph cannulas, we 
found that apoA-V is indeed present in lymph by Western blotting. Animals given an intraduodenal bolus 
of Liposyn III showed a significant increase of apoA-V in lymph, with levels maximal at hour 1 (P<0.005) 
which remained elevated during the 4 h study. A very low level of apoA-V was present in fasting lymph, 
virtually undetectable in some animals. Maximal apoA-V output in lymph preceded maximal lymphatic TG 
output. Flotation ultracentrifugation of chylous lymph revealed apoA-V associating with chylomicrons. 
Since apoA-V was previously found in bile, we tested the hypothesis that biliary apoA-V may be 
transported across the enterocyte into lymph. Using bile-diverted rats, we find that bile diversion 
significantly reduced the appearance of apoA-V in lymph. However, upon restoring lymphatic TG transport 
in these rats, apoA-V in lymph appears in significant amounts, suggesting that active fat transport stimulates 
apoA-V appearance lymph and is independent of the presence of bile in the lumen. This is the first report 
of apoA-V in lymph and whether its mode of action is apical or basolateral to enterocytes warrants further 
investigation.  
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INTRODUCTION 
Synthesized only in the liver, apolipoprotein (apo) A-V was discovered in 2001 to be a major 
regulator of plasma triglyceride (TG) levels (Pennacchio 2001). ApoA-V knockout (KO) mice had plasma 
TG four times higher than wild-type (WT) mice while apoA-V transgenic mice had plasma TG levels one-
third of their WT littermates. Various apoA-V single nucleotide polymorphisms (SNPs) manifest in 
hypertriglyceridemia (Pennacchio 2002), which is an independent risk factor for atherosclerosis (Geurian 
1992) and cardiovascular disease (Jacobson 2007).  
ApoA-V is very hydrophobic and strongly lipid-binding (Beckstead 2003; Weinberg 2003), 
associating with only high-density lipoprotein (HDL) and very low-density lipoprotein (VLDL) in rodents 
(van der Vliet 2001, Fruchart-Najib 2004). In humans, apoA-V was found to associate with VLDL, HDL, 
and chylomicrons in plasma, but not low-density lipoprotein (LDL) (O’Brien 2004). This distribution is 
very similar to apoC-III, which has a strong positive relationship with plasma TG levels (Chan 2008) and 
suggests that the two apolipoproteins regulate plasma TG levels in opposite manners.  
Recent studies from our laboratory suggest a role of apoA-V in modulating the production rate of 
chylomicrons by the intestine (Zhang 2015). ApoA-V KO mice have a two-fold elevation in the lymphatic 
output of dietary TG, concomitant with increased chylomicron particle number. The findings suggest that 
apoA-V serves to inhibit the production of chylomicrons in the gut, possibly by modulating intestinal 
apoB48 production. A subsequent study reports that apoA-V is present in bile and that its secretion into 
bile is stimulated in response to fat absorption (Zhang 2015). While these findings introduce the possibility 
that apoA-V in bile may act on the intestine to modulate chylomicron production, how biliary apoA-V 
interacts with enterocytes is unknown.  
Since apoA-V was found present on human chylomicrons in the plasma (O’Brien 2004), we 
wondered if apoA-V was also present on lymph chylomicrons, since chylomicrons originate from the small 
intestine and its secretion into mesenteric lymph. The aim of this study was to determine if apoA-V was 
present in lymph under fasting and postprandial conditions, using the lymph fistula rat model. Additionally, 
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because apoA-V was recently discovered in bile (Zhang 2015), we also tested the hypothesis that biliary 
apoA-V is transported into lymph using bile-diverted rats.  
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MATERIALS AND METHODS 
Animals. Only 3-4 month male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 300-400 g were 
used in the study. Animals were allowed to acclimate to our animal facilities for at least one week before 
experiments. The animals were maintained on standard rodent chow (LM-485 Mouse/Rat Sterilizable Diet; 
Harlan Laboratories, Madison, WI) and were housed under a 12:12 h light-dark cycle, a controlled 
temperature maintained at 70-74ºF, and humidity maintained at 40-60%. All procedures performed are in 
accordance with the University of Cincinnati Internal Animal Care and Use Committee and in compliance 
with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. 
 
Lymph and duodenal cannulation. The lymph fistula surgical procedure and postoperative care were 
performed as previously described (Kohan 2012). Briefly, animals were fasted overnight before surgery 
with free access to water. Under isoflurane anesthesia, the superior mesenteric lymph duct was cannulated 
with polyvinylchloride tubing (0.20 mm ID; 0.50 mm OD, BIOCORP Aust PTY Ltd, Victoria, Australia) 
according to the method of Bollmann et al. (Bollman 1948) with the modification of securing the cannula 
with tissue glue. The fundus of the stomach was incised and a silicon tube was inserted 2 cm into the 
duodenum.  The tube was secured by a purse-string suture. Postoperatively, the animals were kept in 
Bollman restraining cages maintained at a temperature of 30°F to prevent hypothermia. Animals usually 
nestle together to keep warm but cannot do so due to the restraints, which were necessary to prevent the 
animals from gaining access to the cannula. Despite restraints, the animals still had considerable freedom 
to move forward and backward. Following surgery, the animals were given a continuous intraduodenal 
infusion of a 5% glucose-saline solution at a rate of 3 ml/h to replenish fluid and electrolyte lost during 
lymph drainage as well as to provide some energy. The animals were allowed to recover overnight. 
 
Lipid Infusion and Collection of Chylomicrons. The following morning, the 5% glucose-saline was 
switched to saline alone. Fasting lymph was collected for 1 h before administering lipid. Liposyn III 20% 
7 
 
(Hospira, Lake Forest, IL) was given as a single bolus through the duodenal cannula. Lymph was collected 
hourly by gravity drainage in 10 ml conical Falcon tubes on ice for six hours. A portion of lymph was used 
to measure triglyceride levels and apolipoproteins. The other portion was used to isolate chylomicrons. To 
isolate chylomicrons, lymph samples from hours 2-4 were pooled into round-top Quick-Seal ultracentrifuge 
tubes (Beckman-Coulter, Indianapolis, IN) and immediately ultracentrifuged at 25K at 10°C for 1 hour 
using a Beckman 50.3 Ti rotor (Beckman Instruments, Palo Alto, CA). The creamy top portion, which 
contains chylomicrons plus some other intestinal lipoproteins, was slowly extracted using a 16 gage syringe 
needle, as to not shear the chylomicron particles. Additionally, the supernatant was also obtained by syringe 
and placed in a microcentrifuge tube. Careful attention was placed to not mix the upper chylomicron-rich 
layer and the bottom supernatant. To concentrate the supernatant, Microcon centrifugal filter tubes with 30 
kDa cutoff (EMD Millipore, Billerica, MA) were used according to the manufacturer’s instructions.  
 
Bile fistula surgery with duodenal cannulation. The common bile duct, just below the two hepatic ducts, 
was cannulated with polyvinylchloride tubing (0.20 mm inner diameter (ID); 0.50 mm outer diameter (OD)) 
and exteriorized through a stab wound in the animal’s right flank, as previously described (Tsuchiya 1996). 
The fundus of the stomach was incised to introduce a silicone feeding tube (0.5 mm ID; 0.8 mm OD) 
through the stomach, about 2 cm into the duodenum. The tube was secured by a purse-string suture and the 
incision was sealed with a drop of tissue glue. After surgery, 5% glucose-saline was infused intraduodenally 
at 3 ml/h to replace fluid and electrolyte lost by lymph and bile diversion. After a 24 h recovery from 
surgery, the animals were given a 3 ml bolus intraduodenal injection of either Liposyn III 20% or saline as 
a control. To avoid a volume overload, we waited 30 minutes before given a continuous intraduodenal 
infusion of either saline or a solution of 6.6 mM phosphatidylcholine and 10 mM taurocholate at a constant 
rate of 3.0 ml/h. Bile was collected hourly by gravity drainage during fasting and for 4 hours. 
 
Measurement of lymphatic TG and apoA-V outputs. Lymph TG concentrations were measured by 
chemical assay using a total TG kit (Randox Laboratories, Kearneysville, WV). Briefly, 2 l of lymph was 
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added to 200 l of reagent in 96-well plates. After 5 minutes of incubation at 37°C, the plate was read at 
500 nm. ApoA-V was assayed by Western blotting analysis. Lymph samples (volumes equal to 3 second 
outputs) for every hour were loaded onto 4-15% polyacrylamide gradient gels and transferred to 
polyvinylidene difluoride membranes. Following transfer, membranes were blocked with 5% nonfat milk 
in 0.1% Tween 20 in Tris-buffered saline (TBS) for 1 h. Membranes were incubated with goat antibodies 
raised against rat/mouse apoA-V (1:5000) overnight. After rinsing with TBS with 0.1% Tween 20, 
membranes were incubated with peroxidase-conjugated anti-goat secondary antibody at 1:10,000 for 30 
min and developed with Immobilon Western Chemiluminescent horseradish peroxidase substrate 
(Millipore Corporations, Billerica, MA). Protein quantification was performed by densitometric analysis of 
films using Total Lab Quant Analysis Software (TL100, FOTODYNE, Hartland, WI). 
 
Statistical Analysis. The data shown are mean values ± standard errors of mean (SEM). To compare groups, 
two-way repeated-measures Analysis of Variance (ANOVA) analyses with Sidak multiple comparisons 
post-test analysis were used. Statistical analyses were performed using GraphPad Prism v6. Data were 
considered significant if P < 0.05. 
 
RESULTS  
 
ApoA-V is Present in Lymph during Active Fat Absorption. After an intraduodenal bolus of intralipid or 
saline, lymph was collected hourly by gravity drainage. The presence of apoA-V in lymph was assayed by 
Western blot as described in Methods. ApoA-V was indeed present in lymph as a 40 kDa protein but mostly 
after administration of dietary lipid. Figures 1A, B shows the lymphatic output of apoA-V is maximal 1 
hour after lipid administration (P<0.005) and remains significant in lymph for the duration of the study. 
Little or no apoA-V protein was detected during fasting conditions (hour 0) or when saline was 
administered. The concentration of apoA-V in lymph was significantly less than that of plasma, with its 
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maximal concentration in lymph equaling to approximately one-third of plasma (Fig 1C). In response to 
intralipid, lymph flow decreased at hour 1 (Fig 1D) but increased to levels slightly higher than the saline-
treated group at hour 4 (P<0.05). Figure 1F shows the lymphatic output of TG between the two groups, and 
combined with Figure 1A, indicates that the maximal lymphatic output of apoA-V precedes that of TG. 
Taken together, the data show that apoA-V is present in lymph and its lymphatic output is stimulated by 
dietary lipid.  
 
ApoA-V is Only Associated with Chylomicrons. Because apoA-V was previously found on chylomicrons 
in the plasma (O’Brien 2004), its association with chylomicrons in lymph was assayed. Figure 2 shows a 
Western blot of apoA-V in whole chylous lymph (pooled from hours 2-4 after lipid administration), the 
chylomicron fraction of lymph after flotation ultracentrifugation, the chylomicron free (CF) fraction of 
lymph, and the CF fraction after concentrating the fraction by 10-fold using a semiporous filter membrane 
of 30 kDa. The data show that apoA-V is only associated with chylomicrons in lymph and not in the free 
form in the supernatant. 
 
Bile Diversion Reduces ApoA-V Appearance In Lymph. ApoA-V was recently found present in bile in 
our laboratory (Zhang 2015). Additionally, apoA-V was found as an intact polypeptide in the intestinal 
lumen that is taken up by enterocytes by a caveolin-1-mediated mechanism (Siddiqi 2015). Potentially, 
apoA-V can be absorbed and transported basolaterally, like insulin (Ziv & Bendayan 2000) or bile-salt 
dependent lipase (BSDL) (Bruneau 1998; Bruneau 2003a). To explore the possibility of transport from bile 
to lymph, we diverted the source of apoA-V by using bile fistula rats and assayed for the presence of apoA-
V in lymph. Figures 3A and B show that apoA-V is present in lymph in response to dietary lipid but its 
levels are greatly reduced (although still significant, P<0.05) when compared to bile-intact rats (Figs 1A, 
B). ApoA-V did not appear in lymph in rats given saline. Lymph flow remained between 0.2 to 0.3 ml/h 
between the two groups of animals, except for a drop in flow on hour 1 after lipid treatment (Fig 3C). Figure 
3D shows the lymphatic TG output, which is significantly reduced in bile fistula rats (when compared with 
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bile-intact animals, Fig 1D) and seems to correlate with the appearance of apoA-V in lymph. The data 
shows that apoA-V appears in lymph in bile-diverted animals but to a lesser extent, and which seems to 
correlate with lymphatic TG output.  
 
ApoA-V Appearance in Lymph is Stimulated When Lymphatic TG Output is Restored in Bile Diverted 
Rats. Although bile diversion significantly reduces the appearance of apoA-V in lymph, it also greatly 
reduced lymphatic TG output. Since apoA-V appearance in lymph is stimulated by dietary fat absorption 
(Figure 1), we next sought to restore active fat transport into lymph in bile diverted animals and assay for 
apoA-V in lymph. The animals were given a continuous intraduodenal infusion of phosphatidylcholine and 
taurocholate 2 hours before and during lipid administration, a procedure previously shown in our laboratory 
to restore lymphatic TG transport (Zhang 2015). We find that under these conditions, apoA-V appears in 
lymph at significantly higher levels (Figs 4A, B). Lymphatic TG output was restored and peaked 3 h after 
lipid administration (Fig 4C). These data show that lymphatic apoA-V output correlates with lymphatic TG 
output, and the appearance of apoA-V in lymph in response to fat absorption seems independent of the 
presence of bile in the intestinal lumen.   
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DISCUSSION 
We show for the first time that apoA-V is present in lymph (Fig. 1A, B) and is associated with 
chylomicrons during fat absorption (Fig. 2). Little or no apoA-V protein is present in lymph during fasting 
conditions (Fig. 1). Because apoA-V is recently discovered in bile (Zhang 2015) and as an intact 
polypeptide that can be taken up by enterocytes (Siddiqi 2015), we examined the possibility that biliary 
apoA-V is transported into lymph. Although bile diversion significantly decreases the level of apoA-V in 
lymph (Fig. 3A), it also decreases the transport of TG into lymph. Reinstating lymphatic fat transport by 
restoring luminal phospholipid and bile salt also restored the level of apoA-V appearing in lymph (Fig. 4A). 
The present data suggest that apoA-V appears in lymph during fat absorption, which seems independent of 
the presence of bile in the intestinal lumen. 
ApoA-V is a unique apolipoprotein in that it can dramatically modulate plasma TG levels while 
existing in the plasma in very low concentrations. In rats, the plasma concentration of apoA-V is 1 µg/ml 
(van der Vliet, 2001). In normolipidemic humans, apoA-V plasma concentrations range from 24 to 406 
ug/L (O’Brien 2004), which is very low compared with apoA-I, which averages ~1 g/L. Only 1 in 1000 
apoB containing particles was estimated to contain a molecule of apoA-V (O’Brien 2004). Although a 
variety of mechanisms of apoA-V has been proposed, such as enhancing lipolysis (See Reviews Merkel 
2005; Forte 2009), its low plasma concentration has been a puzzlement to how exactly apoA-V can lower 
plasma TG especially in the postprandial state. Overexpressing apoA-V by either transgene (Fruchart-Najib 
2004) or by adenoviral gene transfer (Schaap 2004) was shown to significantly reduce the postprandial TG 
excursion after a dietary fat challenge. Originally, the mechanism was attributed to enhanced lipolysis 
mediated by lipoprotein lipase. A potential new mechanism was introduced recently in that apoA-V may 
also modulate the influx of TG-rich chylomicron particles delivered by the gut (Zhang 2015). Additionally, 
apoA-V was also recently found in bile, introducing the possibility that biliary apoA-V may interact with 
the gut to modulate lipid absorption.  
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Our finding that apoA-V is present on lymph chylomicrons during fat absorption (Figs 1A, 2) 
introduces a possibility that the intestine could secrete apoA-V that would associate with chylomicrons 
during fat absorption. However, the potential association with chylomicrons likely occurs after lipidation 
of apoB48 particles in the enterocyte since apoA-V was not present in fasting lymph. The intestine 
constitutively secretes apoB48 particles to transport dietary and biliary lipids, irrespective of fasting or fat 
feeding (see review Tso 1984). In the hepatocyte, the association of apoA-V with VLDL was thought to be 
a post-secretory event (Shu 2007; Blade 2011) or related to the lipidation of primordial particles (Shu 2007, 
Shu 2008). ApoA-V was not found associated with apoB within the cell (Shu 2007). However, because the 
lymphatic output of apoA-V peaks 1-2 hours after lipid administration (Fig. 1A) and lymphatic TG output 
peaks after 4 hours (Fig. 1F), this suggests that lymph apoA-V levels and lipidation of chylomicrons are 
not necessarily correlated. Because apoA-V is not synthesized in the intestine, our findings introduce the 
possibility that apoA-V in bile may be transported across the intestinal cells into lymph.  
The finding that apoA-V appearance in lymph is significantly reduced with bile diversion (Fig. 3A, 
B) supports the notion that the apoA-V in lymph may originate from bile. Western blot analysis showed 
that the apoA-V in lymph is ~40 kDa, indicating that the protein was intact. Although most proteins in the 
intestinal lumen are digested into free amino acids and small peptides, by gastric and pancreatic enzymes 
and by peptidases in the intestinal brush border membrane, there is substantial evidence to show that some 
proteins can be absorbed as intact proteins by the intestine. The first evidence for the intestinal absorption 
of an intact protein was insulin in 1987 (Ziv 1987). It was established later that insulin could be taken up 
by enterocytes and transported to the blood circulation (Bendayan 1990; Ziv & Bendayan 2000). Another 
protein, BSDL, a pancreatic lipase, was also demonstrated to be able to enter enterocytes and exit to the 
blood circulation (Bruneau 1998; 2003a). Pancreatic enzymes (such as lipase and amylase) are also shown 
to cross the intestine by transcytosis to reach the intestinal subepithelial space (Cloutier 2006). However, 
while bile diversion decreased the appearance of apoA-V in lymph, it also impedes the transport of TG into 
lymph (Figure 3D). The results could arise from two possibilities: 1) the transport of apoA-V from bile to 
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lymph requires the production of TG-rich chylomicrons or 2) the reduction of apoA-V in lymph is a general 
result of reduced lymphatic TG transport and not of a diversion of bile. 
To explore the latter scenario, bile fistula rats were given an intraduodenal supplement of 
phosphatidylcholine and taurocholate to solubilize lipid and enable transport into lymph. Under these 
conditions, the level of apoA-V was significantly increased in lymph (Figs. 4A, B), with its maximal output 
into lymph preceding maximal TG output (Fig. 4C) and at levels higher than that of a bile-intact animal 
(Fig. 1A). These findings suggest that the appearance of apoA-V in lymph requires the production of TG-
rich chylomicrons; however it does not seem to require the presence of bile in the intestinal lumen. From 
the data alone, we cannot exclude the possibility that minute amounts of apoA-V protein from bile may be 
transported into lymph. Another more feasible notion is that much of the apoA-V in lymph originates from 
blood circulation, as blood capillary permeability is increased in response to fat absorption (Granger 1982). 
ApoA-V associated with plasma HDL may leak into the lymphatics and transfer onto chylomicrons, in a 
manner similar to its transfer from hepatic HDL to VLDL in mice (Fruchart-Najib 2004; Nelbach 2007). 
The possibility that apoA-V derived from circulation may leak into the lymphatics remains to be 
investigated.  
This is the first report of apoA-V on mesenteric lymph chylomicrons. We conclude that the 
appearance of apoA-V in lymph is stimulated with active fat absorption, although the exact origination of 
this apoA-V remains to be determined. While apoA-V may originate from bile, another possibility is that 
apoA-V might originate from plasma. It may be possible that the intestine may take up apoA-V from plasma 
basolaterally and secrete it onto chylomicrons during active fat absorption. ApoA-V may also be taken up 
by the basolateral membrane itself and associates with chylomicrons extracellularly by a mechanism similar 
to what is speculated for hepatocytes (Forte 2008). Whether its mode of action is apical or basolateral to 
enterocytes (or both) is an intriguing question and warrants further investigation. Whether its mode of action 
is apical or basolateral to enterocytes (or both) is an intriguing question and warrants further investigation. 
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Figure 1. ApoA-V is present in lymph during fat absorption. (A) Lymphatic apoA-V output in rats given 
an intraduodenal bolus of dietary lipid or saline, (B) Representative western blots of apoA-V in lymph of 
two rats given lipid and one given saline, (C) A comparison between lymph (chylous) and fasting plasma, 
(D) Lymph flow, (E) Lymphatic TG output. Outputs were determined by concentration x lymph flow. All 
values are mean ± SEM. *P<0.05, ***P<0.005, ****P<0.0001 
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Figure 2. ApoA-V is present on lymph chylomicrons. A comparison of whole lymph (pooled hours 1-4), 
chylomicron fraction after flotation ultracentrifugation, chylomicron-free fraction (CF), and CF-fraction 
after concentration by 10-fold using a 30-kDa cutoff semi-porous membrane filtration microcentrifuge 
column. 
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Figure 3. ApoA-V in lymph in response to dietary fat is significantly reduced in bile-diverted rats. 
(A) Lymphatic apoA-V output in bile-diverted rats given an intraduodenal bolus of dietary lipid or saline, 
(B) Representative western blots of apoA-V in lymph of two bile-diverted rats given lipid and one given 
saline, (C) Lymph flow, (D) Lymphatic TG output. Outputs were determined by concentration x lymph 
flow. All values are mean ± SEM. *P<0.05, **P<0.01.  
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Figure 4. Lymphatic output of apoA-V is significantly increased when active fat transport is restored 
in bile-diverted rats. (A) Lymphatic apoA-V output in bile-diverted rats given an intraduodenal bolus of 
dietary lipid with phosphatidylcholine & taurocholate supplement, (B) Representative western blot of 
lymphatic apoA-V output, (C) Lymphatic TG output. All values are mean ± SEM.  
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APPENDIX IV 
 
 
 
 
Paper IV. ABCG5/G8 deficiency results in reduced dietary triacylglycerol 
and cholesterol transport into the lymph. 
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cholesterol by the intestine, suggesting a novel role for 
the sterol transporter in the formation and secretion of 
chylomicrons.
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ABC  Adenosine triphosphate-binding cassette
GC  Gas chromatography
KO  Knockout
MTP  Microsomal transfer protein
NMR  Nuclear magnetic resonance
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PVC  Polyvinyl chloride
TAG  Triacylglycerol
TICE  Transintestinal cholesterol efflux
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Introduction
The small intestine is the primary site of lipid absorption. 
According to the 2000–2006 National Health and Nutrition 
Survey, an average American adult consumes about 80 g/
day of fat (triacylglycerols or TAG), 300 mg of cholesterol, 
and 100–400 mg of plant sterols. While the small intestine 
absorbs large loads of TAG very efficiently, up to 500 g per 
day in humans [1], it only absorbs a fraction of cholesterol. 
Absorption of cholesterol in healthy individuals is 10–80 % 
[2–4] while absorption of plant sterols, which are structur-
ally similar to cholesterol, are virtually unabsorbed [5]. For 
a long time, the existence of an intestinal transporter that 
limited the absorption of plant sterols was questioned but 
Abstract The adenosine triphosphate-binding cassette 
(ABC) transporter G5/G8 is critical in protecting the body 
from accumulating dietary plant sterols. Expressed in the 
liver and small intestine, it transports plant sterols into the 
biliary and intestinal lumens, thus promoting their excre-
tion. The extent to which G5/G8 regulates cholesterol 
absorption remains unclear. G5/G8 is also implicated in 
reducing the absorption of dietary triacylglycerols (TAG) 
by unknown mechanisms. We hypothesized that G5/G8 
suppresses the production of chylomicrons, and its defi-
ciency would enhance the absorption of both dietary TAG 
and cholesterol. The aim of this study was to investigate the 
effects of G5/G8 deficiency on lipid uptake and secretion 
into the lymph under steady-state conditions. Surprisingly, 
compared with wild-type mice (WT) (n = 9), G5/G8 KO 
(n = 13) lymph fistula mice given a continuous intraduo-
denal infusion of [3H]-TAG and [14C]-cholesterol showed 
a significant (P < 0.05) reduction in lymphatic transport 
of both [3H]-TAG and [14C]-cholesterol, concomitant with 
a significant (P < 0.05) increase of [3H]-TAG and [14C]-
cholesterol accumulated in the intestinal lumen. There was 
no difference in the total amount of radiolabeled lipids 
retained in the intestinal mucosa between the two groups. 
G5/G8 KO mice given a bolus of TAG showed reduced 
intestinal TAG secretion compared with WT, suggesting an 
independent role for G5/G8 in facilitating intestinal TAG 
transport. Our data demonstrate that G5/G8 deficiency 
reduces the uptake and secretion of both dietary TAG and 
L. S. Zhang (*) · M. Xu · Q. Yang · D. Lou · P. N. Howles · 
P. Tso 
Department of Pathology and Laboratory Medicine, University 
of Cincinnati College of Medicine, 2180 E. Galbraith Road, 
Cincinnati, OH 45215, USA
e-mail: zhangld@mail.uc.edu
372 Lipids (2015) 50:371–379
1 3
the limit is now known to be mediated by ATP-binding cas-
sette (ABC) half-transporters G5/G8 [6].
Expressed in the liver and small intestine, G5 and G8 
heterodimerize into a functional unit [7] to promote the 
secretion of sterols, with a preference for plant sterols over 
cholesterol [9]. In the liver, they are expressed on the apical 
membrane of hepatocytes [8] and secrete both cholesterol 
and plant sterols into the bile [10–12]. In the small intes-
tine, they are presumed to be expressed on the apical brush 
border membrane of enterocytes and secrete cholesterol 
and plant sterols into the intestinal lumen [13]. Mutations 
in either G5 or G8 result in a loss of secretion [6, 14], clini-
cally manifested as the autosomal recessive genetic disease 
of sitosterolemia [15]. Patients absorb plant sterols [16–18] 
and lose ability to secrete plant sterols into bile, resulting 
in drastically elevated plasma plant sterol levels which ulti-
mately lead to extensive xanthomas, arthritis, and prema-
ture atherosclerosis. The pathophysiological defects under-
lying the disease highlight the importance of understanding 
the mechanism by which G5/G8 works to excrete sterols 
from the body.
In regards to sterol absorption, G5/G8 is well-estab-
lished to limit the absorption of plant sterols [6, 11, 12, 
19–21]. However, the extent to which G5/G8 limits choles-
terol absorption is unclear. It is important to note that sitos-
terolemic patients have normal or slightly above-average 
plasma cholesterol levels [22] as well as normal cholesterol 
absorption [23, 24]. Interestingly, G5/G8 is also recently 
implicated in intestinal TAG metabolism, in which G5/G8 
deficiency in mice was found to increase total TAG absorp-
tion and secretion by the intestine [25]. What is not known 
is whether G5/G8 serves to limit the absorption of other 
dietary lipids, not just of cholesterol, by affecting the pro-
duction of chylomicrons.
The objective of the study in this report was to test the 
hypothesis that G5/G8 limits the production of chylomi-
crons in the small intestine by investigating the effects of 
G5/G8 deficiency on (1) the transport rate of dietary TAG 
and cholesterol into the lymph, and (2) the stage(s) of the 
absorptive process that may be affected, such as uptake, 
mucosal assimilation, or secretion into the lymph. We 
employed the well-established conscious lymph fistula 
model to directly analyze the steady-state transport rate of 
lipids across the enterocyte.
Materials and Methods
Animals
Male G5/G8 KO mice previously generated by Yu et al. 
[10] were kindly provided to us and were backcrossed >8 
generations to yield animals that were nearly of a pure 
C57BL6/J background. Genotype was verified by PCR. 
Only 3–4 month old mice were used for the study. G5/
G8 KO and WT mice were housed (3–4 mice per cage) in 
temperature-controlled (21 ± 1° C) cages under a normal 
12:12 h light–dark cycle at the University of Cincinnati 
Laboratory Animal Medical Services. The mice had free 
access to water and standard rodent chow (LM-485 Mouse/
Rat Sterilizable Diet, Harlan Laboratories).
Body Composition and Plasma Lipid Analysis
Mice were fasted overnight. Body weights were meas-
ured and body composition was determined by nuclear 
magnetic resonance (NMR) analysis. On a separate day, 
fasting blood samples were drawn from the tail vein into 
heparin capillary tubes. Fasting cholesterol and TAG were 
measured from plasma using Infinity cholesterol assay 
kits (Thermo-Fisher Scientific, Middletown, VA) and Total 
TAG assay kits (Randox Laboratories, Kearneysville, WV). 
Plasma sterol composition was analyzed by gas chroma-
tography (GC) using 5-alpha cholestane as the internal 
standard. Plasma samples were heated in alcoholic KOH 
in glass test tubes at 65 °C for 2 h. Sterols were extracted 
with petroleum, dried under nitrogen and dissolved in hex-
ane for GC analysis. Quantitative analyses were based on 
standard curves for cholesterol, sitosterol, and campesterol 
generated during the same GC run.
Lymph and Duodenal Cannulation
Before surgery, the mice were fasted overnight with 
free access to water. Anesthesia comprised of ketamine 
(80 mg/kg) and xylazine (20 mg/kg) was administered 
intraperitoneally. Under anesthesia, the main mesenteric 
lymph duct was cannulated with a polyvinylchloride 
tube (0.20 mm inner diameter; 0.50 mm outer diame-
ter) according to procedures first described by Bollman 
et al. [26] which were later adapted by us for the mouse 
[27–29]. Due to the delicate nature of the mouse lymph 
duct, the cannula was secured with a drop of cyanoacr-
ylate glue (Krazy Glue, Columbus, OH, USA) instead 
of a suture. A second PVC tube (0.5 mm inner diameter, 
0.8 mm outer diameter) was introduced through the fun-
dus of the stomach into the duodenum and secured by a 
purse-string suture. The fundal incision was closed by 
the cyanoacrylate glue. Following surgery, a 5 % saline-
glucose solution containing 145 mmol/L NaCl, 4 mmol/L 
KCl, and 0.28 mol/L glucose was infused into the duo-
denal cannula at a constant rate of 0.3 mL/h to replen-
ish fluids and electrolytes lost from lymph drainage. The 
animals were allowed to recover overnight in restraining 
cages maintained at 30° C to prevent hypothermia caused 
by surgical stress and single-animal housing. Despite 
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being restrained, the animals still had considerable free-
dom to move. All procedures were performed in accord-
ance with the University of Cincinnati Internal Animal 
Care and Use Committee and in compliance with the 
National Institutes of Health Guide for the Care and Use 
of Laboratory Animals.
Preparation of Lipid Infusate
Lipid emulsions were prepared containing 4 µmol tri-
olein [labeled with [9,10-3H(N)]-triolein, 1 µCi (Perkin-
Elmer, Waltham, MA)] 0.78 µmol cholesterol [labeled 
with [1,2-14C(N)]-cholesterol, 0.1 µCi (Perkin-Elmer, 
Waltham, MA)], 0.78 µmol egg phosphatidylcholine, 
and 5.7 µmol sodium taurocholate (Sigma, St. Louis, 
MO, USA), sonicated in 0.3 ml phosphate-buffered 
saline (pH 6.4). Homogeneity was verified by deter-
mining the radioactivity sampled from the top, middle, 
and bottom of the emulsion. Emulsions were consid-
ered homogeneous if the counts did not vary >1 %. The 
lipid dose was chosen based on the average daily fat and 
cholesterol intake for mice fed a standard rodent chow 
diet (4 % fat, 0.02 % cholesterol by weight). The total 
amount of fat and cholesterol delivered over the course 
of the 6 h study approximated the total daily physiologic 
intake of lipids.
Experimental Procedure
The morning following surgery, the 5 % glucose-saline 
solution was replaced with the lipid emulsion described 
above. The emulsion was continuously infused into the 
duodenum for 6 h at a constant rate of 0.3 mL/h. Lymph 
samples were collected every hour into pre-cooled conical 
centrifuge tubes. Since the animals are conscious during 
lipid infusion, our experiments lack the complications of 
anesthesia which is known to dampen the production of 
chylomicrons [30]. At the end of the 6 h, mice were anes-
thetized for tissue and organ removal. The stomach, small 
intestine, colon, and their luminal contents were collected 
for lipid analysis. The mucosa tissue of the small intes-
tine was left intact, cut into 4 equal length segments, and 
labeled M1–M4 (M1—duodenum, M2 and M3—two 
equal segments of the jejunum, M4—ileum). The intesti-
nal segments were homogenized using a Polytron homog-
enizer. The luminal contents of the stomach, small intes-
tine, and colon were collected from three rinses of 10 mM 
NaTC. Radioactivity of each sample was measured by 
beta-scintillation. Total lymph TAG and cholesterol were 
measured using Total TAG assay kits (Randox Labora-
tories, Kearneysville, WV, USA) and Infinity cholesterol 
assay kits (Thermo-Fisher Scientific, Middletown, VA, 
USA).
Absorptive and Transport Index Calculations
Absorptive and lymph transport indexes were calculated as 
previously described [31]. The absorptive index represents 
the percentage of infused lipid taken up by the enterocyte 
and is calculated from the following equation: absorptive 
index = 100 % − % total dose recovered in the lumen. 
The lymphatic transport index represents the percentage of 
absorbed lipid secreted into the lymph and takes into con-
sideration the uptake of lipid by the small intestine. This 
index is very useful to characterize the ability of the small 
intestine to transport lipid into lymph as chylomicrons 
and is calculated from the equation: Lymphatic transport 
index =  % infused dose recovered in lymph/absorptive 
index × 100.
Intestinal TAG Secretion Studies
Plasma TAG in mice (fasted overnight) was measured using 
a total TAG assay kit (Randox Laboratories, Antrim, UK). 
Intestinal TAG secretion was measured a week later to 
minimize stress-induced variables caused by handling. To 
measure intestinal TAG secretion, mice (fasted overnight) 
were given an intraperitoneal injection of Poloxamer 407 
at 1 mg/g body weight, which was previous shown to be 
optimal for mice to block lipoprotein lipase activity [32]. 
Immediately after injection, the mice were gavaged with 
1 µCi [3H]-triolein in 150 µL olive oil. Tail blood was 
drawn immediately and hourly for 4 h following gavage 
into heparin capillary tubes. Radioactivity in the plasma 
samples was measured by scintillation spectroscopy. The 
intestinal secretion rate was derived from the average 
amount of radioactivity secreted over 4 h.
Statistical Analysis
The data shown are mean values ± standard errors (SE). 
To compare groups throughout the 6 h infusion period, 
two-way repeated measures analysis of variance (ANOVA) 
with Tukey post-test analysis were used. For comparison of 
data that have 2 independent variables, 2-way ANOVA was 
used. A t test was used for comparisons of only 2 groups. 
Statistical analyses were performed using GraphPad Prism 
v6. Data were considered significant if P < 0.05.
Results
Body and Plasma Parameters of G5/G8 KO and WT Mice
No significant differences were found in body weight, fat 
and lean mass, fasting plasma cholesterol and TAG lev-
els between G5/G8 KO and WT mice (Table 1) although 
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G5/G8 KO mice tended to have a lower body weight with 
less fat mass. G5/G8 KO mice had elevated plasma levels 
of sitosterol and campesterol compared with WT, in ratios 
similar to previous reports in chow-fed mice [10, 25].
Lymphatic TAG and Cholesterol Transport Rate
Infusion of the lipid emulsion at 0.3 mL/h, produced a 
steady lymph flow of 0.17–0.20 mL/h for both groups of 
mice (Fig. 1). This showed that lymph flow would not be 
a variable affecting chylomicron output [33]. In WT mice, 
the lymphatic [3H]-TAG transport rate reached a steady 
state of 58 % of the hourly dose after 3 h (Fig. 2a), which 
agreed with previous findings that steady-state absorption 
is achieved by 4 h [34–36]. In contrast, G5/G8 KO mice 
showed a significant (P < 0.05) reduction in the lymphatic 
[3H]-TAG transport rate compared with WT, which was 
evident at 2 h and maximal at 3 h of infusion (Fig. 2a). The 
difference tapered at the end of the infusion period, sug-
gesting that G5/G8 KO mice experienced a delay in reach-
ing maximal TAG transport rates. Output of TAG mass in 
the lymph was also reduced in G5/G8 KO mice (Fig. 2b) 
and paralleled the output of radiolabeled tracer. These 
results were surprising because G5/G8 KO mice were pre-
viously reported to have increased absorption of TAG [25].
G5/G8 KO mice also showed a significant (P < 0.05) 
reduction in the lymphatic transport rate of [14C]-cho-
lesterol compared with WT, which was evident at 2 h 
(Fig. 3a). While WT mice achieved a lymphatic [14C]-cho-
lesterol transport rate of 25 % of the hourly dose at 6 h, G5/
G8 KO mice only achieved 15 % of the hourly dose. These 
results correlated with the output of total lymph choles-
terol (Fig. 3b), although G5/G8 KO mice displayed greater 
variability. Thus, the reduction in lymphatic cholesterol 
transport by G5/G8 KO mice applied to both exogenous 
(radiolabeled) and endogenous plus exogenous (total) cho-
lesterol outputs.
Table 1  Body weight, composition and fasting plasma parameters of 
G5/G8 KO compared with WT control mice
“–” sterols were not detectable by GC
WT G5/G8 KO
Body weight (g) 32.3 ± 0.8 30.1 ± 0.6
Fat mass (g) 3.7 ± 0.5 2.6 ± 0.4
Lean mass (g) 26.4 ± 0.5 25.1 ± 0.4
Plasma cholesterol (mg/dL) 87 ± 6.3 87.5 ± 8.3
Plasma sitosterol (mg/dL) – 25 ± 4.7
Plasma campesterol (mg/dL) – 14.1 ± 3.9
Plasma TAG (mg/dL) 62.3 ± 6.5 54.5 ± 5.6
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Fig. 1  Lymph flow was maintained at a steady continuous rate 
throughout the 6 h infusion period for both G5/G8 KO (n = 13) and 
wild-type control (n = 9) mice. Mesenteric lymph flow was measured 
at hourly intervals immediately after lipid infusion for 6 h. Values are 
means ± SE
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Fig. 2  G5/G8 KO mice (n = 13) display lower TAG transport into 
the lymph compared to WT control mice (n = 9). Lymphatic output 
of a [3H]-TAG and b total TAG are expressed as a percentage of the 
infused hourly dose and molar output, respectively. Lymph fistula 
mice were intraduodenally infused with a lipid emulsion containing 
[3H]-TAG and [14C]-cholesterol for 6 h. Values are means ± SE
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Distribution of Radiolabeled TAG and Cholesterol Along 
Various Segments of the Small Intestine
Figure 4 shows the distribution of the amount of [3H]-TAG 
and [14C]-cholesterol in the mucosa of intestinal segments, 
M1-M4 (M1 representing the duodenum, M2 and M3 the 
jejunum, M4 the ileum). There was no difference between 
the groups in the amount of [3H]-TAG in any of the seg-
ments (Fig. 4a). There was significantly less (P < 0.05) 
[14C]-cholesterol in only the duodenum of G5/G8 KO 
mice (Fig. 4b, M1). Thus, although G5/G8 KO mice had 
decreased lymphatic outputs of [3H]-TAG and [14C]-cho-
lesterol, the data show that the lipids did not accumulate in 
the mucosa.
Total Recovery of Radiolabeled TAG and Cholesterol 
at the End of 6 h
At the end of the 6 h, G5/G8 KO mice showed a significant 
(P < 0.05) reduction of [3H]-TAG in the lymph, no differ-
ence in the mucosa, and an increased (P < 0.05) amount 
recovered from the intestinal lumen (Fig. 5a). Very lit-
tle [3H]-TAG refluxed into the stomach and little was 
recovered from the colon, indicating that most of the TAG 
we infused did not pass on into the feces during the experi-
ment (Fig. 5a).
The total recovery of [14C]-cholesterol was very simi-
lar to the total recovery of [3H]-TAG (Fig. 5b). G5/G8 KO 
mice showed a significant (P < 0.05) reduction of [14C]-
cholesterol in the lymph, no difference in the intestinal 
mucosa, and an increased (P < 0.05) amount recovered 
from the intestinal lumen compared with WT. Very low 
amounts of [14C]-cholesterol were found in the lumens of 
the stomach and colon from both groups (Fig. 5b).
When quantifying the efficiency of lipid uptake and 
secretion by the intestines of the animals (Table 2), we 
found that G5/G8 KO mice had a lower (P < 0.05) absorp-
tive index for [3H]-TAG, indicating that the intestines of 
G5/G8 KO mice had a reduced capacity to take up [3H]-
TAG. G5/G8 KO mice also had a lower (P < 0.05) lym-
phatic transport index for [3H]-TAG than WT. This find-
ing is important because it shows that TAG is not only less 
readily taken up but also its subsequent secretion is poorer 
in G5/G8 KO mice compared with WT. As with TAG, G5/
G8 KO mice had a significantly (P < 0.05) lower absorp-
tive index as well as a lower (P < 0.05) lymphatic transport 
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Fig. 3  G5/G8 KO mice (n = 13) displayed lower cholesterol trans-
port into the lymph compared to WT control mice (n = 9). Lymphatic 
output of a [14C]-cholesterol and b total cholesterol are expressed as a 
percentage of the hourly infused dose and molar output, respectively. 
Lymph fistula mice were intraduodenally infused with a lipid emul-
sion containing [3H]-TAG and [14C]-cholesterol for 6 h. Values are 
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Fig. 4  Distribution of a [3H]-
TAG and b [14C]-cholesterol 
along the small intestine divided 
into 4 segments of equal length, 
from proximal to distal: M1, 
M2, M3, and M4 (M1—duo-
denum, M2 and M3—jejunum, 
M4—ileum). Radioactivity 
was determined by scintillation 
counter. *P < 0.05. Values are 
means ± SE
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index for [14C]-cholesterol than WT, indicating that G5/
G8 KO mice had a compromised ability to absorb choles-
terol and transport the absorbed cholesterol into lymph. 
Taken together, the data clearly indicates that a loss of G5/
G8 function causes impairment in both the uptake and lym-
phatic transport of dietary TAG and cholesterol into lymph. 
How G5/G8 is affecting the mechanism of uptake and the 
packaging of absorbed lipids into chylomicrons warrants 
further study.
Intestinal TAG Secretion
Since G5/G8 KO mice were previously shown to have an 
increased intestinal secretion of TAG [25], we determined 
the intestinal secretion of TAG in our G5/G8 KO mice 
using a different cohort of animals. In contrast, G5/G8 KO 
mice showed lower (P < 0.05) intestinal secretion of [3H]-
TAG (n = 6, 10.1 ± 1.3 % total dose/h) compared with 
WT (n = 6, 15.3 ± 1.5 % total dose/h). Fasting plasma 
TAG and cholesterol were similar between the two groups 
(Table 1).
Discussion
In the present study, we found that G5/G8 deficiency in 
mice decreases the transport rate of both dietary TAG and 
cholesterol into the lymph. The overall reduction of lipids 
delivered to the lymph was accompanied by their accumu-
lation in the intestinal lumen. Interestingly, the lipids did 
not accumulate in the intestinal mucosa. The data show that 
G5/G8 deficiency suppresses the transport of TAG and cho-
lesterol from lumen to lymph, suggesting a novel role of 
G5/G8 in facilitating the production of chylomicrons.
G5/G8 deficiency did not affect the body weight, body 
composition, or fasting plasma TAG and cholesterol lev-
els, although G5/G8 KO mice tended to have a lower body 
weight with less fat mass (Table 1). Under steady state con-
ditions of lipid transport, G5/G8 KO mice were delayed 
in reaching maximal TAG transport rates into the lymph 
(Fig. 2) as well as showed decreased overall transport of 
TAG from lumen to lymph (Fig. 5a; Table 1). G5/G8 KO 
mice were no different from WT mice in the mucosal 
accumulation of TAG (Fig. 4a), suggesting that G5/G8 
deficiency did not increase the intracellular TAG pools of 
the enterocyte. This is unlike the case of CD36 deficiency 
where TAG accumulated in the mucosa, manifesting in 
large cytosolic lipid droplets and reducing intestinal TAG 
secretion [27, 37]. Overall the data suggest that dietary 
TAG uptake into the enterocyte and its secretion into the 
lymph are limited in the state of G5/G8 deficiency.
These results were surprising because G5/G8 deficiency 
was previously found to increase absorption and secretion 
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Fig. 5  Total recovery of a [3H]-TAG and b [14C]-cholesterol in 
WT control (n = 9) and G5/G8 KO (n = 13) mice at the end of the 
6 h lipid infusion. Lymph refers to the total radiolabeled lipid col-
lected from the lymph over the 6-h infusion period. Mucosa refers 
to radioactivity recovered after homogenization of the small intes-
tine. Lumen refers to small intestinal luminal contents that were 
washed and collected at the end of infusion. Very low amounts of 
[3H]-TAG and [14C]-cholesterol were recovered from the colon and 
stomach, indicating little excretion and reflux, respectively. Radioac-
tivity was determined by scintillation counter. *P < 0.05. Values are 
means ± SE
Table 2  Comparison of lipid absorptive and lymph transport indexes for [3H]-TAG and [14C]-cholesterol in WT control (n = 9) and G5/G8 KO 
mice (n = 13)
* P < 0.05. Values are means ± SE
TAG Cholesterol
Absorptive index Lymphatic transport index Absorptive index Lymphatic transport index
WT 95.2 ± 0.7 47.0 ± 5.3 77.1 ± 3.4 20.6 ± 3.1
G5/G8 KO 87.5 ± 2.7* 26.8 ± 4.9* 67.4 ± 4.8* 9.5 ± 2.9*
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of TAG [25]. However, when we measured intestinal TAG 
secretion into the plasma, we observed decreased intestinal 
TAG secretion in G5/G8 KO mice, which is consistent with 
our lymphatic transport results. The difference in results 
may be attributed to the genetic background of the mice 
used in the two studies (129S6SvEv × C57BL/6 J strain 
used in their study versus a nearly pure C57BL/6 J back-
ground used in our study), which could potentially intro-
duce phenotypic variability [38, 39].
Interestingly, G5/G8 deficiency also decreased the lym-
phatic transport rate, as well as mass output, of cholesterol 
(Fig. 3). This decrease was observed concomitant with 
an increase of lipid accumulated in the intestinal lumen 
(Fig. 5b; Table 1), suggesting that G5/G8 deficiency also 
limited the uptake and secretion of dietary cholesterol. A 
study by Wang et al. [20] had reported that G8 KO mice had 
increased cholesterol transport into the lymph. There are 
two key differences in our study design that may explain 
the difference in our observations. Firstly, to account for 
variations in bile composition, the Wang et al. [40] diverted 
the bile duct in animals and supplied “model bile” com-
prised of taurocholate and phospholipid. The lipid infusate 
included only a trace amount of radiolabeled cholesterol. 
In a system where luminal cholesterol is deficient, it is pos-
sible that G5/G8 may efflux cholesterol better under these 
conditions, especially in the presence of bile salt and phos-
pholipid, which are good cholesterol acceptors. Secondly, 
they supplied medium-chain fatty acids as the vehicle and 
hence, TAG-rich chylomicrons are minimally produced in 
their system. Unknown is whether cholesterol transport is 
altered with the addition of dietary TAG in G5/G8 KO ani-
mals. The question of whether cholesterol transport can be 
altered in the presence of TAG was also posed by Sontag 
et al. [41], which they believed cholesterol absorption rates 
are different in delivery vehicles using medium-chain TAG 
versus long-chain TAG.
Because G5/G8 is presumed to efflux sterols into the 
intestinal lumen, its deficiency would expectedly accu-
mulate cholesterol in the mucosa. Also, since G5/G8 is 
expressed differentially along the length of the intestine 
[42], which is thought to contribute to differential degrees 
of absorption [20, 21, 43], we speculated that G5/G8 defi-
ciency would accumulate lipids differently in the various 
intestinal segments. However, we found that G5/G8 defi-
ciency did not affect the mucosal accumulation of cho-
lesterol, except slightly in the duodenum (Fig. 4b). These 
results complement the report from Wang et al. [20], who 
found no differences in [14C]-cholesterol retained in any of 
the intestinal segments between G8 KO and WT mice after 
measuring acute uptake 45 min after lipid dose. Nyugen 
et al. [21]reported that G5/G8 KO mice accumulated [14C]-
cholesterol in the jejunum; however, this was seen after 
a bolus dose of mixed sterols. It is also important to note 
that acute conditions differ from steady-state conditions in 
terms of measuring regional differences in mucosal uptake 
[44]. Regardless of slight differences in regional uptake, the 
data from this study and other laboratories clearly demon-
strate that G5/G8 deficiency does not significantly impact 
the accumulation of lipids in the mucosa.
Since the transport processes of both TAG and choles-
terol are affected from lumen to lymph, the findings illus-
trate a critical role for G5/G8 in the formation and secre-
tion of chylomicrons. G5/G8 KO mice do not have altered 
gene expressions of microsomal transfer protein (MTP) 
and apolipoprotein B, NPC1L1 protein levels [45] nor have 
markers that would indicate ER stress [21], all of which 
would affect chylomicrons assembly. Interestingly, a recent 
report by Nguyen et al. [21]also observed G5/G8 KO mice 
having reduced cholesterol transport into the lymph, con-
comitant with reduced TAG associated with chylomicrons. 
After analyzing chylomicron composition, they concluded 
that G5/G8 KO mice had abnormal chylomicron assembly. 
They speculated that the plant sterols in their lipid infusate 
caused the reduction in lymph cholesterol. However, we 
did not infuse plant sterols and still found a dramatic reduc-
tion in the lymphatic transport of TAG and cholesterol in 
G5/G8 KO mice, suggesting that the effect was independ-
ent of plant sterols. However, since the mice were main-
tained on a chow diet prior to fasting, we cannot exclude 
the possibility that plant sterols derived from the chow may 
have caused interference.
Reports on cholesterol absorption in G5/G8 KO mice 
have varied and may be attributed to the methods used. 
Earlier studies found no difference in fractional choles-
terol absorption between G5/G8 KO and WT mice [10, 19]. 
However the method used in these reports, the fecal dual-
isotope ratio method [46], may be inappropriate for G5/G8 
KO mice because the method depends critically on a non-
absorbable radiolabeled plant sterol marker [3, 45], which 
is well-absorbed in G5/G8 deficient mice [20]. Hence, we 
used the conscious lymph fistula model to directly deter-
mine the absorption of dietary lipids into the lymph, as well 
as to measure their accumulation in the intestinal lumen 
and mucosa under steady-state conditions of lipid transport.
G5/G8 is implicated in the transintestinal cholesterol 
efflux (TICE) pathway, which is responsible for the reverse 
transport of cholesterol from the plasma to the basolateral 
membrane of the enterocyte, its efflux into the intestinal 
lumen, and subsequent elimination into the feces [40, 47]. 
However, G5 deficiency was found to only affect 4 % of 
the daily TICE contribution to cholesterol excretion [48], 
suggesting a minor role for G5/G8 in this reverse trans-
port. Also, the rates of TICE were found to range between 
1–2 nmol/min × 100 g body weight [40], which is consid-
erable less (~10 fold) than the steady-state transport rate of 
cholesterol into the lymph (Fig. 3b). Although our study 
378 Lipids (2015) 50:371–379
1 3
was not designed to examine TICE, we believe that TICE 
has limited contribution to our findings.
Our study has potential limitations. Firstly, the animals 
used in the study were maintained on standard rodent chow 
which has a considerable amount of plant sterols and accu-
mulate in the plasma of G5/G8 KO mice. As a result, the 
plant sterols derived from plasma may interfere with the 
transport processes of TAG or cholesterol in the intestine, 
in our study as well as of other investigators [10, 20, 25]. 
Secondly, G5/G8 KO mice are known to have less biliary 
cholesterol [10], which may be a variable in our analysis. 
However, the cholesterol provided in our lipid emulsion 
per hour is substantially more (~12 fold) than that of bile, 
assuming a gallbladder volume of 16.5 µL of a WT mouse 
[49] with a biliary cholesterol concentration of 4 μmol/mL 
[10], making the contribution of biliary cholesterol mini-
mal in our study.
In conclusion, although the exact mechanism is still 
unknown of how G5/G8 handles TAG and cholesterol in 
the intestine, our studies show that a loss of G5/G8 func-
tion causes a backup of lipid trafficking across the entero-
cyte and subsequent production of chylomicrons. Instead 
of accumulating in the mucosa, the lipids are rate-limited 
and accumulate in the intestinal lumen. Our findings dem-
onstrate a novel role for G5/G8 and provide another insight 
into the complex intracellular processes that orchestrate 
with G5/G8 transporters in the delivery of dietary lipids.
Acknowledgments This work was supported by National Institutes 
of Health Grants DK092138 and DK059630 (University of Cincinnati 
Mouse Metabolic Phenotyping Center) to Dr. Patrick Tso and Ameri-
can Heart Association Grant 13PRE17140013 to Linda Zhang.
Conflict of interest None.
References
 1. Kasper H (1970) Faecal fat excretion, diarrhea, and subjec-
tive complaints with highly dosed oral fat intake. Digestion 
3(6):321–322
 2. Grundy SM, Ahrens EH (1966) An evaluation of the relative mer-
its of two methods of measuring the balance of sterols in man: 
isotopic balance versus chromatographic analysis. J Clin Invest 
45(9):1503–1515
 3. Grundy SM, Ahrens EH (1969) Measurements of cholesterol 
turnover, synthesis, and absorption in man, carried out by isotope 
kinetic and sterol balance methods. J Lipid Res 10(1):91–107
 4. Bosner MS, Ostlund RE, Osofisan O, Grosklos J, Fritschle C, 
Lange LG (1993) Assessment of percent cholesterol absorption in 
humans with stable isotopes. J Lipid Res 34(6):1047–1053
 5. Salen G, Ahrens EH, Grundy SM (1970) Metabolism of 
β-sitosterol in man. J Clin Invest 49(5):952–967
 6. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwit-
erovich P, Shan B, Barnes R, Hobbs HH (2000) Accumulation of 
dietary cholesterol in sitosterolemia caused by mutations in adja-
cent ABC transporters. Science 290(1):1171–1175
 7. Graf GA, Cohen JC, Hobbs HH (2004) Missense mutations in 
ABCG5 and ABCG8 disrupt heterodimerization and trafficking. 
J Biol Chem 279(23):24881–24888
 8. Graf GA, Li WP, Gerald RD, Gelissen I, White A, Cohen JC, 
Hobbs HH (2002) Coexpression of ATP-binding cassette proteins 
ABCG5 and ABCG8 permits their transport to the apical surface. 
J Clin Invest 110(5):659–669
 9. Temel RE, Gebre AK, Parks JS, Rudel LL (2003) Compared 
with Acyl-CoA: cholesterol O-acyltransferase (ACAT) 1 and 
lecithin: cholesterol acyltransferase, ACAT2 displays the greatest 
capacity to differentiate cholesterol from sitosterol. J Biol Chem 
278(48):47594–47601
 10. Yu L, Hammer RE, Li-Hawkins J, Von Bergmann K, Lutjohann 
D, Cohen JC, Hobbs HH (2002) Disruption of Abcg5 and Abcg8 
in mice reveals their crucial role in biliary cholesterol secretion. 
Proc Natl Acad Sci USA 99(25):16237–16242
 11. Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen 
JC, Hobbs HH (2002) Overexpression of ABCG5 and ABCG8 
promotes biliary cholesterol secretion and reduces fractional 
absorption of dietary cholesterol. J Clin Invest 110(5):671–680
 12. Klett EL, Lu K, Kosters A, Vink E, Lee MH, Altenburg M, Shefer 
S, Batta AK, Yu H, Chen J, Klein R, Looije N, Oude-Elferink R, 
Groen AK, Maeda N, Salen G, Patel SB (2004) BMC Med 2(1):5
 13. Tachibana S, Hirano M, Hirata T, Matsuo M, Ikeda I, Ueda K, 
Sato R (2007) Cholesterol and plant sterol efflux from cultured 
intestinal epithelial cells Is mediated by ATP-binding cassette 
transporters. Biosci Biotechnol Biochem 71(8):1886–1895
 14. Lee M, Lu K, Hazard S, Yu H, Shulenin S, Hidaka H, Kojima 
H, Allikmets R, Sakuma N, Pegoraro R, Srivastava AK, Salen 
G, Dean M, Patel SB (2001) Identification of a gene, ABCG5, 
important in the regulation of dietary cholesterol absorption. Nat 
Genet 27(1):79–83
 15. Bhattacharyya AK, Connor WE (1974) β-Sitosterolemia and xan-
thomatosis: a newly described lipid storage disease in two sisters. 
J Clin Invest 53(4):1033–1043
 16. Lin HJ, Wang C, Salen G, Lam KC, Chan TK (1983) Sitosterol 
and cholesterol metabolism in a patient with coexisting phytos-
terolemia and cholestanolemia. Metabolism 32(2):126–133
 17. Salen G, Shore V, Tint GS, Forte T, Shefer S, Horak I, Horak E, 
Dayal B, Nguyen L, Batta AK (1989) Increased sitosterol absorp-
tion, decreased removal, and expanded body pools compensate 
for reduced cholesterol synthesis in sitosterolemia with xan-
thomatosis. J Lipid Res 30(9):1319–1330
 18. Salen G, Shefer S, Nguyen L, Ness GC, Tint GS, Shore V (1992) 
Sitosterolemia. J Lipid Res 33(7):945–955
 19. Plӧsch T, Bloks VW, Terasawa Y, Berdy S, Siegler K, Van Der 
Sluijs F, Kema IP, Groen AK, Shan B, Kuipers F, Schwartz M 
(2004) Sitosterolemia in ABC-transporter G5-deficient mice Is 
aggravated on activation of the liver-X receptor. Gastroenterology 
126(1):290–300
 20. Wang HH, Patel SB, Carey MC, Wang DQ (2007) Quantifying 
anomalous intestinal sterol uptake, lymphatic transport, and bil-
iary secretion in Abcg8-/- mice. Hepatology 45(4):998–1006
 21. Nguyen TM, Sawyer JK, Kelley KL, David MA, Kent CR, Rudel 
LL (2012) ACAT2 and ABCG5/G8 are both required for efficient 
cholesterol absorption in mice: evidence from thoracic lymph 
duct cannulation. J Lipid Res 53(8):1598–1609
 22. Kwiterovich PO, Bachorik PS, Smith HH, McKusick VA, Connor 
WE, Teng B, Sniderman AD (1981) Hyperapobetalipoproteinae-
mia in two families with xanthomas and phytosterolaemia. The 
Lancet 317(8218):466–469
 23. Salen G, Tint GS, Shefer S, Shore V, Nguyen L (1992) Increased 
sitosterol absorption is offset by rapid elimination to prevent 
accumulation in heterozygotes with sitosterolemia. Arterioscler 
Thromb Vasc Biol 12(5):563–568
379Lipids (2015) 50:371–379 
1 3
 24. Lutjohann D, Bjorkhem I, Beil UF, von Bergmann K (1995) 
Sterol absorption and sterol balance in phytosterolemia evalu-
ated by deuterium-labeled sterols: effect of sitostanol treatment. J 
Lipid Res 36(8):1763–1773
 25. Mendez-Gonzales J, Julve J, Rotllan N, Llaverias G, Blanco-Vaca 
F, Escola-Gil JC (2011) ATP-binding cassette G5/G8 deficiency 
causes hypertriglyceridemia by affecting multiple metabolic 
pathways. Biochim Biophys Acta 1811(12):1186–1193
 26. Bollman JL, Cain JC, Grindlay JH (1948) Techniques for the col-
lection of lymph from the liver, small intestine or thoracic duct of 
the rat. J Lab Clin Med 33(1):1349–1352
 27. Nauli AM, Nassir F, Zheng S, Yang Q, Lo CM, von Lehmden SB, 
Lee D, Jandacek RJ, Abumrad NA, Tso P (2006) CD36 is impor-
tant for chylomicron formation and secretion and may mediate 
cholesterol uptake in the proximal intestine. Gastroenterology 
131(4):1197–1207
 28. Lo CM, Nordskog BK, Nauli AM, Zheng S, vonLehmden SB, 
Yang Q, Lee D, Swift LL, Davidson NO, Tso P (2008) Why 
does the gut choose apolipoprotein B48 but not B100 for chy-
lomicron formation? Am J Physiol Gastrointest Liver Physiol 
294(1):G344–G352
 29. Kohan AB, Howles PN, Tso P (2012)Methods for studying 
rodent intestinal lipoprotein production and metabolism. Current 
Protocols in Mouse Biology 2:219–230
 30. Redgrave TG (1970) Formation of cholesteryl ester-rich par-
ticulate lipid during metabolism of chylomicrons. J Clin Invest 
49(3):465–471
 31. Bergstedt SE, Hayashi H, Kritchevsky D, Tso P (1990) A com-
parison of absorption of glycerol tristearate and glycerol trioleate 
by rat small intestine. Am J Physiol 259(3):G386–G393
 32. Wout ZGM, Pec EA, Maggiore JA, Williams RH, Palicharla P, 
Johnston TP (1992) Poloxamer 407-mediated changes in plasma 
cholesterol and triglycerides following intraperitoneal injection to 
rats. PDA J Pharm Sci Tech 46:192–200
 33. Tso P, Pitts V, Granger DN (1985) Role of lymph flow in intesti-
nal chylomicron transport. Am J Physiol 249(1):G21–G28
 34. Clark SB (1978) Chylomicron composition during duodenal tri-
glyceride and lecithin infusion. Am J Physiol 235:E183–E190
 35. Mansbach CM II, Arnold A (1986) Steady-state kinetic analysis 
of triacylglycerol delivery into mesenteric lymph. Am J Physiol 
251(2 Pt 1):G263–G269
 36. Tso P, Balint JA, Rodgers JB (1980) Effect of hydrophobic sur-
factant (Pluronic L-81) on lymphatic lipid transport in the rat. Am 
J Physiol 239:G348–G353
 37. Drover VA, Ajmal M, Nassir F, Davidson NO, Nauli AM, Sahoo 
D, Tso P, Abumrad NA (2005) CD36 deficiency impairs intestinal 
lipid secretion and clearance of chylomicrons from the blood. J 
Clin Invest 115(5):1290–1297
 38. Funkat A, Massa CM, Jovanovska V, Proietto J, Andrikopoulos 
S (2004) Metabolic adaptations of three inbred strains of mice 
(C57BL/6, DBA/2, and 129T2) in response to a high-fat diet. J 
Nutr 134(12):3264–32694
 39. Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P (1985) 
Variation in susceptibility to atherosclerosis among inbred strains 
of mice. Atherosclerosis 57(1):65–73
 40. Van der Velde AE, Vrins CL, van der Oever K, Kunne C, Elferink 
RP, Kuipers F, Groen AK (2007) Direct intestinal cholesterol 
secretion contributes significantly to total fecal neutral sterol 
excretion in mice. Gastroenterology 133(3):967–975
 41. Sontag TJ, Chellan B, Getz GS, Reardon CA (2013) Differing 
rates of cholesterol absorption among inbred mouse strains yield 
differing levels of HDL-cholesterol. J Lipid Res 54(9):2515–2524
 42. Wang DQ-H, Paigen B, Carey MC (2001) Genetic factors at the 
enterocyte level account for variations in intestinal cholesterol 
absorption efficiency among inbred strains of mice. J Lipid Res 
42(11):1820–1830
 43. Duan LP, Wang HH, Wang DQ (2004) Cholesterol absorption is 
mainly regulated by the jejunal and ileal ATP-binding cassette 
sterol efflux transporters Abcg5 and Abcg8 in mice. J Lipid Res 
45(7):1312–1323
 44. Clark SB, Lawergren B, Martin JV (1973) Regional intestinal 
absorptive capacities for triolein: an alternative to markers. Am J 
Physiol 225(3):574–585
 45. Tang W, Ma Y, Jia L, Ioannou YA, Davies JP, Yu L (2009) Genetic 
inactivation of NPC1L1 protects against sitosterolemia in mice 
lacking ABCG5/ABCG8. J Lipid Res 50(2):293–300
 46. Borgstrom B (1968) Quantitative aspects of the intestinal absorp-
tion and metabolism of cholesterol and β-sitosterol in the rat. J 
Lipid Res 9(4):473–481
 47. Van der Velde AE, Vrins CL, van den Oever K, Seemann I, 
Elferink RP, van Eck M, Kuipers F, Groen AK (2008) Regula-
tion of direct transintestinal cholesterol excretion in mice. Am J 
Physiol Gastrointest Liver Physiol 295(1):G203–G208
 48. Van der Veen JN, van Dijk TH, Vrins CL, van Meer H, Havinga 
R, Bijsterveld K, Tietge UJ, Groen AK, Kuipers F (2009) Activa-
tion of the liver X receptor stimulates trans-intestinal excretion of 
plasma cholesterol. J Biol Chem 284(29):19211–19219
 49. Graewin SJ, Kiely JM, Lee KH, Svatek CL, Nakeeb A, Pitt HA 
(2004) Nonobese diabetic mice have diminished gallbladder 
motility and shortened crystal observation time. J Gastrointest 
Surg 8(7):824–830
